Cancer evidence library
Kidney Cancer
PubMed-indexed evidence for renal cell carcinoma and other kidney malignancies.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 859 non-retracted PubMed-indexed records for Kidney Cancer. The structured collection includes 16 guideline or consensus records, 114 evidence syntheses/systematic reviews/meta-analyses, and 82 randomized or phase III studies. 171 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 475 of 859 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
1
2015
1
2017
1
2018
1
2019
4
2020
9
2021
30
2022
128
2023
148
2024
57
2025
475
2026
4
2027
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Reported outcomes
Numerical results extracted from PubMed abstracts
Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.
Non-pooled ratio measures
Reference = 1.0
Hazard, risk, and odds ratios reported in abstracts
0.250.51.02.04.0
View extracted numerical results 60
| Publication | Outcome | Measure | Reported value | Source |
|---|---|---|---|---|
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Odds Ratio | 240.0 | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Odds Ratio | 480.0 | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Percentage Comparison | 31.4percent vs 19.5percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Percentage Comparison | 30.2percent vs 18.7percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Percentage Comparison | 35.3percent vs 21.8percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | progression-free survival | Percentage Comparison | 22.7percent vs 9.0percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | progression-free survival | Percentage Comparison | 25.4percent vs 8.5percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | progression-free survival | Percentage Comparison | 12.5percent vs 11.3percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | response | Percentage Comparison | 48.0percent vs 19.0percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | response | Percentage Comparison | 50.0percent vs 23.0percent | PMID 41786248 |
| Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.Urologic oncology · 2026 | recurrence | Hazard Ratio | 2.38 P = 0.03 | PMID 41266180 |
| Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.Urologic oncology · 2026 | recurrence | Hazard Ratio | 2.92 P = 0.03 | PMID 41266180 |
| Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.Urologic oncology · 2026 | recurrence | Hazard Ratio | 3.68 P = 0.03 | PMID 41266180 |
| Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.La Clinica terapeutica · 2026 | not_reported | Odds Ratio | 0.54 95% CI 0.35–0.84 | PMID 42340793 |
| Evaluating the Feasibility of Standard Ultrasound in the Bosniak Classification of Cystic Renal Masses Compared with Computed Tomography/Magnetic Resonance Imaging: A Multicenter Study.Ultrasound in medicine & biology · 2026 | not_reported | Percentage Comparison | 77.0percent vs 86.0percent p = 0.17 | PMID 41238458 |
| Evaluating the Feasibility of Standard Ultrasound in the Bosniak Classification of Cystic Renal Masses Compared with Computed Tomography/Magnetic Resonance Imaging: A Multicenter Study.Ultrasound in medicine & biology · 2026 | not_reported | Percentage Comparison | 79.0percent vs 78.0percent p = 0.17 | PMID 41238458 |
| Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Risk Ratio | 1.03 95% CI 1.02–1.04 | PMID 40536070 |
| Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Risk Ratio | 1.03 95% CI 1.02–1.05 | PMID 40536070 |
| Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Risk Ratio | 1.07 95% CI 1.03–1.12 | PMID 40536070 |
| Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Risk Ratio | 1.01 95% CI 1.0–1.02 | PMID 40536070 |
| Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma.Anticancer research · 2026 | not_reported | Hazard Ratio | 0.38 95% CI 0.23–0.62 | PMID 42373289 |
| Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma.Anticancer research · 2026 | not_reported | Hazard Ratio | 0.49 95% CI 0.37–0.64 | PMID 42373289 |
| Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma.Anticancer research · 2026 | not_reported | Hazard Ratio | 0.71 95% CI 0.3–1.71 | PMID 42373289 |
| Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma.Anticancer research · 2026 | not_reported | Hazard Ratio | 0.78 95% CI 0.57–1.05 | PMID 42373289 |
| Performance of 99mTc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience.The Journal of urology · 2026 | not_reported | Percentage Comparison | 52.0percent vs 48.0percent | PMID 41433425 |
| New TNM Staging System Predicts Progression of Small Renal Masses Under Active Surveillance: A Retrospective Analysis of a Single-center Prospective Series.European urology oncology · 2026 | not_reported | Percentage Comparison | 46.0percent vs 23.0percent | PMID 41139550 |
| New TNM Staging System Predicts Progression of Small Renal Masses Under Active Surveillance: A Retrospective Analysis of a Single-center Prospective Series.European urology oncology · 2026 | not_reported | Hazard Ratio | 4.63 p < 0.001 | PMID 41139550 |
| Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.Clinical genitourinary cancer · 2026 | not_reported | Hazard Ratio | 0.68 95% CI 0.57–0.79 | PMID 42350220 |
| Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.Clinical genitourinary cancer · 2026 | not_reported | Hazard Ratio | 1.76 95% CI 1.25–2.48 | PMID 42350220 |
| Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.Clinical genitourinary cancer · 2026 | not_reported | Hazard Ratio | 0.97 | PMID 42350220 |
| Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.Clinical genitourinary cancer · 2026 | not_reported | Hazard Ratio | 0.5 | PMID 42350220 |
| Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis.Clinical genitourinary cancer · 2026 | not_reported | Hazard Ratio | 0.56 | PMID 42150922 |
| Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis.Clinical genitourinary cancer · 2026 | not_reported | Hazard Ratio | 0.35 | PMID 42150922 |
| Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis.Clinical genitourinary cancer · 2026 | not_reported | Hazard Ratio | 0.3 | PMID 42150922 |
| From prevention to progression: can belzutifan-based strategies deliver across the RCC disease continuum?The oncologist · 2026 | overall survival | Hazard Ratio | 0.72 P = .0003 | PMID 42143718 |
| From prevention to progression: can belzutifan-based strategies deliver across the RCC disease continuum?The oncologist · 2026 | progression-free survival | Hazard Ratio | 0.7 | PMID 42143718 |
| From prevention to progression: can belzutifan-based strategies deliver across the RCC disease continuum?The oncologist · 2026 | progression-free survival | Percentage Comparison | 52.6percent vs 40.0percent | PMID 42143718 |
| Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.ESMO open · 2026 | not_reported | Odds Ratio | 6.0 | PMID 42127887 |
| Preoperative MRI Model for Predicting Inferior Vena Cava Wall Invasion in Renal Cell Carcinoma with Tumor Thrombus.Radiology. Imaging cancer · 2026 | not_reported | Odds Ratio | 2.64 | PMID 42313081 |
| Preoperative MRI Model for Predicting Inferior Vena Cava Wall Invasion in Renal Cell Carcinoma with Tumor Thrombus.Radiology. Imaging cancer · 2026 | not_reported | Odds Ratio | 3.64 | PMID 42313081 |
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
NCI NIH HHS159
National Natural Science Foundation of China53
Cancer Research UK14
National Natural Science Foundation of China (National Science Foundation of China)10
National Natural Science Foundation of China (NSFC)8
the National Natural Science Foundation of China7
Wellcome Trust7
NHLBI NIH HHS7
View records with declared financial or industry relationships 12
Economic and health impact of integrating smoking cessation services into NHS cancer care pathways in England: a modelling study.
MG, ETT, SH and RoM are employees of York Health Economics Consortium; their institution received consulting fees from Manchester University NHS Foundation Trust for undertaking this research. In the past 36 months, GW received a grant in a related field by the National Cancer Institute, royalties from the Medical University of South Carolina in an unrelated field, consulting fees from the Canadian Partnership Against Cancer, payment/honoraria (speaker fees) from nonprofit organizations, participated in data safety monitoring/advisory boards for Varian and non-profit universities, and worked as a medical, research and expertise consultant. RaM’s university received grants from Yorkshire Cancer Research (NOT414; RA/2023/R2/113), Cancer Research UK (PICATR-2022/100010), the UK Prevention Research Partnership (MR/S037519/1) and Horizon 2020 (ID: 848294). RaM also received a travel bursary from the International Association for the Study of Lung Cancer for travelling to a conference, participated in a data safety monitory/advisory board for the University of Birmingham, is a Trustee for the Action on Smoking and Health, and is a member of the Royal College of Physicians’ Tobacco Advisory Group. In the past 36 months, MC has received a grant/contract from Yorkshire Cancer Research and the National Institute for Health Research. Disclaimer: Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.
PMID 42824467 · 2026Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma.
Declaration of interests E.M.V.A. reports advisory/consulting relationships with Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Serinus Bio, and TracerDx. E.M.V.A. has received research support from Novartis, BMS, Sanofi, and NextPoint. E.M.V.A. holds equity in Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics, Serinus Bio, Syapse, and TracerDx. E.M.V.A. reports no travel reimbursement. E.M.V.A. is involved in institutional patents filed on chromatin mutations and immunotherapy response, as well as methods for clinical interpretation, and provides intermittent legal consulting on patents for Foaley & Hoag. E.M.V.A. serves on the editorial board of Science Advances. T.K.C. reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria within the past 5 years, ongoing or not, from Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, and CME events (including Peerview, OncLive, MJH, and CCO), outside of the submitted work. T.K.C. holds equity in Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura Therapeutics, and Primium. T.K.C. is involved in institutional patents filed on molecular alterations and immunotherapy response/toxicity and ctDNA. T.K.C. serves on committees including NCCN, GU Steering Committee, ASCO (Board of Directors 6-2024–), ESMO, ACCRU, and KidneyCan. Medical writing and editorial assistance support may have been funded by communications companies in part. T.K.C. reports no speaker's bureau. T.K.C. has mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/foreign components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding from drug companies and/or royalties potentially involved in research around the subject matter. T.K.C. is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School, the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund, and the Loker Pinard Funds for Kidney Cancer Research at DFCI. D.A.B. reports share options in Elephas; advisory board, consulting, or personal fees from Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post and Harborside, Targeted Oncology, Merck, Pfizer, MedScape, Accolade 2nd MD, DLA Piper, AbbVie, Compugen, Link Cell Therapies, Scholar Rock, NeoMorph, Nimbus, Exelixis, AVEO, Eisai, Daiichi Sankyo, and Elephas; and research support from Exelixis and AstraZeneca, outside of the submitted work. J.J.I. reports the following relationships: personal fees from Related Sciences (consulting), Danger Bio (consulting/equity), Phenomic AI (consulting/equity), Kronos Bio (equity), and grants from AstraZeneca (sponsored research agreement) outside of the submitted work. Z.B. reports honoraria from UpToDate and serves as an Associate Editor at Journal of Clinical Oncology: Clinical Cancer Informatics (JCO CCI). Z.B. reports non-financial (volunteer, unpaid) activities, including serving as co-chair of the American Society of Clinical Oncology’s International Medical Graduate Community of Practice (ASCO IMG CoP) and as co-founder of the IMG Oncologists nonprofit non-governmental organization. E.S. reports research funding from Roche/Genentech. C.L. reports research funding from Roche/Genentech. K.M. is currently an employee of RBC Capital Markets.
PMID 41175876 · 2025Real-world comparative outcomes of first-line immune combinations (ICI-ICI vs ICI-TKI) in metastatic renal cell carcinoma with sarcomatoid features.
Rebuzzi reports honoraria, travel fees from BMS, Ipsen, Eisai, Astellas, Amgen, GSK. Buti reports advisory roles from AstraZeneca, BMS, Ipsen, Merck, Eisai, MSD, Novartis, Gentili, Astellas, Pfizer, research funding from Novartis, Pfizer. Lolli reports honoraria, travel fees from MSD, Ipsen, BMS, Johnson&Johnson, Merck. Dalla Volta reports consultation fees from Astellas, Bayer, BMS, MSD, Ipsen, travel fees from Ipsen. Bonomi reports honoraria from AstraZeneca, BMS, Ipsen, MSD, travel fees from Ipsen, Janssen. Maiorano reports consulting roles for Astellas, AstraZeneca, Ipsen, Johnson&Johnson, Merck; speaker honoraria from AstraZeneca, Bayer, BMS, Ipsen, Johnson&Johnson, Merck, MSD; travel fees from Ipsen, Johnson&Johnson, Merck; institutional research funding from Merck. Tondulli reports consultation fees, travel fees from Roche, Servier, BMS, Merck-Serono, Novartis, Janssen-Cilag, Sanofi. Conteduca reports consultancy roles for Johnson&Johnson, Astellas, Merck, AstraZeneca, Amgen, Eisai, Recordati, GSK, Novartis, Ipsen, Bayer, speaker honoraria, travel fees from Astellas, Johnson&Johnson, Ipsen, Bayer, GSK, Gilead, Novartis, BMS. Vitale reports consulting roles for Angelini, BMS, Johnson&Johnson, speaker roles for BMS, Ipsen, MSD, Astellas, Eisai, Recordati, Johnson&Johnson, AstraZeneca. Bronte reports honoraria or consultation fees from Novartis, Pierre Fabre, Eisai, Ipsen, BMS, MSD, travel fees from MSD, Pierre Fabre. Tucci reports consultation fees from BMS, MSD, Ipsen, Astellas, Novartis, Janssen, Bayer, Eisai. Scagliarini reports advisory roles from BMS, MSD, Ipsen, Merck, Eisai, Astellas, Johnson&Johnson, Gentili, Novartis. Caserta reports consulting roles from Astellas, Novartis, Merck, AstraZeneca, MSD. Bimbatti reports advisory roles, travel grants from Ipsen, Astellas, Janssen, MSD, Gentili, Eisai, Bayer, Merck, AstraZeneca, Novartis.
PMID 42912018 · 2026Efficacy and safety of single-fraction stereotactic body radiotherapy (SBRT) for the curative treatment of extracranial primary Tumors: A collaborative systematic review on behalf of the SBRT Focus Group of the European Society for Radiotherapy & Oncology (ESTRO).
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Francesco Cuccia: speaker honoraria and research grants from Accuray; J. Hörner-Rieber: speaker honoraria: ViewRay Inc., Pfizer Inc., Accuray Sarl, Sanofi, and Astra Zeneca, travel grants: Varian Medical Systems, research grants: IntraOP Medical and Varian Medical Systems outside the submitted work.].
PMID 42898625 · 2027Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Rana R. McKay . Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion Therapeutics, Calithera Biosciences, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seagen, Telix Pharmaceuticals, Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, AstraZeneca, Myovant Sciences, Precede Bio. Research Funding: Bayer (Inst), Tempus (Inst), AstraZeneca (Inst), Exelixis (Inst), Bristol Myers Squibb (Inst), Oncternal Therapeutics (Inst), Artera (Inst). Karla V. Ballman . This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Consulting or Advisory Role: GlaxoSmithKline. Expert Testimony: Janssen. Archana Ajmera . Honoraria: NCCN. Consulting or Advisory Role: Janssen Biotech. Tareq Al Baghdadi . Stock and Other Ownership Interests: Bristol Myers Squibb. Honoraria: Cardinal Health. Consulting or Advisory Role: Bristol Myers Squibb, AstraZeneca, Cardinal Health, Genentech/Roche. Brian C. Baumann . Stock and Other Ownership Interests: Myovant Sciences. Honoraria: Mevion Medical Systems, Varian Medical Systems, Boston Scientific. Consulting or Advisory Role: Sanofi/Regeneron, Sanofi/Regeneron (I), Galera Therapeutics, Boston Scientific, Varian Medical Systems, Myovant Sciences, Blue Earth Diagnostics, Novartis. Speakers' Bureau: Boston Scientific. Research Funding: Varian Medical Systems (Inst). Himisha Beltran . Consulting or Advisory Role: AstraZeneca, Pfizer, Daiichi Sankyo, Bayer, Sanofi, Merck, Novartis. Research Funding: Bristol Myers Squibb Foundation (Inst), Daiichi Sankyo (Inst), Novartis (Inst), Circle Pharma (Inst). Travel, Accommodations, Expenses: Janssen Oncology. Stephanie Berg . Honoraria: Aptitude Health, Curio Science. Consulting or Advisory Role: Eisai, Exelixis, Zencor, J&J, AstraZeneca, Daiichi Sankyo/AstraZeneca. Research Funding: Pfizer (Inst). Ronald C. Chen . Employment: University of Kansas Medical Center. Consulting or Advisory Role: Medivation/Astellas, Accuray, Bayer, Blue Earth Diagnostics, Accuray, AbbVie, Myovant Sciences, Genentech, Pfizer, Astellas Pharma, Janssen, VIR Biotechnology. Research Funding: Accuray. Travel, Accommodations, Expenses: Telix Pharmaceuticals, RefleXion Medical. Atish D. Choudhury . Employment: LeMaitre Vascular (I). Honoraria: Targeted Oncology, Aptitude Health, Pfizer, Lantheus Medical Imaging, Wiley, Color Genomics, Physicians' Education Resource, Outcomes4Me, DAVA Oncology, Medscape, MDoutlook, Conexiant, Oncology Learning Network, MECC Global Meetings, Curio Science, Total Health, Bayer. Consulting or Advisory Role: Pfizer, Astellas Pharma, Bayer, Pfizer, Daiichi Sankyo, Boundless Bio, Johnson & Johnson/Janssen, Tolmar, Novartis, Bayer. Research Funding: Pfizer (Inst), Lilly (Inst), Sumitomo Pharma Oncology (Inst), Bayer (Inst), Pfizer (Inst), Merck (Inst). Travel, Accommodations, Expenses: Astellas Pharma, Bayer, Novartis, MECC Global Meetings, Oncology Learning Network. Open Payments Link: https://openpaymentsdata.cms.gov/physician/145387. Suzanne Cole . Research Funding: Merck (Inst). Heather A. Jacene . Consulting or Advisory Role: Luminance Biosciences. Research Funding: Blue Earth Diagnostics (Inst), Lantheus Medical Imaging (Inst), Boston Scientific (I). Travel, Accommodations, Expenses: Abbott Laboratories (I), Abiomed (I), Medtronic (I), Biotronik International (I). Open Payments Link: https://openpaymentsdata.cms.gov/physician/1095124. Joshua M. Lang . Leadership: Eolas Diagnostics, INC. Stock and Other Ownership Interests: Eolas Diagnostics, INC. Consulting or Advisory Role: Sanofi, Janssen, Pfizer/Astellas, Gilead Sciences, Arvinas, Pfizer/Myovant, 4D Pharma, AstraZeneca, Pfizer, MacroGenics, Foundation Medicine, Daiichi Sankyo/AstraZeneca, Bayer. Research Funding: Medivation (Inst), Agensys (Inst), GlaxoSmithKline (Inst), Immunomedics (Inst), Bristol Myers Squibb (Inst), Janssen (Inst), Gilead Sciences (Inst), Arvinas (Inst). Patents, Royalties, Other Intellectual Property: I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC, although no commercial products are available. Deepak Kilari . Honoraria: Exelixis. Consulting or Advisory Role: Exelixis, Pfizer, Eisai, Janssen Oncology, Foundation Medicine, Aptitude Health, MJH Life Sciences, Cardinal Health, IntegraConnect, Curio Science. Speakers' Bureau: Janssen, Exelixis, Astellas Pharma, AVEO, Eisai, MJH Life Sciences. Research Funding: Astellas Pharma (Inst), Exelixis (Inst), Genentech (Inst). Travel, Accommodations, Expenses: Exelixis, Janssen, Astellas Pharma, AVEO. Bradley McGregor . Consulting or Advisory Role: Exelixis, Astellas Pharma, Pfizer, Eisai, Bristol Myers Squibb, Gilead Sciences, Arcus Biosciences, Loxo/Lilly, Daiichi Sankyo/AstraZeneca, Genmab, AVEO, Hexagon, AstraZeneca, Merck. Research Funding: Bristol Myers Squibb (Inst), Exelixis (Inst), Seattle Genetics/Astellas (Inst), Pfizer (Inst), Gilead Sciences (Inst), AVEO (Inst). Michael J. Morris . Employment: Memorial Sloan-Kettering Cancer Center. Stock and Other Ownership Interests: Doximity. Consulting or Advisory Role: Flare Therapeutics, Transtherabio, Mashup Media, Amgen, Molecular Partners, Wren Laboratories, Isotopia, Actinium Pharmaceuticals, Sofinnova, ARTbio, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, AdvanCell. Research Funding: Janssen (Inst), Novartis (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst). Patents, Royalties, Other Intellectual Property: Telix Pharmaceuticals (Inst). Travel, Accommodations, Expenses: APCCC, Memorial Sloan-Kettering Cancer Center, AbbVie, Amgen. Uncompensated Relationships: Bayer, Janssen Oncology, Novartis, Amgen, Halda Therapeutics. Mamta Parikh . Consulting or Advisory Role: Pfizer, Exelixis, Bicycle Therapeutics, Lilly, AstraZeneca. Research Funding: Karyopharm Therapeutics (Inst), Gilead Sciences, Lilly (Inst). Umang Swami . This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Consulting or Advisory Role: Astellas Pharma, Exelixis, AstraZeneca, Pfizer, Gilead Sciences, Adaptimmune, Janssen Scientific Affairs, Flatiron Health, Kairos Therapeutics, Merck. Research Funding: Janssen (Inst), Seattle Genetics/Astellas (Inst), Exelixis (Inst), Merck (Inst), Loxo/Lilly (Inst), LAVA Therapeutics (Inst), ORIC Pharmaceuticals (Inst), Seagen (Inst), Pfizer/Astellas (Inst), AstraZeneca (Inst). Alan Tan . Employment: Tempus. Leadership: Tempus. Honoraria: Exelixis, Aveo. Speakers' Bureau: Exelixis, AVEO. Yuanquan A. Yang . Stock and Other Ownership Interests: Pfizer. Consulting or Advisory Role: The WhiteOak Group, Exelixis, Xencor, Cardinal Health. Speakers' Bureau: AstraZeneca. Research Funding: Incyte (Inst), Novartis (Inst), Amgen (Inst), Recordati (Inst), Xencor (Inst). Tian Zhang . Leadership: Capio BioSciences (I), Archimmune Therapeutics (I). Stock and Other Ownership Interests: Capio Biosciences (I), Archimmune Therapeutics (I). Honoraria: MJH Life Sciences, Aptitude Health, Curio Science, PeerView, Clinical Care Options, Mashup Media, Dava Oncology. Consulting or Advisory Role: Exelixis, Pfizer, Bristol Myers Squibb, Eisai, Bayer, Lilly, AVEO, Merck, Novartis, Gilead Sciences, EMD Serono, AstraZeneca, Loxo/Lilly, Xencor, Johnson & Johnson/Janssen, Dendreon, Summit Therapeutics, Arcus Biosciences. Research Funding: Loxo/Lilly (Inst), Tempus (Inst), Pfizer (Inst), ALX Oncology (Inst), Exelixis (Inst), OncoC4, Astellas Pharma (Inst), Janssen (Inst), Janux Therapeutics (Inst), Bayer (Inst), Kura Oncology (Inst), Merck (Inst), Daiichi Sankyo/AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: Circulating tumor cell novel capture by c-MET technology (Inst), Prochelators as Targeted Prodrugs for Prostate Cancer (Inst). Travel, Accommodations, Expenses: Janux Therapeutics, Johnson & Johnson/Janssen, Kura Oncology. Other Relationship: ASCO, Kidney Cancer Association, KidneyCan, Myrovlytis Trust, Winn Foundation. Matthew Galsky . Consulting or Advisory Role: Janssen, Merck, Bristol Myers Squibb, Pfizer, EMD Serono, Gilead Sciences, AbbVie. Research Funding: Janssen Oncology (Inst), Dendreon (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Merck (Inst), AstraZeneca (Inst), Genentech/Roche (Inst). Patents, Royalties, Other Intellectual Property: METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792. Jonathan Rosenberg . Honoraria: Astellas Pharma, Merck. Consulting or Advisory Role: Lilly, Merck, Roche/Genentech, Bristol Myers Squibb, Seagen, Bayer, Astellas Pharma, Boehringer Ingelheim, Tyra Biosciences, Gilead Sciences, AstraZeneca, EMD Serono, Pfizer, Generate Biomedicines, Aktis Oncology, Samsung Bioepis, Johnson & Johnson/Janssen, Domain Therapeutics, Summit Therapeutics. Research Funding: Astellas Pharma (Inst), Acrivon Therapeutics, Lilly, Pfizer, Bristol Myers Squibb. Patents, Royalties, Other Intellectual Property: Predictor of platinum sensitivity (Inst), Amplification of chromosome 1q23 to predict cancer outcomes (Inst). Travel, Accommodations, Expenses: Astellas Pharma, Merck. Uncompensated Relationships: Alliance for Clinical Trials in Oncology, KaliVir Immunotherapeutics. Daniel George . Leadership: Capio BioSciences. Stock and Other Ownership Interests: Pfizer, BMS. Honoraria: Bayer, OncLive, Pfizer, UroToday, Axess Oncology, Janssen Oncology, Millennium Medical Publishing, Novartis, AstraZeneca, Eisai, IDEOlogy Health, Merck, Astellas Pharma, Sumitomo, Candel Therapeutics. Consulting or Advisory Role: Bayer, Pfizer, Astellas Pharma, Janssen, Merck Sharp & Dohme, AstraZeneca, Michael J. Hennessy Associates, Physicians' Education Resource, Novartis, Candel Therapeutics. Research Funding: Exelixis (Inst), Janssen Oncology (Inst), Novartis (Inst), Pfizer (Inst), Astellas Pharma (Inst), Bristol Myers Squibb (Inst), Bayer (Inst), Merck (Inst), Corvus Pharmaceuticals (Inst), Bayer (Inst), AstraZeneca (Inst), Convergent Therapeutics (Inst). Expert Testimony: Exelixis. Travel, Accommodations, Expenses: Exelixis, Pfizer, Novartis, Bayer, Merck. Toni K. Choueiri . Leadership: ASCO. Stock and Other Ownership Interests: Precede Bio, Osel, Tempest Therapeutics, Pionyr, Curesponse, Inndura, Primium, Abalytics Oncology, Bicycle Therapeutics, Faron Pharmaceuticals. Honoraria: HiberCell, Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, AstraZeneca, Exelixis, Prometheus, Ipsen, Sanofi/Aventis, Peloton Therapeutics, UpToDate, NCCN, Michael J. Hennessy Associates, Analysis Group, Clinical Care Options, PlatformQ Health, Navinata Health, Harborside Press, ASCO, The New England Journal of Medicine, Lancet Oncology, EMD Serono, Lilly, Tempest Therapeutics, Arcus Biosciences, Alkermes, Gilead Sciences, Scholar Rock, Janssen Oncology, Precede Bio, Aravive, Infinity Pharmaceuticals, ESMO, NiKang Therapeutics, Kanaph Therapeutics, Gilead Sciences, MashupMD. Consulting or Advisory Role: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, AstraZeneca, Exelixis, Prometheus, Ipsen, Sanofi/Aventis, Peloton Therapeutics, UpToDate, NCCN, Michael J. Hennessy Associates, Analysis Group, Clinical Care Options, PlatformQ Health, Navinata Health, Harborside Press, ASCO, The New England Journal of Medicine, Lancet Oncology, EMD Serono, Lilly, Tempest Therapeutics, alkermes, Gilead Sciences, Scholar Rock, Janssen Oncology, Precede Bio, Aravive, Infinity Pharmaceuticals, ESMO, NiKang Therapeutics, Kanaph Therapeutics, Gilead Sciences, Neomorph, Arcus Biosciences, Curesponse, Bicycle Therapeutics, Caris Life Sciences. Research Funding: Pfizer (Inst), Novartis (Inst), Merck (Inst), Exelixis (Inst), TRACON Pharma (Inst), GlaxoSmithKline (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst), Peloton Therapeutics (Inst), Roche/Genentech (Inst), Agensys (Inst), Eisai (Inst), Takeda (Inst), Ipsen (Inst), Seattle Genetics/Astellas (Inst), Bayer (Inst), Roche (Inst), Calithera Biosciences (Inst), NiKang Therapeutics (Inst), Arcus Biosciences (Inst), AVEO (Inst). Patents, Royalties, Other Intellectual Property: International Patent Application No. PCT/US2018/058430, titled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst),” International Patent Application No. PCT/US2018/12209, titled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst),” ctDNA Technologies. Travel, Accommodations, Expenses: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, Cerulean Pharma, AstraZeneca, Exelixis, Prometheus, alligent, Ipsen, Corvus Pharmaceuticals, Lpath, Alexion Pharmaceuticals, Sanofi/Aventis, UpToDate, Peloton Therapeutics, NCCN, Michael J. Hennessy Associates, Analysis Group, Kidney Cancer Association, Clinical Care Options, PlatformQ Health, Harborside Press, Navinata Health, The New England Journal of Medicine, Lancet Oncology, EMD Serono, HERON, Lilly, ESMO. Other Relationship: Other Medical Communication Companies. Uncompensated Relationships: AACR Scientific Advisory Council. No other potential conflicts of interest were reported.
PMID 42507969 · 2026Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Samer A. Srour . Consulting or Advisory Role: Novartis. Travel, Accommodations, Expenses: Allogene Therapeutics. Jad Chahoud . Consulting or Advisory Role: AVEO, DAVA Pharmaceuticals, Pfizer, Exelixis, Eisai, Merck. Research Funding: Pfizer (Inst), Exelixis (Inst), Allogene Therapeutics (Inst), Merck (Inst), AB Science (Inst), Xilio Therapeutics (Inst). Alexandra Drakaki . Employment: Athos Therapeutics (I), Attica Sciences (I), Dyania Health (I). Leadership: Athos Therapeutics (I), Attica Sciences (I). Stock and Other Ownership Interests: Urogen Pharma (I), Kynan Therapeutics (I), Athos Therapeutics (I), Attica Sciences, Dyania Health (I), Moderna Therapeutics (I), Proteas Bioanalytics (I). Honoraria: AstraZeneca. Consulting or Advisory Role: Bristol Myers Squibb, AstraZeneca, Radmetrix, Seagen, Janssen, PACT Pharma, Merck, Roche/Genentech, Exelixis, Dyania Health, Aveo, EMD Serono, Loxo/Lilly, Infinity Pharmaceuticals, Daiichi Sankyo. Research Funding: Kite/Gilead, AstraZeneca (Inst), Genentech/Roche (Inst), BMS (Inst), Merck Sharp & Dohme (Inst), Jounce Therapeutics (Inst), Infinity Pharmaceuticals (Inst), Seattle Genetics/Astellas (Inst), Immunomedics/Gilead (Inst), Pfizer (Inst). Patents, Royalties, Other Intellectual Property: My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I). Travel, Accommodations, Expenses: Lilly, AstraZeneca, Seagen. Brendan D. Curti . Consulting or Advisory Role: Merck, AstraZeneca, Iovance Biotherapeutics. Research Funding: Bristol Myers Squibb (Inst), Ankyra Therapeutics (Inst), AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: Biomarkers for OX40 response (Inst). Geoffrey T. Gibney . Consulting or Advisory Role: Merck, Iovance Biotherapeutics, HUYA Bioscience International, Immunocore, Replimune. Speakers' Bureau: Immunocore. Research Funding: Exelixis (Inst). Lily Tang . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Yizhou Jiang . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Sara Charmsaz . Employment: Sonoma Biotherapeutics, Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics, Sonoma Biotherapeutics. Paul B. Robbins . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Jeffrey McLeroy . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Travel, Accommodations, Expenses: Allogene Therapeutics. Christopher J. Severyn . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. John B. Le Gall . Employment: Instil Bio, Allogene Therapeutics. Stock and Other Ownership Interests: Johnson & Johnson/Janssen, Allogene Therapeutics. Patents, Royalties, Other Intellectual Property: TIL patents pending. Uncompensated Relationships: CRM Nepal. Zachary J. Roberts . Employment: Allogene Therapeutics. Leadership: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Travel, Accommodations, Expenses: Allogene Therapeutics. Nizar M. Tannir . Stock and Other Ownership Interests: Amgen, Johnson & Johnson/Janssen, Vanguard Health Care, SPDR S&P Pharmaceuticals ETF, AbbVie, Gilead Sciences, Pfizer, Coherus BioSciences, ImmunityBio, ABSCI, Allogene Therapeutics, Cabaletta Bio, Moderna Therapeutics, Arcus Biosciences, Summit Therapeutics. Honoraria: Bristol Myers Squibb, Eisai, Merck Sharp & Dohme, Oncorena, Ipsen, Nektar, Exelixis. Research Funding: Bristol Myers Squibb (Inst), Nektar (Inst), Novartis (Inst), Calithera Biosciences (Inst), Arrowhead Pharmaceuticals Inc (Inst), Oncorena (Inst), Pfizer (Inst). Sumanta Pal . Speakers' Bureau: MJH Life Sciences, IntrinsiQ, PeerView. Research Funding: Exelixis (Inst), Merck (Inst), Osel (Inst), Genentech (Inst), CRISPR therapeutics (Inst), Adicet Bio (Inst), ArsenalBio (Inst), Xencor (Inst), MIYARISAN pharmaceutical (Inst). Travel, Accommodations, Expenses: CRISPR Therapeutics, Ipsen, Exelixis. Open Payments Link: https://openpaymentsdata.cms.gov/physician/259259. Ritesh R. Kotecha . Consulting or Advisory Role: Eisai, Eisai, Guidepoint Inc, Merck. Research Funding: Pfizer (Inst), Takeda (Inst), Novartis (Inst), Allogene Therapeutics (Inst), Exelixis (Inst), Xencor (Inst), ArsenalBio (Inst). No other potential conflicts of interest were reported.
PMID 42447427 · 2026Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
Competing interests: P.J.N. had research funding from Roche Genentech, B.M.S., M.S.D., CRISPR Therapeutics and Beigene. S.S. had research funding from M.S.D., Varian, Bayer Pharmaceuticals and speaker honoraria from Accuray.
PMID 42420295 · 2026Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
Conflict of Interest Disclosures: Dr Pedrosa reported serving as an advisor for Health Tech International Warrants outside the submitted work. Dr Garant reported personal fees from Teleflex Medical, travel support from Naslund Medical, and grants from Elekta outside the submitted work. Dr Margulis reported serving as a consultant for Merck, Johnson & Johnson, Veracyte, and Lantheus outside the submitted work. No other disclosures were reported.
PMID 42879162 · 2026Early dynamics of eosinophils and the neutrophil-to-lymphocyte ratio are associated with severe immune-related adverse events during nivolumab therapy for metastatic renal cell carcinoma.
OF received honoraria from Novartis, Janssen, Merck, Ipsen, BMS, MSD, Pierre Fabre, and Pfizer for consultations and lectures unrelated to this project. JKo has received consulting fees from Bristol Myers Squibb, Novartis, Pfizer, Merck, MSD, Ipsen; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, MSD, Merck, Novartis and Pfizer. All of the above are unrelated to the present paper. MV has received consulting fees from Merck, Roche, MSD; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from BMS, MSD, Merck, Novartis, AstraZeneca, Roche and Pfizer. All of the above are unrelated to the present paper. TB has received research support: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Merck KGaA, MSD, and Novartis; consulting fees from Bristol Myers Squibb, Astellas, Janssen, and Sanofi/Aventis; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, AstraZeneca, Roche, Servier, Accord, MSD, and Pfizer. All unrelated to the present paper. HŠ has received consulting fees from Bristol Myers Squibb, MSD, Ipsen, Novartis, Astellas and Janssen; payment or honoraria for lectures, presentations, speakers’ bureaus, or educational events from Ipsen, Merck, Bristol Myers Squibb, Novartis, MSD, and Pfizer. All of the above are unrelated to the present paper. JO has received payment for speakers’ bureaus, presentations, lectures or educational events from MSD, Astellas, Bayer, and Ipsen and Janssen. All the above are unrelated to this paper. MM has received consulting fees from Novartis, MSD, Astellas; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, BMS, MSD, Merck, Novartis, Eisa, AstraZeneca, Roche and Pfizer. All of the above are unrelated to the present paper. RL has received payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Roche, Janssen, Bristol Myers Squibb, MSD and Merck. All of the above are unrelated to the present paper. BM received honoraria from Novartis, Pfizer, Bayer-Schering, Astellas, and Roche for lectures and advisory boards unrelated to this project. PPa has received consulting fees from Bristol Myers Squibb, Astellas, Pfizer and Merck; payment for speakers’ bureaus, presentations, lectures or educational events from Bayer, MSD, Novartis, Ipsen, Janssen, Bristol Myers Squibb, Merck, Astellas and Pfizer. All the above are unrelated to this paper. AP has received consulting fees from Bristol Myers Squibb, Roche, Eisai, Astellas, Johnson & Johnson, Zentiva, Novartis, Pfizer, Merck, MSD, Ipsen; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Bristol Myers Squibb, MSD, Merck, Novartis, Eisai, Astellas, Johnson & Johnson and Pfizer. All of the above are unrelated to the present paper. The remaining author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
PMID 42935928 · 2026Understanding the Challenges of Refractory Chronic Cough: Insights from a Knowledge, Attitudes, and Practices Survey of US Healthcare Professionals.
Declarations. Conflict of Interest: Suvapun Bunniran, Christine Henning, and Bhavini Parikh are all employed by GSK and hold financial equities in GSK. Eric Davenport, Carolyn Sweeney, and Sarah Calhoun are all employed by RTI Health Solutions and received funding from GSK to conduct the research summarized in this publication. Kaiser G. Lim served as a consultant for GSK and received consulting fees. Ethical Approval: This study complied with all applicable laws regarding subject privacy, including the Helsinki Declaration of 1964, and its later amendments. The RTI Office of Research Protection determined that this study met the criteria for exemption from institutional board review on October 22, 2024, as the types of questions asked did not relate to specific procedures or topics of a sensitive nature whose disclosure might be potentially damaging to reputation. Respondents were anonymized in the survey; study results are in tabular form and presented as aggregate analyses that omit subject identification. Eligible respondents were required to read an informed consent form (ICF) and provide electronic acknowledgment of consent before proceeding to the survey questions. The ICF specified that de-identified data would be provided to the study sponsor in aggregate only and would not be linked to individual respondents. The study sponsor was blinded in the ICF.
PMID 42934378 · 2026Moving Beyond Responders: A Post Hoc Analysis Identifying Criteria for Chronic Cough Control.
Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: N. D. was supported by Sanofi Genzyme, Canada, and reports payment or honoraria for lectures, presentations, manuscript writing, or educational events from AstraZeneca and Sanofi-Regeneron outside the submitted work. D. B. reports consultancy fees from Khure Health; payment or honoraria for lectures, presentations, manuscript writing, or educational events from AstraZeneca, Glaxo Smith Kline, and Sanofi-Regeneron; support for attending meetings from GSK; participation on a data safety monitoring board or advisory board with GSK and Sanofi; and participation in the Chronic Cough Working Group. W. H. reports consultancy fees from GSK for participation on advisory boards. R. S. received grants from AstraZeneca, Biohaven, Third Harmonics Bio, and Jasper; consultancy fees from AstraZeneca and Areteia Therapeutics, Inc.; and payment or honoraria for lectures, presentations, manuscript writing, or educational events from AstraZeneca and GSK. G. M. G. reports research funding from AstraZeneca, Genentech, Third Harmonics Bio, Biohaven, and Jasper paid to the institution and personal fees from AstraZeneca, Third Harmonics Bio, Allakos, Biohaven, Jasper, and Blueprint. P. M. O. reports grants from AstraZeneca, Merck, Biohaven, and Jasper; consultancy fees from AstraZeneca, GSK, Sage, Teva, and Affibody; payment or honoraria for lectures, presentations, manuscript writing, or educational events from AstraZeneca, GSK, and Covis; and serving as a section editor for the European Respiratory Journal. I. S. is supported by the Canada Research Chair program and reports grants from Merck, MITACS, GSK, Bellus, Trevi Therapeutics, Bayer, and Genentech; consultancy fees from Merck, GSK, Bellus, Sanofi-Regeneron, Methapharm, and Nocion; and payment or honoraria for lectures, presentations, manuscript writing, or educational events from Merck, GSK, AstraZeneca, Vitalograph, and Sanofi-Regeneron. None declared (M. W., E. K., A. O., S. B., C. S., J. W., L. W., K. H., K. K.).
PMID 42140485 · 2026A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.
Jad Chahoud has received advisory board or consultancy fees during his lifetime from Merck, Pfizer, Exelixis, Aveo, Eisai, and Mycaregorythm. Jad Chahoud was an editor for PDQ NCI. Jad Chahoud received honorarium for non-branded educational programs supported by DAVA Oncology and MJH Life Sciences. Jad Chahoud has received research funding during his lifetime (to Jad Chahoud’s institution) from Allogene, Astellas, Bristol Meyers, Eisai, Eli Lilly, Exelixis, Genentech, Merck, and Pfizer. Jad Chahoud is the co-founder of AI-OS LLC. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
PMID 42719952 · 202601
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
International journal of radiation oncology, biology, physics · 2026
PMID 41580163Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.
The Lancet. Oncology · 2025
PMID 41038202What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026
PMID 42373875Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer · 2026
PMID 41871874Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.
ESMO open · 2026
PMID 42914499[Update renal cell carcinoma : Guideline update on small renal masses].
Urologie (Heidelberg, Germany) · 2026
PMID 42726211SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
PMID 41067863Updated 2025 French guidelines for renal cell carcinoma.
The French journal of urology · 2025
PMID 41109639Kidney transplantation from donors with cancer or history of cancer: Transplantation and cancerology committee of Association Française d'Urologie guidelines (CTAFU/CCAFU).
The French journal of urology · 2025
PMID 41271370Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology).
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025
PMID 40934605Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.
World journal of urology · 2026
PMID 42604476Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
PMID 4083577302
Highest-Priority Research
Performance of Machine Learning Models Based on Medical Imaging in Predicting Pathological Grade of Clear Cell Renal Cell Carcinoma.
Cancer medicine · 2026
BACKGROUND: Predicting clear cell renal cell carcinoma (ccRCC) pathological grade preoperatively is critical for clinical management. This study aims to evaluate the diagnostic accuracy and clinical utility of machine learning (ML)-based imaging models. METHODS: The Cochrane Library, PubMed, Embase, and Scopus databases were searched systematically for studies published before January 2026. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 and the Radiomics Quality Score. Pooled sensitivity, specificity, positive/negative likelihood ratios (PLRs/NLRs), diagnostic scores, diagnostic odds ratios (DORs), and summary receiver operating characteristic (SROC)…
PMID 42693958International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
International journal of radiation oncology, biology, physics · 2026
PURPOSE: Stereotactic ablative body radiation therapy (SABR) is an emerging indication for localized renal cell carcinoma (RCC), yet there is a need for standardizing contouring practices, as accurate target delineation is essential to ensure optimal outcomes. Our objective was to develop consensus guidelines for target volume contouring for RCC SABR. METHODS AND MATERIALS: An international panel of RCC SABR experts affiliated with IROCK was convened. All were asked to contour target volumes for 4 relevant clinical scenarios: a large tumor (>10 cm) with inferior vena cava tumor thrombus; a central tumor abutting the renal hilum; a local recurrence following nephrectomy; and an ablation cavit…
PMID 41580163Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.
The Lancet. Oncology · 2025
Pathological response is a surrogate marker of efficacy of neoadjuvant therapy in various tumour types, but there is no consensus on reporting pathological response for renal cell carcinoma. We aimed to assess the status of pathological response reporting in renal cell carcinoma and develop a recommendation on tissue preparation and response reporting for neoadjuvant treatment. We conducted a systematic review of publications on the PubMed and Web of Science databases to identify manuscripts reporting response to pre-surgical therapy in renal cell carcinoma. 119 eligible papers were identified. Only five (4%) studies included details of how pathological response had been assessed. Qualitativ…
PMID 41038202Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.
Targeted oncology · 2026
BACKGROUND: Immune checkpoint inhibitor (ICI)-based regimens are the standard first-line therapy for advanced renal cell carcinoma (RCC). However, their comparative effectiveness and safety in routine clinical practice remain incompletely characterised. OBJECTIVE: The aim of this study was to systematically synthesise comparative real-world evidence on the efficacy and safety of ICI-based regimens in patients with advanced RCC. METHODS: A systematic search of MEDLINE, Embase, and Scopus was conducted from database inception to 21 January 2026, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Observational cohort studies evaluating…
PMID 42218357What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026
BACKGROUND AND OBJECTIVE: Renal cell carcinoma (RCC) is a common manifestation in Von-Hippel Lindau (VHL) syndrome, accounting for almost 30% of the patients. However, since VHL syndrome is relatively rare, there are no clear guidelines regarding the approach to VHL patients with RCC. This article aims to provide evidence-based insights for diagnosis, treatment, and surveillance in VHL patients with RCC. METHODS: The articles indexed between 1977 and 2025 in PubMed was searched. Only articles in English were included. RESULTS: Renal cysts are quite common in VHL patients and these cysts predispose for RCC. VHL patients are characterized with early-onset, multifocal and/or bilateral, recurren…
PMID 42373875Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer · 2026
Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number of patients, fully transforming the standard of care in first-line and subsequent-line settings. More recently, ICIs are also being used in the adjuvant setting for high-risk patients. However, treatment with ICIs requires a nuanced understanding of topics such as patient selection…
PMID 41871874Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.
ESMO open · 2026
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma (RCC) were published in May 2024 and adapted in December 2025 according to previously established standard methodology to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with RCC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with RCC representing the oncological societies of China [Chinese Society of Clinical Oncology (CSCO)], Indonesia [Indonesian Society of Hematology and Medical Oncolo…
PMID 42914499[Update renal cell carcinoma : Guideline update on small renal masses].
Urologie (Heidelberg, Germany) · 2026
Small renal masses (kidney tumors < 4 cm) are benign in up to 30% of cases and often exhibit slow growth, yet they are still frequently primarily managed by surgery. A tumor biopsy should be performed before initiating active surveillance. As up to 8% of renal tumors could have a hereditary component, risk factors such as a diagnosis before the age of 47 years old, bilateral or multifocal lesions and syndrome-associated extrarenal manifestations, should be systematically assessed and clarified by a genetic evaluation. In patients with clear cell renal cell carcinoma and intermediate-high or high recurrence risk, as well as in metastatic with no evidence of disease (MINED) cases, adjuvant tre…
PMID 42726211The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not been comprehensively characterized. METHODS: A systematic review was conducted following PRISMA guidelines. PubMed/MEDLINE, Google Scholar, ScienceDirect, Embase, Web of Science, a…
PMID 42611330SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
Anatomic imaging of renal masses provides limited information on the histology or likely aggressiveness of the tumor, leading to the use of invasive procedures such as renal mass biopsy or empiric partial or radical nephrectomy. Molecular imaging can assist in risk stratification of indeterminate renal masses, potentially contributing to optimal patient decision-making. Two primary approaches have been explored for renal mass molecular imaging. The first is the use of agents that target carbonic anhydrase IX (CAIX), a cell-surface protein that is over-expressed on clear cell renal cell carcinoma (ccRCC) and generally not expressed on other renal tumors. A recent phase III trial (ZIRCON) is w…
PMID 41067863Updated 2025 French guidelines for renal cell carcinoma.
The French journal of urology · 2025
The 2025 update of the French guidelines for localized renal cell carcinoma highlights several major advances. Renal biopsy reaffirms its central role in guiding therapeutic decisions and reducing overtreatment, with growing evidence supporting a broader "biopsy-all" strategy. Active surveillance is now established as a safe and effective option for small renal masses, including selected complex cystic lesions, providing oncological outcomes comparable to immediate intervention. Among alternative approaches, stereotactic body radiotherapy has emerged as a credible and well-tolerated treatment for medically inoperable patients. In hereditary syndromes, progress includes improved characterizat…
PMID 41109639Kidney transplantation from donors with cancer or history of cancer: Transplantation and cancerology committee of Association Française d'Urologie guidelines (CTAFU/CCAFU).
The French journal of urology · 2025
INTRODUCTION: Potential donors for transplantation are screened for malignancies that can be transmitted on to the recipient. The discovery of cancer or a history of cancer often leads to contraindications for organ donation, while in some cases the cancer transmission risk is very low. The current context of organ shortage leads us to reconsider the use of organs from donors with cancer or a history of cancer when the risk of transmission is minimal or less than the risk of death on the waiting list. The Transplantation Committee (CTAFU) in partnership with the Cancer Committee (CCAFU) of the Association Française d'Urology (AFU) were asked to publish guidelines for clinical practice concer…
PMID 4127137003
Latest Research — Last 24 Months
2027
Efficacy and safety of single-fraction stereotactic body radiotherapy (SBRT) for the curative treatment of extracranial primary Tumors: A collaborative systematic review on behalf of the SBRT Focus Group of the European Society for Radiotherapy & Oncology (ESTRO).
Clinical and translational radiation oncology · PMID 42898625
2027
Near-infrared spectroscopy for urine-based cancer detection: a systematic characterization of the analytical challenges of a complex biofluid matrix.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · PMID 42679547
2027
PI-AttnGAN: Physics-informed attention generative modeling for cross-modal FT-IR-to-Raman serum spectral reconstruction.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · PMID 42721811
2027
Not only as a Cullin3 ligase adaptor, SPOP may also act as a molecular bridge.
Genes & diseases · PMID 42871460
2026
Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma.
Annals of medicine · PMID 41566198
2026
Robot-assisted versus open partial nephrectomy in patients with a solitary kidney: a systematic review and meta-analysis of perioperative and functional outcomes.
Journal of robotic surgery · PMID 42934344
2026
Pan-cancer multi-omics machine learning defines a lactylation-associated immune-excluded tumor state with proteomic and experimental corroboration.
Computational biology and chemistry · PMID 42556016
2026
2026
Global Landscape of Clinical Studies Open to Enrollment in Carbon Ion Radiotherapy: A PTCOG Review.
International journal of particle therapy · PMID 42893060
2026
Association of AI-derived abdominal organ volumetry with postoperative outcomes in clear cell renal cell carcinoma: a multicentre study.
Annals of medicine · PMID 42723375
2026
2026
2026
2026
2026
FOXM1-mediated transcriptional activation of CILP2 promotes malignant phenotypes and EMT-associated remodeling in clear cell renal cell carcinoma.
Pathology, research and practice · PMID 42828966
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
preliminary evidence
partial nephrectomy
57 linked PMIDs953807 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, renal function, recurrence, overall survival, recurrence-free survival, disease-free survival
- Populations represented
- general population; localized; metastatic; localized; advanced; papillary renal cell carcinoma; metastatic
- Mechanism
- Limitations include modest cohort size, retrospective design, and predominant ultrasound guidance potentially affecting targeting accuracy We conducted a comprehensive search across four major electronic databases: PubMed, Embase, Web of Science, and the Cochrane Library, targeting studies published in English up to April 2024
preliminary evidence
Biomarkers, Tumor
57 linked PMIDs6790 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, recurrence, recurrence-free survival, mortality, progression-free survival
- Populations represented
- general population; clear cell renal cell carcinoma; advanced; clear cell renal cell carcinoma; advanced; papillary renal cell carcinoma; metastatic
- Mechanism
- The complex and context-dependent effects of dysregulated m6A modifications in urological cancers are described, along with the potential for aberrantly expressed m6A regulators to provide valuable diagnostic and prognostic biomarkers as well as new therapeutic targets Standardized analytical and reporting frameworks, coupled with validation in larger, well-characterized cohorts, are needed to accelerate clinical implementation of RCC metabolomic biomarkers and metabolism-informed targets
preliminary evidence
Immune Checkpoint Inhibitors
36 linked PMIDs14672 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, reported clinical outcomes, response rate, objective response rate, overall survival, progression-free survival, recurrence, disease-free survival
- Populations represented
- general population; metastatic; advanced; first-line; metastatic; first-line; localized; advanced
- Mechanism
- Mechanistically, this sequence aligns vascular reprogramming, antigen-specific priming, and checkpoint release, converting an immune-excluded tumor into a T-cell-dominated, cytotoxic niche Collectively, these findings identify temporal coordination as a critical determinant of therapeutic success and establish a mechanistically grounded framework for integrating vascular preconditionning, tumor-antigen vaccination, and PD-1 blockade as a curative immunotherapy strategy in renal carcinoma
preliminary evidence
radical nephrectomy
28 linked PMIDs12354 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence, mortality, overall survival, renal function, recurrence-free survival, disease-free survival
- Populations represented
- general population; metastatic; localized; advanced; clear cell renal cell carcinoma; CAIX; locally advanced; advanced; metastatic
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Nivolumab
17 linked PMIDs1611 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, reported clinical outcomes, objective response rate, response rate, overall survival, progression-free survival, disease-free survival
- Populations represented
- metastatic; metastatic; first-line; metastatic; first-line; second-line; advanced; clear cell renal cell carcinoma; general population
- Mechanism
- Antibodies targeted against immune checkpoint inhibitors such as anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab), anti-CTLA-4 antibodies (e.g., Ipilimumab), and experimental drugs targeting LAG-3 and TIM-3, aim to block these interactions and unleash the immune system's ability to recognise and destroy cancer cells BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC)
preliminary evidence
pembrolizumab
13 linked PMIDs5260 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, overall survival, recurrence, reported clinical outcomes, disease-free survival, progression-free survival, objective response rate, response rate
- Populations represented
- advanced; metastatic; clear cell renal cell carcinoma; localized; metastatic; general population; clear cell renal cell carcinoma; locally advanced; advanced; metastatic; first-line; PD-L1
- Mechanism
- Preliminary data suggest inhibition of Receptor Activator of Nuclear Factor-κB Ligand (RANKL) signaling may potentiate ICI efficacy PY314 is a humanized monoclonal antibody targeting TREM2 that depletes tumor-associated macrophages
moderate-confidence evidence
Antineoplastic Agents
13 linked PMIDs596 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence, progression-free survival, objective response rate, response rate, adverse events, serious adverse events
- Populations represented
- general population; papillary renal cell carcinoma; advanced; metastatic; clear cell renal cell carcinoma; clear cell renal cell carcinoma; advanced
- Mechanism
- Renal tumour targeting is mediated by the preferential binding of zinc ions to metallothionein-1X proteins, which are constitutively overexpressed in Caki-2 renal tumour cells BACKGROUND: Dysregulated cholesterol metabolism is a hallmark of clear cell renal cell carcinoma (ccRCC), but therapeutic strategies targeting this vulnerability remain limited
preliminary evidence
Protein Kinase Inhibitors
11 linked PMIDs3448 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, overall survival, progression-free survival, objective response rate, response rate, reported clinical outcomes, disease-free survival
- Populations represented
- advanced; advanced; first-line; general population; metastatic; advanced; metastatic; older adults; metastatic; first-line
- Mechanism
- Our goal was to repurpose known fluorescent ligands, originally developed for other targets, to study EGFR expression at the kidney cell membrane in healthy and diseased conditions, providing a potential tool for disease detection and staging BACKGROUND: Targeting of angiogenesis has become a major therapeutic approach for the treatment of various advanced cancers
preliminary evidence
ipilimumab
9 linked PMIDs381 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, progression-free survival, disease-free survival
- Populations represented
- metastatic; metastatic; first-line; advanced; clear cell renal cell carcinoma; general population
- Mechanism
- Antibodies targeted against immune checkpoint inhibitors such as anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab), anti-CTLA-4 antibodies (e.g., Ipilimumab), and experimental drugs targeting LAG-3 and TIM-3, aim to block these interactions and unleash the immune system's ability to recognise and destroy cancer cells BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC)
limited evidence
MicroRNAs
9 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- clear cell renal cell carcinoma; general population; localized; advanced
- Mechanism
- Dual-luciferase reporting assay and RIP assay were used to evaluate the targeting relationship between circAGAP1/miR-216a-3p/MKNK2 Mechanistically, circAGAP1 sponged the tumor suppressor miR-216a-3p, thereby preventing miR-216a-3p from inhibiting MAPK2
preliminary evidence
axitinib
8 linked PMIDs5353 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, response rate, progression-free survival, adverse events
- Populations represented
- metastatic; metastatic; first-line; advanced; metastatic; older adults; clear cell renal cell carcinoma; localized; advanced; first-line; locally advanced; advanced; metastatic
- Mechanism
- Mechanistically, this sequence aligns vascular reprogramming, antigen-specific priming, and checkpoint release, converting an immune-excluded tumor into a T-cell-dominated, cytotoxic niche Collectively, these findings identify temporal coordination as a critical determinant of therapeutic success and establish a mechanistically grounded framework for integrating vascular preconditionning, tumor-antigen vaccination, and PD-1 blockade as a curative immunotherapy strategy in renal carcinoma
moderate-confidence evidence
Biomarkers
8 linked PMIDs2375 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, mortality, overall survival
- Populations represented
- general population; clear cell renal cell carcinoma
- Mechanism
- PURPOSE: Type 2 (T2) inflammatory biomarkers are established therapeutic targets in asthma and non-asthmatic eosinophilic bronchitis (NAEB), but their relevance in chronic cough remains unclear Patients with CCAst/EB received inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) therapy, while those without evidence of T2 inflammation or who had failed ICS/LABA were treated with neuromodulators
limited evidence
Contrast Media
7 linked PMIDs135 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence
- Populations represented
- general population; papillary renal cell carcinoma; early-stage
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
cabozantinib
6 linked PMIDs469 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- objective response rate, response rate, adverse events, reported clinical outcomes, progression-free survival
- Populations represented
- advanced; advanced; metastatic; older adults; papillary renal cell carcinoma; advanced; metastatic; papillary renal cell carcinoma
- Mechanism
- BACKGROUND: Targeting of angiogenesis has become a major therapeutic approach for the treatment of various advanced cancers
preliminary evidence
Radiopharmaceuticals
6 linked PMIDs432 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- clear cell renal cell carcinoma; metastatic; CAIX; clear cell renal cell carcinoma; stage IV; children; general population; metastatic
- Mechanism
- We designed three radiotracers targeting CAIX to improve the diagnostic value of imaging by increasing tumor uptake and the liver excretion pathway METHODS: This study developed three novel CAIX-targeting radiotracers, which were evaluated in vitro and in vivo; The study also included 8 patients with ccRCC, all of whom had paired [68Ga]Ga-NOTA-FZCI-3 PET/CT and [18F]-FDG PET/CT
preliminary evidence
Antibodies, Monoclonal, Humanized
6 linked PMIDs257 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, recurrence, reported clinical outcomes, overall survival, progression-free survival
- Populations represented
- advanced; metastatic; localized; general population; locally advanced; advanced; metastatic
- Mechanism
- Preliminary data suggest inhibition of Receptor Activator of Nuclear Factor-κB Ligand (RANKL) signaling may potentiate ICI efficacy PY314 is a humanized monoclonal antibody targeting TREM2 that depletes tumor-associated macrophages
moderate-confidence evidence
Sunitinib
5 linked PMIDs147 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- progression-free survival, objective response rate, response rate, reported clinical outcomes, overall survival
- Populations represented
- papillary renal cell carcinoma; advanced; metastatic; advanced; clear cell renal cell carcinoma; metastatic; clear cell renal cell carcinoma; advanced
- Mechanism
- Mechanistically, YTHDF1 functions in an m6A-dependent manner to directly promote the translational efficiency of the epigenetic modifier SETD2 BACKGROUND: Dysregulated cholesterol metabolism is a hallmark of clear cell renal cell carcinoma (ccRCC), but therapeutic strategies targeting this vulnerability remain limited
preclinical evidence only
Ubiquitin-Protein Ligases
5 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- clear cell renal cell carcinoma; clear cell renal cell carcinoma; PD-L1
- Mechanism
- Elevated SPTAN1 levels were found to inhibit the proliferation and metastasis of ccRCC, while the downregulation of SPTAN1 reversed the inhibition of cell survival caused by NOSIP knockdown Then, we showed that inhibition of RBCK1 inactivated the AKT and MAPK signaling pathways, which might be one of the main reasons why RBCK1 induces sunitinib resistance in ccRCC cells
05
Conflicting Research
higher-confidence evidence
67 studiespartial nephrectomy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 45null: 18benefit: 2harm: 1mixed: 1
higher-confidence evidence
14 studiesImmune Checkpoint Inhibitors · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 9benefit: 3null: 1harm: 1
higher-confidence evidence
10 studiesNivolumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 7mixed: 1null: 1benefit: 1
higher-confidence evidence
9 studiesnivolumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 5harm: 1benefit: 2null: 1
higher-confidence evidence
8 studiesIpilimumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 5mixed: 1null: 1benefit: 1
higher-confidence evidence
7 studiespembrolizumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1null: 1unknown: 4benefit: 1
limited evidence
6 studieslenvatinib · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1null: 1unknown: 3benefit: 1
limited evidence
6 studiescabozantinib · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1null: 1unknown: 3benefit: 1
higher-confidence evidence
6 studiescabozantinib · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: advanced; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 4harm: 1benefit: 1
higher-confidence evidence
6 studiesnivolumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: advanced; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 4harm: 1benefit: 1
moderate-confidence evidence
4 studiesipilimumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: not reported.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 2harm: 1benefit: 1
moderate-confidence evidence
3 studiescabozantinib · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
null: 1benefit: 1unknown: 1
06
Failed or Negative Trials
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
randomized controlled trial · 2024 · PMID 39255440
The long-term impact of single intraoperative instillation of pirarubicin after radical nephroureterectomy on local and systemic cancer control: a prospective, multicenter, randomized trial.
randomized controlled trial · 2025 · PMID 40080123
A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.
randomized controlled trial · 2026 · PMID 42849355
Suitability of the MP1000 system for robot-assisted partial nephrectomy: a multicenter randomized controlled noninferiority trial.
randomized controlled trial · 2024 · PMID 38349210
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
randomized controlled trial · 2026 · PMID 42507969
Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial.
randomized controlled trial · 2024 · PMID 39133792
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy.
randomized controlled trial · 2026 · PMID 41360001
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy.
randomized controlled trial · 2024 · PMID 37684178
Randomized controlled trial of the effect of general anesthetics on postoperative recovery after minimally invasive nephrectomy.
randomized controlled trial · 2024 · PMID 37232074
Transperitoneal vs retroperitoneal laparoscopic radical nephrectomy: a double-arm, parallel-group randomized clinical trial.
randomized controlled trial · 2024 · PMID 38310213
07
Emerging and Experimental Research
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
randomized controlled trial · 2026 · PMID 42633754
A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.
randomized controlled trial · 2026 · PMID 42849355
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
randomized controlled trial · 2026 · PMID 42507969
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.
randomized controlled trial · 2026 · PMID 41934036
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
randomized controlled trial · 2026 · PMID 42235464
Pan-cancer multi-omics machine learning defines a lactylation-associated immune-excluded tumor state with proteomic and experimental corroboration.
unclassified · 2026 · PMID 42556016
Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191.
randomized controlled trial · 2026 · PMID 42158981
Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
phase 2 clinical trial · 2026 · PMID 42879162
Toward precision adjuvant immunotherapy in high-risk clear cell renal cell carcinoma: integrating plasma multiomics with PD-1 blockade.
phase 2 clinical trial · 2026 · PMID 42785920
Cough hypersensitivity risk increases during heatwaves and can be reduced by inhalation of alkaline aerosols of endogenous ions.
preclinical or laboratory · 2026 · PMID 42744885
08
Evidence Gaps
Detailed risk-of-bias assessment remains limited
PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care66 records
Rank112.0
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
International journal of radiation oncology, biology, physics · 2026 · PMID 41580163
PURPOSE: Stereotactic ablative body radiation therapy (SABR) is an emerging indication for localized renal cell carcinoma (RCC), yet there is a need for standardizing contouring practices, as accurate target delineation is essential to ensure optimal outcomes. Our objective was to develop consensus guidelines for target volume contouring for RCC SABR. METHODS AND MATERIALS: An international panel of RCC SABR experts affiliated with IROCK was convened. All were asked to contour target volumes for 4 relevant clinical…
Rank112.0
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.
The Lancet. Oncology · 2025 · PMID 41038202
Pathological response is a surrogate marker of efficacy of neoadjuvant therapy in various tumour types, but there is no consensus on reporting pathological response for renal cell carcinoma. We aimed to assess the status of pathological response reporting in renal cell carcinoma and develop a recommendation on tissue preparation and response reporting for neoadjuvant treatment. We conducted a systematic review of publications on the PubMed and Web of Science databases to identify manuscripts reporting response to p…
Rank110.0
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.
ESMO open · 2026 · PMID 42914499
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma (RCC) were published in May 2024 and adapted in December 2025 according to previously established standard methodology to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with RCC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatmen…
Rank110.0
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer · 2026 · PMID 41871874
Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number of patients, fully transforming the standard of care in first-line and subsequent-line settings. More …
Rank110.0
SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025 · PMID 41067863
Anatomic imaging of renal masses provides limited information on the histology or likely aggressiveness of the tumor, leading to the use of invasive procedures such as renal mass biopsy or empiric partial or radical nephrectomy. Molecular imaging can assist in risk stratification of indeterminate renal masses, potentially contributing to optimal patient decision-making. Two primary approaches have been explored for renal mass molecular imaging. The first is the use of agents that target carbonic anhydrase IX (CAIX)…
Rank110.0
[Update renal cell carcinoma : Guideline update on small renal masses].
Urologie (Heidelberg, Germany) · 2026 · PMID 42726211
Small renal masses (kidney tumors < 4 cm) are benign in up to 30% of cases and often exhibit slow growth, yet they are still frequently primarily managed by surgery. A tumor biopsy should be performed before initiating active surveillance. As up to 8% of renal tumors could have a hereditary component, risk factors such as a diagnosis before the age of 47 years old, bilateral or multifocal lesions and syndrome-associated extrarenal manifestations, should be systematically assessed and clarified by a genetic evaluati…
Rank110.0
Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology).
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025 · PMID 40934605
Renal cell carcinoma represents the 14th most frequent tumour worldwide, but its incidence is increasing partly due to incidental diagnoses. As a result, these tumours are diagnosed in patients at an increasingly advanced age, often frail and with comorbidities. Most renal cell carcinoma cases are clear cell carcinoma (80 %), with papillary tumours being the second most frequent histological subtype. The standard of care for localized RCC is surgery, with partial nephrectomy or radical nephrectomy being recommended…
Rank110.0
Kidney transplantation from donors with cancer or history of cancer: Transplantation and cancerology committee of Association Française d'Urologie guidelines (CTAFU/CCAFU).
The French journal of urology · 2025 · PMID 41271370
INTRODUCTION: Potential donors for transplantation are screened for malignancies that can be transmitted on to the recipient. The discovery of cancer or a history of cancer often leads to contraindications for organ donation, while in some cases the cancer transmission risk is very low. The current context of organ shortage leads us to reconsider the use of organs from donors with cancer or a history of cancer when the risk of transmission is minimal or less than the risk of death on the waiting list. The Transplan…
Rank110.0
Updated 2025 French guidelines for renal cell carcinoma.
The French journal of urology · 2025 · PMID 41109639
The 2025 update of the French guidelines for localized renal cell carcinoma highlights several major advances. Renal biopsy reaffirms its central role in guiding therapeutic decisions and reducing overtreatment, with growing evidence supporting a broader "biopsy-all" strategy. Active surveillance is now established as a safe and effective option for small renal masses, including selected complex cystic lesions, providing oncological outcomes comparable to immediate intervention. Among alternative approaches, stereo…
Rank110.0
What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026 · PMID 42373875
BACKGROUND AND OBJECTIVE: Renal cell carcinoma (RCC) is a common manifestation in Von-Hippel Lindau (VHL) syndrome, accounting for almost 30% of the patients. However, since VHL syndrome is relatively rare, there are no clear guidelines regarding the approach to VHL patients with RCC. This article aims to provide evidence-based insights for diagnosis, treatment, and surveillance in VHL patients with RCC. METHODS: The articles indexed between 1977 and 2025 in PubMed was searched. Only articles in English were includ…
Rank106.6
Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42604476
BACKGROUND: We aimed to systematically summarize data on efficacy of local salvage therapies for local recurrence of renal cell carcinoma (RCC). METHODS: We searched MEDLINE, Embase, Web of Science, CENTRAL, and Google Scholar through 05/08/2026, for studies on local salvage therapies for local recurrence of RCC following radical nephrectomy, partial nephrectomy, or ablation (PROSPERO: CRD42024623099). Meta-analyses were conducted using random-effects models. Risk of bias (RoB) was assessed using ROBINS-I. RESULTS:…
Rank105.7
Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026 · PMID 40835773
PURPOSE: Spinal metastases affect up to 70% of systemic cancer patients, with overall survival averaging less than six months. Traditional chemotherapeutic agents have unsatisfactory results, leading to immunotherapy (IT) investigations. There is no clear consensus on the benefits and risks of IT for spinal tumors. This study assesses the current literature to determine IT safety and survival efficacy for tumors involving spinal column. METHODS: Following PRISMA guidelines, a systematic search was conducted across …
Rank103.9
Thermal Ablation Modalities That Best Compete with Partial Nephrectomy for T1A and T1B Renal Cell Carcinoma: A Network Meta-Analysis.
Journal of vascular and interventional radiology : JVIR · 2025 · PMID 40617477
PURPOSE: To address the lack of consensus on the ranking of thermal ablation (TA) for treating T1A and T1B renal cell carcinoma (RCC), a network meta-analysis was conducted to compare the efficacy and safety of different TA modalities for managing early-stage RCC. METHODS: The Cochrane Library, PubMed, Scopus, and Web of Science were systematically searched for studies comparing percutaneous and laparoscopic radiofrequency ablation (RFA), cryoablation (CRA), and microwave ablation (MWA) with open, laparoscopic, and…
Rank100.0
Quality Indicators for Renal Cancer Care: A Systematic Review.
European urology oncology · 2025 · PMID 40483206
BACKGROUND AND OBJECTIVE: Quality indicators (QIs) are crucial for evaluating health care delivery, including effectiveness, safety, and patient-centered outcomes. In contrast to other fields, the definition and implementation of QIs for renal cell carcinoma (RCC) present distinct challenges and remain unmet needs. We summarized the available data on QIs for RCC, focusing on their characterization throughout the care pathway and the potential areas for further development. METHODS: A systematic review of the Englis…
Rank97.0
Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
World journal of urology · 2023 · PMID 35867141
PURPOSE: The high incidence of upper urinary tract urothelial carcinoma (UTUC) in Taiwan is largely due to exposure to aristolochic acid (AA), a principal component of Aristolochia-based herbal medicines. Here we systematically review the molecular epidemiology, clinical presentation and biomarkers associated with AA-induced UTUC. METHODS: This is a narrative review. Medline, Embase, and Web of Science were searched from inception to December 31, 2021. Studies evaluating the association, detection, and clinical cha…
Rank96.0
Pan-cancer multi-omics machine learning defines a lactylation-associated immune-excluded tumor state with proteomic and experimental corroboration.
Computational biology and chemistry · 2026 · PMID 42556016
BACKGROUND: Histone lactylation links lactate metabolism to chromatin regulation, but whether lactylation-program-associated transcriptional patterns delineate recurrent pan-cancer tumor states remains unclear. METHODS: We integrated mRNA, lncRNA, and miRNA profiles from 9712 TCGA tumors across 33 cancer types with GTEx references, six GEO cohorts, IMvigor210, and an institutional clear-cell renal cell carcinoma (ccRCC) cohort used for exploratory DIA-NN proteomic corroboration. Random-effects co-expression meta-an…
Rank80.5
Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.
Urologic oncology · 2026 · PMID 41266180
PURPOSE: To compare KEYNOTE-564 and American Urological Association (AUA) risk classifications in clear cell renal cell carcinoma (ccRCC), as recurrence after treatment for localized RCC remains a significant clinical challenge, and no consensus exists on how to define high-risk disease. MATERIALS AND METHODS: We conducted a retrospective multicenter study of surgically treated patients with nonmetastatic ccRCC. Patients were stratified by AUA and KEYNOTE-564 criteria, and overall survival (OS), cancer specific sur…
Rank73.4
Comparison of glass-based and whole-slide image-based grade assignment for clear-cell and papillary renal cell carcinoma: a multi-cohort, international reproducibility study.
Histopathology · 2026 · PMID 41171031
BACKGROUND AND AIMS: Histological grading of renal cell carcinoma (RCC) is an important part of diagnostic evaluation. Reproducibility of RCC grading using whole-slide imaging (WSI) compared to glass-slide microscopy is understudied. The aim of the study was a head-to-head evaluation of WSI-based and glass-based grading approaches in clear-cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) subtypes. METHODS: Four cohorts of patient cases with glass slides and corresponding digitized WSI were included …
Rank73.3
Radiological differentiation of succinate dehydrogenase-deficient renal cell carcinoma from renal oncocytoma and chromophobe renal cell carcinoma.
BMC cancer · 2026 · PMID 42067868
PURPOSE: To characterize the imaging features of succinate dehydrogenase-deficient renal cell carcinoma (SDH-RCC) and compare them with those of renal oncocytoma (RO) and chromophobe RCC (chRCC). METHODS: This retrospective two-center study was approved by the institutional review board, and informed consent was waived. Patients with histologically confirmed SDH-RCC, RO, or chRCC who underwent pre-treatment contrast-enhanced CT between November 2015 and October 2024 were included. Imaging features were independentl…
Rank73.0
Evaluating the Feasibility of Standard Ultrasound in the Bosniak Classification of Cystic Renal Masses Compared with Computed Tomography/Magnetic Resonance Imaging: A Multicenter Study.
Ultrasound in medicine & biology · 2026 · PMID 41238458
OBJECTIVE: To investigate the diagnostic performance of standard ultrasound (US) using a US-adapted Bosnian classification for characterizing cystic renal masses (CRMs) compared with computed tomography/magnetic resonance imaging (CT/MRI) as the current standard. METHODS: From July 2016 to June 2022, pathology-proven CRMs and CRMs with ≥3 y of follow-up from six centers were reviewed. Four readers with varying levels of expertise in US categorized CRMs using a US-based Bosnian classification, followed by a consensu…
Rank54.5
Generation of Automated Nephrometry Scores Through Direct Prediction of Each Component.
Urology · 2026 · PMID 41856377
OBJECTIVE: To evaluate whether a deep learning model could automate R.E.N.A.L. nephrometry score generation and predict clinically significant outcomes. METHODS: A ResNet-50 neural network was trained on 599 patients from the 2023 KiTS Challenge dataset to predict numeric R.E.N.A.L. score components (excluding the anterior/posterior designation) using preoperative CT images and expert-derived segmentation masks. Five-fold cross-validation produced automated scores, which were compared with consensus human scores fr…
Rank53.1
Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.
Cancer research communications · 2026 · PMID 42008739
UNLABELLED: The ccrcc1-4 transcriptomic subtypes were previously identified in fresh-frozen clear-cell renal cell carcinoma (ccRCC) samples and have proven their prognostic value after nephrectomy/metastasectomy and predictive value for first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). We aimed to create a consensus molecular classification approach called Clearseq1-4 on formalin-fixed, paraffin-embedded (FFPE) tissues and to evaluate its prognostic and predictive value …
Rank50.7
Long-Term Locoregional Control and Pattern of Recurrences After Implementation of Highly Conformal Flank Target Volumes and Image-Guided Intensity Modulated Arc Therapy for Pediatric Wilms Tumors.
International journal of radiation oncology, biology, physics · 2026 · PMID 42140503
PURPOSE: Excellent outcomes in patients with Wilms tumors (WT) have allowed efforts to reduce toxicity and treatment burden while sustaining effectiveness. Concerning radiation therapy, "conventional" flank target volumes combined with 2 opposing photon beams are now being replaced by highly conformal flank target volumes combined with image-guided intensity modulated arc therapy, allowing better sparing of the organs-at-risk, but outcome descriptions based on large cohorts are scarce. Previously, a cohort of 36 pa…
Rank50.1
Construction and validation of renal cell carcinoma tumor cell differentiation-related prognostic classification (RCC-TCDC): an integrated bioinformatic analysis and clinical study.
Annals of medicine · 2025 · PMID 40248945
BACKGROUND: Renal cell carcinoma (RCC) is a heterogeneous malignancy with diverse gene expression patterns, molecular landscapes, and differentiation characteristics of tumor cells. It is imperative to develop molecular RCC classification based on tumor cell differentiation for precise risk stratification and personalized therapy. METHODS: We obtained scRNA-seq profiles from GSE159115 and bulk RNA-seq profiles from TCGA-KIRC cohort. We then performed scRNA-seq cluster analysis, monocle2 pseudotime analysis, and pro…
Rank49.4
Computed tomography-based unsupervised clustering identifies clusters associated with progression free survival in clear cell renal cell carcinoma.
Cancer imaging : the official publication of the International Cancer Imaging Society · 2025 · PMID 41287074
BACKGROUND: This study aimed to develop and validate a radiologic clustering model using CT imaging features to stratify clear cell renal cell carcinoma (ccRCC) patients by prognosis and identify key imaging predictors of 5-year progression free survival (PFS). METHODS: This retrospective study included 164 ccRCC patients with multiphase kidney CT and next-generation sequencing (NGS) between September 2003 and October 2024. Qualitative imaging features were extracted, and unsupervised consensus clustering was perfo…
Diagnosis And Screening218 records
Rank107.6
Clinical application of radiomics for the prediction of treatment outcome and survival in patients with renal cell carcinoma: a systematic review.
World journal of urology · 2024 · PMID 39325194
PURPOSE: The management of renal cell carcinoma (RCC) relies on clinical and histopathological features for treatment decisions. Recently, radiomics, which involves the extraction and analysis of quantitative imaging features, has shown promise in improving RCC management. This review evaluates the current application and limitations of radiomics for predicting treatment and oncological outcomes in RCC. METHODS: A systematic search was conducted in Medline, EMBASE, and Web of Science databases or studies that used …
Rank107.2
Meta-analysis and systematic review of factors predicting conversion to radical nephrectomy following robotic-assisted partial nephrectomy in renal cancer patients.
Journal of robotic surgery · 2024 · PMID 39443332
Evaluating the risk factors for the conversion from robotic-assisted partial nephrectomy (RAPN) to radical nephrectomy (RN). Through a comprehensive database search encompassing PubMed, Web of Science, Embase, and the Cochrane Library, we identified pertinent English-language research published by June 2024. We utilized the NOS scale for quality assessment. The aggregate effect was quantified via the odds ratio (OR), alongside a 95% confidence interval (CI). Sensitivity analyses were conducted using both fixed-effe…
Rank107.0
Prognostic value of primary tumor location in colorectal cancer: an updated meta-analysis.
Clinical and experimental medicine · 2023 · PMID 37405571
The clinical, histological, and molecular differences between right-sided colon cancer (RCC) and left-sided colon cancer (RCC) have received considerable attention. Over the past decade, many articles have been published concerning the association between primary tumor location (PTL) of colorectal cancer and survival outcomes. Therefore, there is a growing need for an updated meta-analysis integrating the outcomes of recent studies to determine the prognostic role of right vs left-sidedness of PTL in patients with …
Rank106.8
Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma.
Annals of medicine · 2026 · PMID 41566198
BACKGROUND AND AIMS: Systemic inflammation is closely linked to the development and progression of various cancers, as well as poorer patient outcomes. The role of the c-reactive protein to albumin ratio (CAR) as a predictor of poor prognosis in renal cell carcinoma (RCC) remains insufficiently recognized. METHODS: A literature search was conducted in major English-language databases, including PubMed, EMBASE, and the Cochrane Library, with the search updated to 25 June 2025. Both the odds ratio (OR) and diagnostic…
Rank105.2
Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach.
European journal of pediatrics · 2024 · PMID 38019286
This paper aims to explore the epidemiology, clinical characteristics, and prognosis of extracranial malignant rhabdoid tumors (eMRTs) in children. A systematic review and meta-analysis of studies published in PUBMED, MEDLINE, Web of Science, Embase, Cochrane, and China National Knowledge Infrastructure (CNKI) was conducted. The search was limited to studies published between Jan 1, 1990 to Dec 31, 2022, with the last search done on Jan 31, 2023. We identified 496 papers through the literature search, and 12 retros…
Rank104.8
Clinical features, laboratory findings and treatment of juxtaglomerular cell tumors: a systemic review.
Hypertension research : official journal of the Japanese Society of Hypertension · 2024 · PMID 38438720
Juxtaglomerular cell tumors (JGCTs) or reninoma are rare kidney tumors leading to secondary hypertension, and the non-specific clinical manifestations bring about challenges to the diagnosis. This study is to summarize the clinical features, laboratory findings, and treatment of JGCTs. The PubMed, EMBASE database, and manual search were utilized to find all cases, and 158 reports containing 261 patients were identified. Data on patients' demographics, clinical features, diagnostic methods, and treatment options wer…
Rank102.3
Proportion of malignancy in Bosniak classification of cystic renal masses version 2019 (v2019) classes: systematic review and meta-analysis.
European radiology · 2023 · PMID 35999371
OBJECTIVES: Determine the proportion of malignancy within Bosniak v2019 classes. METHODS: MEDLINE and EMBASE were searched. Eligible studies contained patients with cystic renal masses undergoing CT or MRI renal protocol examinations with pathology confirmation, applying Bosniak v2019. Proportion of malignancy was estimated within Bosniak v2019 class. Risk of bias was assessed using QUADAS-2. RESULTS: We included 471 patients with 480 cystic renal masses. No class I malignant masses were observed. Pooled proportion…
Rank100.0
Contrast-enhanced ultrasound (CEUS) as a follow-up method after the focal treatment of renal tumors: systematic review and meta-analysis.
International urology and nephrology · 2024 · PMID 38851652
CONTEXT: Contrast-enhanced ultrasound (CEUS) is a cost-effective radiation-free diagnostic method that can be used for renal tumor postoperative visualization after ablative treatment. OBJECTIVE: To assess CEUS diagnostic accuracy comparing with CT and MRI as a follow-up method in short-term and long-term postoperative periods after renal tumor ablation. MATERIALS AND METHODS: A systematic review and meta-analysis were performed in Scopus and Medline databases using the query "(kidney OR rena* OR RCC) AND (ablation…
Rank100.0
Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study.
Clinical & experimental metastasis · 2024 · PMID 39739072
Immune-based combinations have significantly improved the treatment of metastatic renal cell carcinoma (mRCC); however, immunotherapy has reported varying degrees of efficacy across different metastatic sites, with liver and bone metastases traditionally considered more challenging to treat. In MOUSEION-08 study, we aimed to investigate the association between lung, liver, and bone metastases and clinical outcomes such as Overall Survival (OS) and Progression- Free Survival (PFS) in mRCC patients receiving immune-b…
Rank100.0
A systematic investigation of clear cell renal cell carcinoma using meta-analysis and systems biology approaches.
Molecular genetics and genomics : MGG · 2024 · PMID 39283494
Renal cell carcinoma with clear cells (ccRCC) is the most frequent kind; it accounts for almost 70% of all kidney cancers. A primary objective of current research was to find genes that may be used in ccRCC gene therapy to understand better the molecular pathways underlying the disease. Based on PubMed microarray searches and meta-analyses, we compared overall survival and recurrence-free survival rates in ccRCC patients with those in healthy samples. The technique was followed by a KEGG pathway and Gene Ontology (…
Rank100.0
The influence of manual segmentation strategies and different phases selection on machine learning-based computed tomography in renal tumors: a systematic review and meta-analysis.
La Radiologia medica · 2024 · PMID 38740709
BACKGROUND: Delineating the region/volume of interest (ROI/VOI) and selecting the phases are of importance in developing machine learning (ML). The results will change when choosing different methods of drawing the ROI/VOI and selecting different phases. However, there is no related standard for delineating the ROI/VOI and selecting the phases in renal tumors to develop ML based on computed tomography (CT). METHODS: The PubMed and Web of Science were searched for related studies published until March 1, 2023. Inclu…
Rank99.5
Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review.
Journal of neurology · 2023 · PMID 36050418
BACKGROUND: The link between paraneoplastic neurological syndromes (PNS) and renal cell and bladder cancer (RCC/BC) is rare and uncertain. Our aim was to clinically evaluate, in light of the updated PNS criteria, these uncommon associations. METHODS: Retrospective nationwide cohort chart review study and systematic review of the literature. RESULTS: After excluding 5 patients due to the diagnosis of another co-occurrent malignancy, 10/18 patients with RCC and 8/18 patients with BC were identified. A total of 31 cas…
Rank97.0
Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
World journal of urology · 2023 · PMID 35867141
PURPOSE: The high incidence of upper urinary tract urothelial carcinoma (UTUC) in Taiwan is largely due to exposure to aristolochic acid (AA), a principal component of Aristolochia-based herbal medicines. Here we systematically review the molecular epidemiology, clinical presentation and biomarkers associated with AA-induced UTUC. METHODS: This is a narrative review. Medline, Embase, and Web of Science were searched from inception to December 31, 2021. Studies evaluating the association, detection, and clinical cha…
Rank96.0
Molecular mechanisms and therapeutic targets of traditional Chinese Medicine compounds in renal cell carcinoma: A comprehensive narrative review.
Journal of ethnopharmacology · 2026 · PMID 42276388
ETHNOPHARMACOLOGICAL RELEVANCE: Advanced renal cell carcinoma (RCC) often stops responding to targeted drugs, and those drugs can be toxic. Traditional Chinese Medicine (TCM) works differently: it hits many targets at once and tries to rebalance the whole body. That makes TCM a plausible add-on, not a replacement. AIM OF THE REVIEW: This review aims to comprehensively summarize and critically appraise the molecular mechanisms by which TCM components and formulas exert anti-RCC activities, focusing on key signaling …
Rank85.0
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
World journal of urology · 2023 · PMID 37698632
BACKGROUND: Upper urinary tract urothelial carcinoma (UTUC) is often locally advanced at initial diagnosis and is associated with high recurrence and mortality rates after radical nephroureterectomy (RNU). Adjuvant platinum-based chemotherapy has shown a recurrence-free survival benefit in a randomised phase III trial, while neoadjuvant treatment seems promising in retrospective series. On the contrary, little is known about the role of perioperative immunotherapy and its combination with chemotherapy for UTUC pati…
Rank85.0
Current status and future perspective of immunotherapy for renal cell carcinoma.
International journal of clinical oncology · 2024 · PMID 38108981
In the last decade, the standard treatment for advanced renal cell carcinoma (RCC) has evolved, mainly driven by the development and approval of immune checkpoint inhibitors (ICIs). Currently, ICI monotherapy and ICI-based combinations with tyrosine kinase inhibitors and targeted therapies against mammalian target of rapamycin or vascular endothelial growth factor have become new standard treatments for first-line and subsequent-line therapies. ICIs play an important role as an adjuvant postoperative therapy, and t…
Rank82.0
Papillary Renal Cell Carcinoma: A Review of Prospective Clinical Trials.
Current treatment options in oncology · 2023 · PMID 37407886
PRCC is a unique histologic entity compared to other forms of renal cell carcinoma, harboring distinct molecular drivers. The WHO 2022 classification is further emphasizing the molecular biology by making molecular classifications of PRCC subclassifications and discontinuing the morphologic type 1 and type 2 classification system. We agree with this functional classification system and encourage all future clinical trials to only include patients with similar diagnosis instead of conducting basket trials (including…
Rank81.5
Association of AI-derived abdominal organ volumetry with postoperative outcomes in clear cell renal cell carcinoma: a multicentre study.
Annals of medicine · 2026 · PMID 42723375
BACKGROUND: CT-derived body composition parameters are associated with clinical outcomes in clear cell renal cell carcinoma (ccRCC), but the prognostic value of abdominal solid organ volumes remains unclear. METHODS: In this multicentre study, 1,720 patients with ccRCC who underwent nephrectomy across four centres and 3,052 healthy controls were included. A deep learning algorithm was used to automatically quantify abdominal organ volumes. Organ volume indices were calculated by normalizing volumes to body surface …
Rank79.4
Prognostic significance of systemic immunoinflammatory biomarkers and pathological features in clear cell renal cell carcinoma: a multicenter study.
Annals of medicine · 2026 · PMID 42669053
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) exhibits heterogeneous postoperative outcomes. This study aimed to evaluate systemic immunoinflammatory biomarkers and pathological features and develop an integrated prognostic model for overall survival (OS) in patients with ccRCC. METHODS: This multicenter retrospective study initially screened 1,662 patients who underwent surgery between January 2010 and December 2024. After excluding 27 patients with substantial missing data, 1,635 were included in baseline a…
Rank78.7
Development and validation of nomograms and integrated software incorporating preoperative C-reactive protein level for prognostic prediction of nonmetastatic clear cell renal cell carcinoma: Results from the International Marker Consortium for Renal Cancer (INMARC) Registry.
World journal of urology · 2025 · PMID 39786437
PURPOSE: Preoperative C-reactive protein (CRP) is a valuable prognostic biomarker in nonmetastatic clear cell renal cell carcinoma (nmccRCC). Incorporation of CRP into prognostic models may improve the prediction of oncologic outcomes. Herein, we aimed to develop and validate prognostic nomograms and an integrated software incorporating preoperative CRP level in nmccRCC. METHODS: An international multi-institutional database was retrospectively analyzed for nmccRCC patients undergoing surgery. A total of 2284 patie…
Rank78.6
Identification and validation of a chronic kidney disease prediction model after radical nephrectomy: a multicenter cohort retrospective study.
Annals of medicine · 2026 · PMID 42808223
INTRODUCTION: Long-term renal function is an important follow-up after radical nephrectomy for renal carcinoma. Predictive models can help identify patients at risk for chronic kidney disease (CKD) progression and enable early intervention. METHODS: We retrospectively analyzed 649 patients who underwent radical nephrectomy at eight medical centers. The primary cohort from the Affiliated Hospital of Qingdao University comprised 329 patients, randomly divided into training sets (n = 229) and internal validation sets …
Rank76.0
Construction and clinical validation of a cascaded deep learning system for classification of benign and malignant solid small renal masses based on MRI.
European journal of radiology · 2026 · PMID 42556272
OBJECTIVE: This study aims to develop a cascaded deep learning (DL) system based on multiparametric MRI to establish an automated pipeline for the segmentation and classification of small renal masses (SRMs). MATERIALS AND METHODS: A retrospective collection of SRM patients with pathologically confirmed from three institutions was conducted. MRI data from Institution 1 were randomly divided into a training set and an internal test set. Data from other institutions served as the external test set. A cascaded DL syst…
Rank75.0
Assessing visibility and bone changes of spinal metastases in CT scans: a comprehensive analysis across diverse cancer types.
Skeletal radiology · 2024 · PMID 38407627
OBJECTIVES: To analyze the characteristics of spinal metastasis in CT scans across diverse cancers for effective diagnosis and treatment, using MRI as the gold standard. METHODS: A retrospective study of 309 patients from four centers, who underwent concurrent CT and spinal MRI, revealing spinal metastasis, was conducted. Data on metastasis including total number, volume, visibility on CT (visible, indeterminate, or invisible), and type of bone change were collected. Through chi-square and Mann-Whitney U tests, we …
Rank74.9
Percutaneous radiofrequency ablation is an effective treatment option for small renal masses, comparable to partial nephrectomy.
European radiology · 2023 · PMID 37280356
OBJECTIVES: The standard therapy for small renal masses (SRMs) remains partial nephrectomy (PN), which is associated with relatively high morbidity and complication rate. Therefore, percutaneous radiofrequency ablation (PRFA) emerges as an alternative therapy. This study aimed to compare the efficacy, safety, and oncological outcomes of PRFA versus PN. METHODS: A multicenter non-inferiority study with retrospective analysis of 291 patients with SRMs (N0M0), who underwent PN or PRFA (2:1), recruited prospectively fr…
Rank74.5
The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
International journal of clinical oncology · 2024 · PMID 38797782
BACKGROUND: Nivolumab plus ipilimumab (NIVO + IPI) is the first-line treatment for patients with metastatic renal cell carcinoma (mRCC). While approximately 40% of patients treated with NIVO + IPI achieve a durable response, 20% develop primary resistance with severe consequences. Therefore, there is a clinical need for criteria to select patients suitable for NIVO + IPI therapy to optimize its therapeutic efficacy. Accordingly, our aim was to evaluate the association between candidate biomarkers measured before tr…
Evidence Syntheses96 records
Rank114.2
Performance of Machine Learning Models Based on Medical Imaging in Predicting Pathological Grade of Clear Cell Renal Cell Carcinoma.
Cancer medicine · 2026 · PMID 42693958
BACKGROUND: Predicting clear cell renal cell carcinoma (ccRCC) pathological grade preoperatively is critical for clinical management. This study aims to evaluate the diagnostic accuracy and clinical utility of machine learning (ML)-based imaging models. METHODS: The Cochrane Library, PubMed, Embase, and Scopus databases were searched systematically for studies published before January 2026. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 and the Radiomics Quality Score. Pool…
Rank111.1
Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.
Targeted oncology · 2026 · PMID 42218357
BACKGROUND: Immune checkpoint inhibitor (ICI)-based regimens are the standard first-line therapy for advanced renal cell carcinoma (RCC). However, their comparative effectiveness and safety in routine clinical practice remain incompletely characterised. OBJECTIVE: The aim of this study was to systematically synthesise comparative real-world evidence on the efficacy and safety of ICI-based regimens in patients with advanced RCC. METHODS: A systematic search of MEDLINE, Embase, and Scopus was conducted from database …
Rank110.0
What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026 · PMID 42373875
BACKGROUND AND OBJECTIVE: Renal cell carcinoma (RCC) is a common manifestation in Von-Hippel Lindau (VHL) syndrome, accounting for almost 30% of the patients. However, since VHL syndrome is relatively rare, there are no clear guidelines regarding the approach to VHL patients with RCC. This article aims to provide evidence-based insights for diagnosis, treatment, and surveillance in VHL patients with RCC. METHODS: The articles indexed between 1977 and 2025 in PubMed was searched. Only articles in English were includ…
Rank110.0
The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026 · PMID 42611330
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not …
Rank110.0
Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.
Journal of endocrinological investigation · 2024 · PMID 38530620
BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…
Rank110.0
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.
ESMO open · 2026 · PMID 42914499
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma (RCC) were published in May 2024 and adapted in December 2025 according to previously established standard methodology to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with RCC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatmen…
Rank110.0
[Update renal cell carcinoma : Guideline update on small renal masses].
Urologie (Heidelberg, Germany) · 2026 · PMID 42726211
Small renal masses (kidney tumors < 4 cm) are benign in up to 30% of cases and often exhibit slow growth, yet they are still frequently primarily managed by surgery. A tumor biopsy should be performed before initiating active surveillance. As up to 8% of renal tumors could have a hereditary component, risk factors such as a diagnosis before the age of 47 years old, bilateral or multifocal lesions and syndrome-associated extrarenal manifestations, should be systematically assessed and clarified by a genetic evaluati…
Rank109.2
Comparative outcomes of robot-assisted and open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42624966
For patients with renal cell carcinoma (RCC) complicated by inferior vena cava (IVC) tumor thrombus, radical nephrectomy combined with thrombectomy remains a key surgical option. Open radical nephrectomy with IVC thrombectomy (O-RNTT) has long been regarded as the traditional operative strategy, whereas robot-assisted radical nephrectomy with IVC thrombectomy (R-RNTT) is now being used more frequently in high-experience centers. Direct comparative data, however, remain limited. This study aimed to compare periopera…
Rank109.1
Machine Learning for Predicting Ki-67 Expression in Renal Tumors: A Systematic Review And Meta-Analysis.
Academic radiology · 2026 · PMID 42443009
RATIONALE AND OBJECTIVES: To systematically evaluate the diagnostic performance of machine learning (ML) models for predicting Ki-67 expression in renal tumors and assess their potential for clinical translation. MATERIALS AND METHODS: We systematically searched PubMed, Web of Science, Cochrane Library, and Embase up to November 2025. Studies using ML to predict Ki-67 with immunohistochemistry as reference standard were included. Quality was assessed with QUADAS-2. A bivariate random-effects model pooled diagnostic…
Rank108.9
CAIX-targeted PET/CT in clear cell renal cell carcinoma: a systematic review of current evidence and clinical perspectives.
Minerva urology and nephrology · 2026 · PMID 42823864
BACKGROUND: Carbonic anhydrase IX (CAIX)-targeted PET/CT is an emerging molecular imaging approach for clear cell renal cell carcinoma (ccRCC). This systematic review aimed to summarize the clinical evidence on CAIX-targeted PET/CT for ccRCC detection and characterization. METHODS: PubMed/MEDLINE, Embase, and the Cochrane Library were searched on March 29, 2026, according to PRISMA 2020. Original clinical studies evaluating CAIX-targeted PET/CT in adult patients with suspected or confirmed renal masses or metastati…
Rank108.8
Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Cancer · 2026 · PMID 42779347
The objective of this systematic review and meta-analysis was to evaluate the validity of progression-free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma. The MEDLINE, Embase, and Cochrane CENTRAL databases were searched from inception to June 10, 2025. Associations between treatment effects on OS, PFS, and ORR were assessed using Pearson correlation coefficients (r). Surrogate threshold…
Rank108.3
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42634038
Single-port robot-assisted partial nephrectomy (SP-RAPN) is increasingly used for selected renal tumors, but its comparative value over multi-port robot-assisted partial nephrectomy (MP-RAPN) remains uncertain. We performed a systematic review and meta-analysis of comparative studies, prioritizing propensity score-matched data when available. PubMed, Scopus, Web of Science, and Google Scholar were searched. Three studies involving 442 patients were included (210 SP-RAPN and 232 MP-RAPN). SP-RAPN was associated with…
Rank108.0
Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis.
Cancer · 2026 · PMID 42590929
BACKGROUND: Disease-free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting. METHODS: The authors conducted a systematic review and trial-level meta-analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. D…
Rank107.6
Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Medical oncology (Northwood, London, England) · 2026 · PMID 42484760
To update a network meta-analysis of first-line immunotherapy combinations in advanced renal cell carcinoma (RCC) using short-term data for primary analysis and long-term plus newly published randomized controlled trials (RCTs) for subgroup analyses. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese databases for articles from inception to 22 December 2024, performing a Bayesian network meta-analysis. Overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and…
Rank107.6
Clinical application of radiomics for the prediction of treatment outcome and survival in patients with renal cell carcinoma: a systematic review.
World journal of urology · 2024 · PMID 39325194
PURPOSE: The management of renal cell carcinoma (RCC) relies on clinical and histopathological features for treatment decisions. Recently, radiomics, which involves the extraction and analysis of quantitative imaging features, has shown promise in improving RCC management. This review evaluates the current application and limitations of radiomics for predicting treatment and oncological outcomes in RCC. METHODS: A systematic search was conducted in Medline, EMBASE, and Web of Science databases or studies that used …
Rank107.6
Robot-assisted versus laparoscopic partial nephrectomy for localized renal tumors: a systematic review and meta-analysis of oncological, perioperative, and renal functional outcomes.
Journal of robotic surgery · 2026 · PMID 42474798
To update the comparative evidence on robot-assisted partial nephrectomy (RAPN) and laparoscopic partial nephrectomy (LPN) for patients with cT1-cT2 renal tumors, with emphasis on cancer control, perioperative recovery, and postoperative kidney function. Four databases were queried for English-language comparative studies published between January 30, 2016 and March 1, 2026. Eligible reports enrolled adults with localized renal tumors treated with RAPN or LPN and provided extractable oncological, perioperative, or …
Rank107.4
First-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma: a network meta-analysis and cost-effectiveness analysis.
Frontiers in immunology · 2026 · PMID 42876805
OBJECTIVE: This study aimed to systematically evaluate the efficacy of first-line immune checkpoint inhibitors (ICIs) combined with targeted therapy for advanced renal cell carcinoma (RCC) and assess their cost-effectiveness from the perspective of the Chinese healthcare system. METHODS: Phase III randomized controlled trials comparing ICI-targeted combinations versus sunitinib as first-line treatment for advanced RCC were identified through systematic searches of PubMed, EMBASE, and the Cochrane Library. A network…
Rank107.3
Effect of tobacco avoidance on the incidence of non-hereditary renal cell carcinoma in patients over 18 years of age: systematic review and meta-analysis.
International urology and nephrology · 2026 · PMID 42118473
OBJECTIVE: Risk factors for kidney cancer are divided into modifiable and non-modifiable factors. Among the former, smoking stands out, whose relationship with the disease has been extensively studied, from the intensity of consumption to the effects of cessation. However, the impact of avoiding smoking is not precisely known. This study aimed to estimate the effect of avoiding tobacco use on the risk of renal cell carcinoma (RCC) in patients over 18 years of age with no family history. METHODS: A systematic review…
Rank107.2
Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.
La Clinica terapeutica · 2026 · PMID 42340793
BACKGROUND: Radical nephrectomy for high-complexity renal tumors, stage T2-T4, size ≥7 cm, and/or inferior vena cava (IVC) involvement, represents one of the most technically demanding procedures in urologic oncology. Robot-assisted radical nephrectomy (RARN) has expanded rapidly in adoption, yet its comparative benefit over laparoscopic radical nephrectomy (LRN) in the high-complexity subpopulation remains undefined. No systematic review has restricted analysis to T2-T4 disease or applied a multidisciplinary outco…
Rank107.2
Meta-analysis and systematic review of factors predicting conversion to radical nephrectomy following robotic-assisted partial nephrectomy in renal cancer patients.
Journal of robotic surgery · 2024 · PMID 39443332
Evaluating the risk factors for the conversion from robotic-assisted partial nephrectomy (RAPN) to radical nephrectomy (RN). Through a comprehensive database search encompassing PubMed, Web of Science, Embase, and the Cochrane Library, we identified pertinent English-language research published by June 2024. We utilized the NOS scale for quality assessment. The aggregate effect was quantified via the odds ratio (OR), alongside a 95% confidence interval (CI). Sensitivity analyses were conducted using both fixed-effe…
Rank107.1
Adjunctive topical hemostatic agents combined with renorrhaphy versus renorrhaphy alone during partial nephrectomy: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42627530
PURPOSE: Partial nephrectomy (PN) is the standard of care for T1 renal tumors, offering oncological outcomes equivalent to radical nephrectomy while preserving renal function. Intraoperative hemostasis remains a critical challenge, as warm ischemia time is independently associated with postoperative renal functional decline. Topical hemostatic agents have been increasingly adopted as adjuncts to renorrhaphy; however, their incremental benefit over suture alone remains unestablished. This study aimed to compare the …
Rank107.0
Prognostic value of primary tumor location in colorectal cancer: an updated meta-analysis.
Clinical and experimental medicine · 2023 · PMID 37405571
The clinical, histological, and molecular differences between right-sided colon cancer (RCC) and left-sided colon cancer (RCC) have received considerable attention. Over the past decade, many articles have been published concerning the association between primary tumor location (PTL) of colorectal cancer and survival outcomes. Therefore, there is a growing need for an updated meta-analysis integrating the outcomes of recent studies to determine the prognostic role of right vs left-sidedness of PTL in patients with …
Rank106.8
Perioperative, functional and oncologic outcomes of percutaneous ablation versus minimally invasive partial nephrectomy for clinical T1 renal tumors: outcomes from a pooled analysis.
Journal of robotic surgery · 2024 · PMID 39105944
The objective of this study was to perform a comprehensive pooled analysis aimed at comparing the efficacy and safety of percutaneous ablation (PCA) versus minimally invasive partial nephrectomy (MIPN), including robotic and laparoscopic approaches, in patients diagnosed with cT1 renal tumors. We conducted a comprehensive search across four major electronic databases: PubMed, Embase, Web of Science, and the Cochrane Library, targeting studies published in English up to April 2024. The primary outcomes evaluated in …
Rank106.8
Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma.
Annals of medicine · 2026 · PMID 41566198
BACKGROUND AND AIMS: Systemic inflammation is closely linked to the development and progression of various cancers, as well as poorer patient outcomes. The role of the c-reactive protein to albumin ratio (CAR) as a predictor of poor prognosis in renal cell carcinoma (RCC) remains insufficiently recognized. METHODS: A literature search was conducted in major English-language databases, including PubMed, EMBASE, and the Cochrane Library, with the search updated to 25 June 2025. Both the odds ratio (OR) and diagnostic…
Rank106.6
Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42604476
BACKGROUND: We aimed to systematically summarize data on efficacy of local salvage therapies for local recurrence of renal cell carcinoma (RCC). METHODS: We searched MEDLINE, Embase, Web of Science, CENTRAL, and Google Scholar through 05/08/2026, for studies on local salvage therapies for local recurrence of RCC following radical nephrectomy, partial nephrectomy, or ablation (PROSPERO: CRD42024623099). Meta-analyses were conducted using random-effects models. Risk of bias (RoB) was assessed using ROBINS-I. RESULTS:…
Landmark Evidence73 records
Rank110.0
Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.
Journal of endocrinological investigation · 2024 · PMID 38530620
BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…
Rank109.0
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.
European urology · 2022 · PMID 35346519
CONTEXT: The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC. EVIDENCE ACQUISITION: For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering…
Rank107.9
Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor.
Medicine · 2024 · PMID 39259118
BACKGROUND: To date, no meta-analysis has been conducted to compare the effectiveness and safety of adjuvant tyrosine kinase inhibitors (TKIs) and adjuvant immunotherapies (IMTs) in renal cell carcinoma (RCC) patients using reconstructed individual patient data (IPD). This study aims to fill that gap by assessing the efficacy and safety profiles of these treatments in such patients. METHODS: This study employed a systematic approach for identifying relevant literature from the PubMed and EMBASE databases. We includ…
Rank107.6
Clinical application of radiomics for the prediction of treatment outcome and survival in patients with renal cell carcinoma: a systematic review.
World journal of urology · 2024 · PMID 39325194
PURPOSE: The management of renal cell carcinoma (RCC) relies on clinical and histopathological features for treatment decisions. Recently, radiomics, which involves the extraction and analysis of quantitative imaging features, has shown promise in improving RCC management. This review evaluates the current application and limitations of radiomics for predicting treatment and oncological outcomes in RCC. METHODS: A systematic search was conducted in Medline, EMBASE, and Web of Science databases or studies that used …
Rank107.2
Meta-analysis and systematic review of factors predicting conversion to radical nephrectomy following robotic-assisted partial nephrectomy in renal cancer patients.
Journal of robotic surgery · 2024 · PMID 39443332
Evaluating the risk factors for the conversion from robotic-assisted partial nephrectomy (RAPN) to radical nephrectomy (RN). Through a comprehensive database search encompassing PubMed, Web of Science, Embase, and the Cochrane Library, we identified pertinent English-language research published by June 2024. We utilized the NOS scale for quality assessment. The aggregate effect was quantified via the odds ratio (OR), alongside a 95% confidence interval (CI). Sensitivity analyses were conducted using both fixed-effe…
Rank107.0
Prognostic value of primary tumor location in colorectal cancer: an updated meta-analysis.
Clinical and experimental medicine · 2023 · PMID 37405571
The clinical, histological, and molecular differences between right-sided colon cancer (RCC) and left-sided colon cancer (RCC) have received considerable attention. Over the past decade, many articles have been published concerning the association between primary tumor location (PTL) of colorectal cancer and survival outcomes. Therefore, there is a growing need for an updated meta-analysis integrating the outcomes of recent studies to determine the prognostic role of right vs left-sidedness of PTL in patients with …
Rank107.0
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · PMID 34991070
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide managem…
Rank107.0
[Renal cell carcinoma of the kidney transplant: The French guidelines from CTAFU].
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie · 2021 · PMID 33423743
OBJECTIVE: To propose recommendations for the management of renal cell carcinomas (RCC) of the renal transplant. METHOD: Following a systematic approach, a review of the literature (Medline) was conducted by the CTAFU to evaluate prevalence, diagnosis and management of RCC arousing in the renal transplant. References were assessed according to a predefined process to propose recommendations with levels of evidence. RESULTS: Renal cell carcinomas of the renal transplant affect approximately 0.2% of recipients. Mostl…
Rank106.8
Perioperative, functional and oncologic outcomes of percutaneous ablation versus minimally invasive partial nephrectomy for clinical T1 renal tumors: outcomes from a pooled analysis.
Journal of robotic surgery · 2024 · PMID 39105944
The objective of this study was to perform a comprehensive pooled analysis aimed at comparing the efficacy and safety of percutaneous ablation (PCA) versus minimally invasive partial nephrectomy (MIPN), including robotic and laparoscopic approaches, in patients diagnosed with cT1 renal tumors. We conducted a comprehensive search across four major electronic databases: PubMed, Embase, Web of Science, and the Cochrane Library, targeting studies published in English up to April 2024. The primary outcomes evaluated in …
Rank106.7
Acquired Cystic Disease-Associated Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Clinical genitourinary cancer · 2024 · PMID 38502982
Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is a common subtype of renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients. The current systematic review and meta-analysis was performed to evaluate the clinicopathological, and genetic characteristics of patients with ACD-RCC. A systematic search on three electronic databases including the Pubmed, Scopus, and Web of Science databases were performed until December 31, 2022. A meta-analysis was performed following the PRISMA 2020 Gu…
Rank106.4
Percutaneous ablation versus robotic‑assisted partial nephrectomy for cT1 renal cell carcinoma: an evidence-based analysis of comparative outcomes.
Journal of robotic surgery · 2024 · PMID 39078530
This investigation sought to conduct a comprehensive meta-analysis to assess the comparative effectiveness and safety of percutaneous ablation (PCA) versus robotic-assisted partial nephrectomy (RAPN) among individuals diagnosed with cT1 renal tumors. This study rigorously followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to conduct a systematic review and meta-analysis. A systematic search was carried out in the PubMed, Embase, Web of Science, and Cochrane Library d…
Rank106.3
Comparison of the perioperative outcomes of robot-assisted laparoscopic transperitoneal versus retraperitoneal partial nephrectomy for posterior-lateral renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2024 · PMID 38683492
The study aims to assess the available literature and compare the perioperative outcomes of robotic-assisted partial nephrectomy (RAPN) for posterior-lateral renal tumors using transperitoneal (TP) and retroperitoneal (RP) approaches. Systematically searched the Embase, PubMed, and Cochrane Library databases for literature. Eligible studies were those that compared TP-RAPN and RP-RAPN for posterior-lateral renal tumors. The data from the included studies were analyzed and summarized using Review Manager 5.3, which …
Rank106.2
Renal cell carcinoma detection: a systematic review in diagnostic urinary biomarkers.
BMC cancer · 2025 · PMID 41168704
BACKGROUND: Renal cell carcinoma (RCC) accounts for 90% of all renal neoplasms and is often incidentally detected through unrelated imaging procedures. Differentiating between benign and malignant renal masses remains challenging using imaging alone. Urinary biomarkers may aid in this distinction, yet none are currently implemented in the clinic. Moreover, a comprehensive overview of urinary diagnostic biomarkers for RCC is lacking. Therefore, we aimed to systematically review and summarize existing literature on p…
Rank106.0
Comparison of single-port versus multi-port robotic assisted partial nephrectomy: a systematic review and meta-analysis of perioperative and oncological outcomes.
Journal of robotic surgery · 2024 · PMID 39136882
The safety and efficacy of single-port and multi-port robot-assisted partial nephrectomy (SP-RAPN and MP-RAPN, respectively) were assessed for treating partial nephrectomy in this study. A systematic review of PubMed, Cochrane Library, and Web of Science databases was conducted up to June 2024 to compare studies on SP-RAPN and MP-RAPN. Primary outcomes included perioperative results, complications, and oncological outcomes. Eight studies involving 1014 patients were analyzed. For binary outcomes, comparisons were p…
Rank105.2
Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach.
European journal of pediatrics · 2024 · PMID 38019286
This paper aims to explore the epidemiology, clinical characteristics, and prognosis of extracranial malignant rhabdoid tumors (eMRTs) in children. A systematic review and meta-analysis of studies published in PUBMED, MEDLINE, Web of Science, Embase, Cochrane, and China National Knowledge Infrastructure (CNKI) was conducted. The search was limited to studies published between Jan 1, 1990 to Dec 31, 2022, with the last search done on Jan 31, 2023. We identified 496 papers through the literature search, and 12 retros…
Rank105.2
Comparison of AirSeal versus conventional insufflation system for robot-assisted partial nephrectomy: a meta-analysis and systematic review.
Journal of robotic surgery · 2024 · PMID 38922386
A systematic review and meta-analysis were performed to investigate the efficacy of the AirSeal Valveless Trocar Needle Insufflation System in robot-assisted partial nephrectomy (RAPN). The study compared the differences in perioperative outcomes between the AirSeal insufflation group (AIS) and the conventional insufflation group (CIS). A systematic search of databases such as PubMed, Embase, Cochrane library, and Web of science was performed to identify studies reporting perioperative outcomes between the AirSeal …
Rank105.0
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
European urology · 2019 · PMID 30803729
CONTEXT: The European Association of Urology Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To provide an updated RCC guideline based on standardised methodology including systematic reviews, which is robust, transparent, reproducible, and reliable. EVIDENCE ACQUISITION: For the 2019 update, evidence synthesis was undertaken based on a comprehensive and structured literature assessment for new and relevant data. Where neces…
Rank105.0
Robot-assisted versus open partial nephrectomy in patients with a solitary kidney: a systematic review and meta-analysis of perioperative and functional outcomes.
Journal of robotic surgery · 2026 · PMID 42934344
A patient whose renal tumor develops in a solitary kidney has no contralateral organ able to compensate, and therefore offers the clearest setting in which operative injury to the kidney can be studied. Robot-assisted partial nephrectomy (RAPN) has become routine practice among the wider surgical population, yet no systematic appraisal has established whether it is both safe and effective when the tumor is confined to a solitary kidney. To address this gap we conducted a systematic review and meta-analysis comparin…
Rank104.8
Clinical features, laboratory findings and treatment of juxtaglomerular cell tumors: a systemic review.
Hypertension research : official journal of the Japanese Society of Hypertension · 2024 · PMID 38438720
Juxtaglomerular cell tumors (JGCTs) or reninoma are rare kidney tumors leading to secondary hypertension, and the non-specific clinical manifestations bring about challenges to the diagnosis. This study is to summarize the clinical features, laboratory findings, and treatment of JGCTs. The PubMed, EMBASE database, and manual search were utilized to find all cases, and 158 reports containing 261 patients were identified. Data on patients' demographics, clinical features, diagnostic methods, and treatment options wer…
Rank104.1
Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out.
Urologic oncology · 2023 · PMID 37331822
INTRODUCTION: While surgical management of renal cell carcinoma (RCC) is curative for many patients, others may relapse and could benefit from adjuvant treatments. Immune checkpoint inhibitors (ICI) have been proposed as a potential adjuvant therapy for improving survival in these patients, but the benefit/risk ratio of ICI in the perioperative setting remains unclear. METHODS: A systematic review and a meta-analysis of phase III trials of perioperative ICI (anti PD1/PD-L1 alone or in combination with anti-CTLA4 ag…
Rank103.0
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
Journal of the National Comprehensive Cancer Network : JNCCN · 2020 · PMID 32886895
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for…
Rank103.0
2017 AUA Renal Mass and Localized Renal Cancer Guidelines: Imaging Implications.
Radiographics : a review publication of the Radiological Society of North America, Inc · 2018 · PMID 30339517
Renal cell carcinoma (RCC) is a common cancer that is increasing in incidence because of the increased prevalence of risk factors, including tobacco use, hypertension, and obesity, and the improved detection of these tumors due to increased use of imaging. Localized renal cancer now accounts for more than 60%-70% of new RCC cases. Renal masses suggestive of cancer include enhancing solid renal lesions and Bosniak III and IV complex cystic lesions. Most of these tumors are detected incidentally, and many are slow gr…
Rank102.9
Open versus robot-assisted partial nephrectomy for highly complex renal masses: a meta-analysis of perioperitive and functional outcomes.
Journal of robotic surgery · 2023 · PMID 37415066
Robot-assisted partial nephrectomy (RAPN) is increasingly being used for the complex surgical management of renal masses. The comparison of RAPN with open partial nephrectomy (OPN) has not yet led to a unified conclusion with regard to perioperative outcomes. To conduct a systematic review and meta-analysis of the literature on the perioperative outcomes of RAPN compared with OPN. We performed a systematic search in PubMed, Embase, Web of Science, and Cochrane Library database for randomized control trials (RCTs) a…
Rank102.3
Proportion of malignancy in Bosniak classification of cystic renal masses version 2019 (v2019) classes: systematic review and meta-analysis.
European radiology · 2023 · PMID 35999371
OBJECTIVES: Determine the proportion of malignancy within Bosniak v2019 classes. METHODS: MEDLINE and EMBASE were searched. Eligible studies contained patients with cystic renal masses undergoing CT or MRI renal protocol examinations with pathology confirmation, applying Bosniak v2019. Proportion of malignancy was estimated within Bosniak v2019 class. Risk of bias was assessed using QUADAS-2. RESULTS: We included 471 patients with 480 cystic renal masses. No class I malignant masses were observed. Pooled proportion…
Rank102.0
First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy.
BJU international · 2024 · PMID 38659099
OBJECTIVE: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. PATIENTS AND METHODS: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first-line ICI-b…
Most Effective Evidence Supported Treatments93 records
Rank110.0
Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.
Journal of endocrinological investigation · 2024 · PMID 38530620
BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…
Rank110.0
The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026 · PMID 42611330
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not …
Rank110.0
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.
ESMO open · 2026 · PMID 42914499
The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma (RCC) were published in May 2024 and adapted in December 2025 according to previously established standard methodology to produce the Pan-Asian adapted ESMO consensus guidelines for the management of Asian patients with RCC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatmen…
Rank110.0
[Update renal cell carcinoma : Guideline update on small renal masses].
Urologie (Heidelberg, Germany) · 2026 · PMID 42726211
Small renal masses (kidney tumors < 4 cm) are benign in up to 30% of cases and often exhibit slow growth, yet they are still frequently primarily managed by surgery. A tumor biopsy should be performed before initiating active surveillance. As up to 8% of renal tumors could have a hereditary component, risk factors such as a diagnosis before the age of 47 years old, bilateral or multifocal lesions and syndrome-associated extrarenal manifestations, should be systematically assessed and clarified by a genetic evaluati…
Rank109.2
Comparative outcomes of robot-assisted and open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42624966
For patients with renal cell carcinoma (RCC) complicated by inferior vena cava (IVC) tumor thrombus, radical nephrectomy combined with thrombectomy remains a key surgical option. Open radical nephrectomy with IVC thrombectomy (O-RNTT) has long been regarded as the traditional operative strategy, whereas robot-assisted radical nephrectomy with IVC thrombectomy (R-RNTT) is now being used more frequently in high-experience centers. Direct comparative data, however, remain limited. This study aimed to compare periopera…
Rank108.8
Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Cancer · 2026 · PMID 42779347
The objective of this systematic review and meta-analysis was to evaluate the validity of progression-free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma. The MEDLINE, Embase, and Cochrane CENTRAL databases were searched from inception to June 10, 2025. Associations between treatment effects on OS, PFS, and ORR were assessed using Pearson correlation coefficients (r). Surrogate threshold…
Rank108.3
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42634038
Single-port robot-assisted partial nephrectomy (SP-RAPN) is increasingly used for selected renal tumors, but its comparative value over multi-port robot-assisted partial nephrectomy (MP-RAPN) remains uncertain. We performed a systematic review and meta-analysis of comparative studies, prioritizing propensity score-matched data when available. PubMed, Scopus, Web of Science, and Google Scholar were searched. Three studies involving 442 patients were included (210 SP-RAPN and 232 MP-RAPN). SP-RAPN was associated with…
Rank108.0
Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis.
Cancer · 2026 · PMID 42590929
BACKGROUND: Disease-free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting. METHODS: The authors conducted a systematic review and trial-level meta-analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. D…
Rank107.6
Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Medical oncology (Northwood, London, England) · 2026 · PMID 42484760
To update a network meta-analysis of first-line immunotherapy combinations in advanced renal cell carcinoma (RCC) using short-term data for primary analysis and long-term plus newly published randomized controlled trials (RCTs) for subgroup analyses. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese databases for articles from inception to 22 December 2024, performing a Bayesian network meta-analysis. Overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and…
Rank107.6
Clinical application of radiomics for the prediction of treatment outcome and survival in patients with renal cell carcinoma: a systematic review.
World journal of urology · 2024 · PMID 39325194
PURPOSE: The management of renal cell carcinoma (RCC) relies on clinical and histopathological features for treatment decisions. Recently, radiomics, which involves the extraction and analysis of quantitative imaging features, has shown promise in improving RCC management. This review evaluates the current application and limitations of radiomics for predicting treatment and oncological outcomes in RCC. METHODS: A systematic search was conducted in Medline, EMBASE, and Web of Science databases or studies that used …
Rank107.4
First-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma: a network meta-analysis and cost-effectiveness analysis.
Frontiers in immunology · 2026 · PMID 42876805
OBJECTIVE: This study aimed to systematically evaluate the efficacy of first-line immune checkpoint inhibitors (ICIs) combined with targeted therapy for advanced renal cell carcinoma (RCC) and assess their cost-effectiveness from the perspective of the Chinese healthcare system. METHODS: Phase III randomized controlled trials comparing ICI-targeted combinations versus sunitinib as first-line treatment for advanced RCC were identified through systematic searches of PubMed, EMBASE, and the Cochrane Library. A network…
Rank107.3
Effect of tobacco avoidance on the incidence of non-hereditary renal cell carcinoma in patients over 18 years of age: systematic review and meta-analysis.
International urology and nephrology · 2026 · PMID 42118473
OBJECTIVE: Risk factors for kidney cancer are divided into modifiable and non-modifiable factors. Among the former, smoking stands out, whose relationship with the disease has been extensively studied, from the intensity of consumption to the effects of cessation. However, the impact of avoiding smoking is not precisely known. This study aimed to estimate the effect of avoiding tobacco use on the risk of renal cell carcinoma (RCC) in patients over 18 years of age with no family history. METHODS: A systematic review…
Rank107.2
Meta-analysis and systematic review of factors predicting conversion to radical nephrectomy following robotic-assisted partial nephrectomy in renal cancer patients.
Journal of robotic surgery · 2024 · PMID 39443332
Evaluating the risk factors for the conversion from robotic-assisted partial nephrectomy (RAPN) to radical nephrectomy (RN). Through a comprehensive database search encompassing PubMed, Web of Science, Embase, and the Cochrane Library, we identified pertinent English-language research published by June 2024. We utilized the NOS scale for quality assessment. The aggregate effect was quantified via the odds ratio (OR), alongside a 95% confidence interval (CI). Sensitivity analyses were conducted using both fixed-effe…
Rank107.1
Adjunctive topical hemostatic agents combined with renorrhaphy versus renorrhaphy alone during partial nephrectomy: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42627530
PURPOSE: Partial nephrectomy (PN) is the standard of care for T1 renal tumors, offering oncological outcomes equivalent to radical nephrectomy while preserving renal function. Intraoperative hemostasis remains a critical challenge, as warm ischemia time is independently associated with postoperative renal functional decline. Topical hemostatic agents have been increasingly adopted as adjuncts to renorrhaphy; however, their incremental benefit over suture alone remains unestablished. This study aimed to compare the …
Rank106.8
Perioperative, functional and oncologic outcomes of percutaneous ablation versus minimally invasive partial nephrectomy for clinical T1 renal tumors: outcomes from a pooled analysis.
Journal of robotic surgery · 2024 · PMID 39105944
The objective of this study was to perform a comprehensive pooled analysis aimed at comparing the efficacy and safety of percutaneous ablation (PCA) versus minimally invasive partial nephrectomy (MIPN), including robotic and laparoscopic approaches, in patients diagnosed with cT1 renal tumors. We conducted a comprehensive search across four major electronic databases: PubMed, Embase, Web of Science, and the Cochrane Library, targeting studies published in English up to April 2024. The primary outcomes evaluated in …
Rank106.6
Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42604476
BACKGROUND: We aimed to systematically summarize data on efficacy of local salvage therapies for local recurrence of renal cell carcinoma (RCC). METHODS: We searched MEDLINE, Embase, Web of Science, CENTRAL, and Google Scholar through 05/08/2026, for studies on local salvage therapies for local recurrence of RCC following radical nephrectomy, partial nephrectomy, or ablation (PROSPERO: CRD42024623099). Meta-analyses were conducted using random-effects models. Risk of bias (RoB) was assessed using ROBINS-I. RESULTS:…
Rank106.4
Percutaneous ablation versus robotic‑assisted partial nephrectomy for cT1 renal cell carcinoma: an evidence-based analysis of comparative outcomes.
Journal of robotic surgery · 2024 · PMID 39078530
This investigation sought to conduct a comprehensive meta-analysis to assess the comparative effectiveness and safety of percutaneous ablation (PCA) versus robotic-assisted partial nephrectomy (RAPN) among individuals diagnosed with cT1 renal tumors. This study rigorously followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to conduct a systematic review and meta-analysis. A systematic search was carried out in the PubMed, Embase, Web of Science, and Cochrane Library d…
Rank106.3
Comparison of the perioperative outcomes of robot-assisted laparoscopic transperitoneal versus retraperitoneal partial nephrectomy for posterior-lateral renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2024 · PMID 38683492
The study aims to assess the available literature and compare the perioperative outcomes of robotic-assisted partial nephrectomy (RAPN) for posterior-lateral renal tumors using transperitoneal (TP) and retroperitoneal (RP) approaches. Systematically searched the Embase, PubMed, and Cochrane Library databases for literature. Eligible studies were those that compared TP-RAPN and RP-RAPN for posterior-lateral renal tumors. The data from the included studies were analyzed and summarized using Review Manager 5.3, which …
Rank106.2
Single‑port versus multi‑port robotic-assisted partial nephrectomy: a systematic review and meta-analysis of propensity score-matched cohort studies.
International urology and nephrology · 2026 · PMID 42287517
PURPOSE: The effectiveness of single-port (SP) versus multi-port (MP) robotic-assisted partial nephrectomy (RAPN) has been compared in many studies, but the comparative superiority remains unclear. The purpose of this article is to comprehensively review the existing literature and conduct a more precise comparison of the two surgical methods. METHODS: We performed a thorough literature search in PubMed, Web of Science, Embase, and Cochrane CENTRAL databases to identify relevant studies published before April 2026.…
Rank106.0
Comparison of single-port versus multi-port robotic assisted partial nephrectomy: a systematic review and meta-analysis of perioperative and oncological outcomes.
Journal of robotic surgery · 2024 · PMID 39136882
The safety and efficacy of single-port and multi-port robot-assisted partial nephrectomy (SP-RAPN and MP-RAPN, respectively) were assessed for treating partial nephrectomy in this study. A systematic review of PubMed, Cochrane Library, and Web of Science databases was conducted up to June 2024 to compare studies on SP-RAPN and MP-RAPN. Primary outcomes included perioperative results, complications, and oncological outcomes. Eight studies involving 1014 patients were analyzed. For binary outcomes, comparisons were p…
Rank105.9
Kidney-sparing Treatments for Local Recurrence in Renal Cell Tumours After Partial Nephrectomy or Focal Therapy: A Systematic Review.
European urology focus · 2026 · PMID 41412889
BACKGROUND AND OBJECTIVE: Kidney-sparing treatments are salvage options for renal cell carcinoma (RCC) after local recurrence. However, there is no level 1 evidence in the literature examining the efficacy of focal therapies (FTs) and partial nephrectomy (PN) in a head-to-head, randomised comparison. METHODS: A systematic search (PROSPERO CRD420251033642) was performed. The present analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. KEY FINDINGS AND LIMITATIONS: Ove…
Rank105.9
Robot-assisted versus non-robotic partial nephrectomy for completely endophytic renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42828586
Completely endophytic renal tumors (CERTs), which are entirely confined within the renal parenchyma, present substantial technical challenges during nephron-sparing surgery. We conducted a systematic review and meta-analysis to compare robot-assisted partial nephrectomy (RAPN) with laparoscopic partial nephrectomy (LPN) and open partial nephrectomy (OPN) specifically for CERTs. PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were searched through August 24, 2026. Eligible comparative studies direct…
Rank105.8
Sutureless versus renorrhaphy in robot-assisted off-clamp partial nephrectomy: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42704544
BACKGROUND: The necessity of routine parenchymal renorrhaphy during off-clamp robot-assisted partial nephrectomy (RAPN) remains uncertain. This study aimed to compare perioperative, functional, safety, and oncological outcomes between sutureless and conventional renorrhaphy. METHODS: We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. Comparative studies evaluating sutureless versus conventional renorrhaphy during purely off-clamp RAPN were included. Trifecta achievement was the pri…
Rank105.4
Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 42350220
Immune checkpoint inhibitor (ICI)-based combination therapies have transformed the management of metastatic renal cell carcinoma (mRCC). However, their benefit in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) favorable-risk disease remains uncertain, raising concerns about potential overtreatment. We conducted a meta-analysis incorporating extended follow-up survival data to evaluate the long-term benefits of ICI-based combinations in this subgroup. PubMed, EMBASE, Web of Science, and the…
Rank105.2
Extracranial malignant rhabdoid tumors in children: high mortality even with the help of an aggressive clinical approach.
European journal of pediatrics · 2024 · PMID 38019286
This paper aims to explore the epidemiology, clinical characteristics, and prognosis of extracranial malignant rhabdoid tumors (eMRTs) in children. A systematic review and meta-analysis of studies published in PUBMED, MEDLINE, Web of Science, Embase, Cochrane, and China National Knowledge Infrastructure (CNKI) was conducted. The search was limited to studies published between Jan 1, 1990 to Dec 31, 2022, with the last search done on Jan 31, 2023. We identified 496 papers through the literature search, and 12 retros…
New Research Last 24 Months171 records
Rank106.8
Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma.
Annals of medicine · 2026 · PMID 41566198
BACKGROUND AND AIMS: Systemic inflammation is closely linked to the development and progression of various cancers, as well as poorer patient outcomes. The role of the c-reactive protein to albumin ratio (CAR) as a predictor of poor prognosis in renal cell carcinoma (RCC) remains insufficiently recognized. METHODS: A literature search was conducted in major English-language databases, including PubMed, EMBASE, and the Cochrane Library, with the search updated to 25 June 2025. Both the odds ratio (OR) and diagnostic…
Rank105.0
Robot-assisted versus open partial nephrectomy in patients with a solitary kidney: a systematic review and meta-analysis of perioperative and functional outcomes.
Journal of robotic surgery · 2026 · PMID 42934344
A patient whose renal tumor develops in a solitary kidney has no contralateral organ able to compensate, and therefore offers the clearest setting in which operative injury to the kidney can be studied. Robot-assisted partial nephrectomy (RAPN) has become routine practice among the wider surgical population, yet no systematic appraisal has established whether it is both safe and effective when the tumor is confined to a solitary kidney. To address this gap we conducted a systematic review and meta-analysis comparin…
Rank100.0
Efficacy and safety of surgical management for Rathke's cleft cysts in pediatric patients: a systematic review and meta-analysis.
Neurosurgical review · 2024 · PMID 39738909
Rathke's cleft cysts (RCCs) are benign, cystic lesions that account for less than 5% of cases in the pediatric population. While asymptomatic RCCs often require only conservative management, symptomatic cases may necessitate surgical intervention. Advances in surgical techniques have improved the safety of these procedures. This comprehensive review and single-arm meta-analysis evaluates the outcomes of surgical management in pediatric patients. PubMed, Embase, and Web of Science were systematically searched for st…
Rank100.0
Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis.
Clinical & experimental metastasis · 2024 · PMID 39680251
Studies conducted in the last few years have suggested a connection between clinical outcomes and the time of immune checkpoint inhibitors (ICIs) infusion. However, few data are available regarding the differences between early and late time-of-day (ToD) administration in metastatic renal cell carcinoma (mRCC) patients receiving immunotherapy and immune-based combinations. In this meta-analysis, we aimed to fully investigate the influence of timing of administration on the efficacy of mRCC immunotherapy, by compari…
Rank100.0
Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study.
Clinical & experimental metastasis · 2024 · PMID 39739072
Immune-based combinations have significantly improved the treatment of metastatic renal cell carcinoma (mRCC); however, immunotherapy has reported varying degrees of efficacy across different metastatic sites, with liver and bone metastases traditionally considered more challenging to treat. In MOUSEION-08 study, we aimed to investigate the association between lung, liver, and bone metastases and clinical outcomes such as Overall Survival (OS) and Progression- Free Survival (PFS) in mRCC patients receiving immune-b…
Rank96.0
Efficacy of immune-oncology combinations versus sunitinib in patients with bone metastases from renal cell carcinoma: A systematic review and meta-analysis of phase III trials with long-term follow-up.
Journal of bone oncology · 2026 · PMID 42898627
BACKGROUND: Bone metastases occur in approximately one-third of patients with metastatic clear-cell renal cell carcinoma (ccRCC) and are associated with poor prognosis. Although immune-oncology (IO)-based combinations are the standard first-line treatment, the relative efficacy of IO plus tyrosine kinase inhibitor (IO+TKI) versus dual immunotherapy (IO+IO) in this subgroup remains uncertain. METHODS: We performed a systematic review and meta-analysis of phase III randomized trials comparing first-line IO-based comb…
Rank96.0
Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.
European journal of clinical pharmacology · 2024 · PMID 39285057
BACKGROUND: Recent evidence suggests an association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and a higher risk of renal cancer. OBJECTIVE: We conducted a pharmacovigilance analysis using the US FDA Adverse Event Reporting System (FAERS) to investigate the disproportionate association between SGLT2 inhibitors and renal cancer. METHODS: We used AERSMine to mine data from FAERS, covering the period from 2014 Q1 to 2023 Q3. The control group was treated with other glucose-lowering medications (ATC-A10B…
Rank96.0
Efficacy and safety of single-fraction stereotactic body radiotherapy (SBRT) for the curative treatment of extracranial primary Tumors: A collaborative systematic review on behalf of the SBRT Focus Group of the European Society for Radiotherapy & Oncology (ESTRO).
Clinical and translational radiation oncology · 2027 · PMID 42898625
Single-fraction stereotactic body radiotherapy (SF-SBRT) represents one of the most advanced frontiers in modern radiation oncology. While ultra-hypofractionation has entered everyday clinical practice in different fields of the oncological care, curative treatments in one session are increasingly attractive for the potential favorable combination of logistic advantages with safety and clinical outcomes. This collaborative systematic review promoted by the ESTRO SBRT Focus Group in participation with members of dif…
Rank96.0
Pan-cancer multi-omics machine learning defines a lactylation-associated immune-excluded tumor state with proteomic and experimental corroboration.
Computational biology and chemistry · 2026 · PMID 42556016
BACKGROUND: Histone lactylation links lactate metabolism to chromatin regulation, but whether lactylation-program-associated transcriptional patterns delineate recurrent pan-cancer tumor states remains unclear. METHODS: We integrated mRNA, lncRNA, and miRNA profiles from 9712 TCGA tumors across 33 cancer types with GTEx references, six GEO cohorts, IMvigor210, and an institutional clear-cell renal cell carcinoma (ccRCC) cohort used for exploratory DIA-NN proteomic corroboration. Random-effects co-expression meta-an…
Rank88.0
Global Landscape of Clinical Studies Open to Enrollment in Carbon Ion Radiotherapy: A PTCOG Review.
International journal of particle therapy · 2026 · PMID 42893060
BACKGROUND: Radiotherapy with high linear energy transfer (LET) has shown promise for improving cancer outcomes. Carbon ion radiotherapy (CIRT) combines charged-particle dose conformality with enhanced biological effectiveness. However, clinical development remains constrained by limited center availability, modest trial accrual, and few randomized studies. We reviewed the global landscape of CIRT studies open to enrollment to identify current priorities and gaps. METHODS: This Particle Therapy Cooperative Group (P…
Rank85.0
[Non-clear cell renal cell carcinoma].
Urologie (Heidelberg, Germany) · 2024 · PMID 39589483
Non-clear cell renal cell carcinomas (nccRCC) account for approximately 20-25% of renal cell carcinomas. Approximately 20 different histologically and/or molecularly defined entities are subsumed under nccRCC. Many entities only have a share of 1% or less. Due to the rarity of the subpopulations, there are currently no larger randomized studies and there is a some uncertainty regarding the optimal treatment recommendations. The previous treatment recommendations for localized and advanced nccRCC are presented. Data…
Rank81.5
Association of AI-derived abdominal organ volumetry with postoperative outcomes in clear cell renal cell carcinoma: a multicentre study.
Annals of medicine · 2026 · PMID 42723375
BACKGROUND: CT-derived body composition parameters are associated with clinical outcomes in clear cell renal cell carcinoma (ccRCC), but the prognostic value of abdominal solid organ volumes remains unclear. METHODS: In this multicentre study, 1,720 patients with ccRCC who underwent nephrectomy across four centres and 3,052 healthy controls were included. A deep learning algorithm was used to automatically quantify abdominal organ volumes. Organ volume indices were calculated by normalizing volumes to body surface …
Rank79.5
Real-world comparative outcomes of first-line immune combinations (ICI-ICI vs ICI-TKI) in metastatic renal cell carcinoma with sarcomatoid features.
Oncoimmunology · 2026 · PMID 42912018
INTRODUCTION: Although first-line immune-based combinations have reshaped the management of metastatic renal cell carcinoma (mRCC), relevant unmet clinical needs remain. Sarcomatoid feature is a negative prognostic factor that confers sensitivity to immunotherapy, yet the optimal ICI combination in this subgroup is still unclear. METHODS: The Meet-URO 33 is an Italian multicenter retrospective/prospective observational study enrolling patients with mRCC receiving first-line systemic therapy in routine clinical prac…
Rank79.4
Prognostic significance of systemic immunoinflammatory biomarkers and pathological features in clear cell renal cell carcinoma: a multicenter study.
Annals of medicine · 2026 · PMID 42669053
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) exhibits heterogeneous postoperative outcomes. This study aimed to evaluate systemic immunoinflammatory biomarkers and pathological features and develop an integrated prognostic model for overall survival (OS) in patients with ccRCC. METHODS: This multicenter retrospective study initially screened 1,662 patients who underwent surgery between January 2010 and December 2024. After excluding 27 patients with substantial missing data, 1,635 were included in baseline a…
Rank78.7
Development and validation of nomograms and integrated software incorporating preoperative C-reactive protein level for prognostic prediction of nonmetastatic clear cell renal cell carcinoma: Results from the International Marker Consortium for Renal Cancer (INMARC) Registry.
World journal of urology · 2025 · PMID 39786437
PURPOSE: Preoperative C-reactive protein (CRP) is a valuable prognostic biomarker in nonmetastatic clear cell renal cell carcinoma (nmccRCC). Incorporation of CRP into prognostic models may improve the prediction of oncologic outcomes. Herein, we aimed to develop and validate prognostic nomograms and an integrated software incorporating preoperative CRP level in nmccRCC. METHODS: An international multi-institutional database was retrospectively analyzed for nmccRCC patients undergoing surgery. A total of 2284 patie…
Rank78.6
Identification and validation of a chronic kidney disease prediction model after radical nephrectomy: a multicenter cohort retrospective study.
Annals of medicine · 2026 · PMID 42808223
INTRODUCTION: Long-term renal function is an important follow-up after radical nephrectomy for renal carcinoma. Predictive models can help identify patients at risk for chronic kidney disease (CKD) progression and enable early intervention. METHODS: We retrospectively analyzed 649 patients who underwent radical nephrectomy at eight medical centers. The primary cohort from the Affiliated Hospital of Qingdao University comprised 329 patients, randomly divided into training sets (n = 229) and internal validation sets …
Rank77.0
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma.
World journal of urology · 2025 · PMID 39747746
PURPOSE: Immune Checkpoints Inhibitors (ICI) have changed the therapeutic landscape of metastatic renal cell carcinoma first-line treatment with complete response (CR) at metastatic sites observed in 10 to 15% of cases. Delayed nephrectomy could be discussed for patients having a clinical benefit from immunotherapy-based treatment. However, it is unclear whether prior immunotherapy exposure adversely influences the complexity of surgery. The aim of this study was to assess oncological outcomes of differed nephrecto…
Rank76.6
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
Oncoimmunology · 2026 · PMID 42366526
Non-clear cell renal cell carcinoma (nccRCC) represents a biologically heterogeneous group of tumors for which optimal systemic treatment strategies remain poorly defined despite recent therapeutic advances. To address this gap, we evaluated the clinical activity and safety of cabozantinib plus nivolumab in patients with advanced nccRCC. In this nationwide, multicenter retrospective cohort study conducted in the Republic of Korea, 62 patients received the combination across multiple lines of therapy, with most trea…
Rank71.2
Polygenic score for body mass index in relation to mortality among patients with renal cell cancer.
International journal of obesity (2005) · 2024 · PMID 39152336
BACKGROUND: The association between body mass index (BMI) and mortality among individuals with renal cell cancer (RCC) is debated, with some observational studies suggesting a lower mortality associated with higher BMI. However, methodological issues such as confounding and reverse causation may bias these findings. Using BMI-associated genetic variants can avoid these biases and generate more valid estimates. METHODS: In this prospective cohort study, we included 1264 RCC patients (446 deaths) from the UK Biobank.…
Rank67.9
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
Cancer medicine · 2025 · PMID 39945382
BACKGROUND: Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL with checkpoint blockade may result in improved response to immunotherapy. METHODS: NCT02419495 was a multiarm phase IB study of SEL in combination with other standard regimens in patients with advanced malignancies. Arm M utilized twice weekly oral SEL and intravenous nivolumab (NIVO). Arm N utilized weekly o…
Rank65.0
FOXM1-mediated transcriptional activation of CILP2 promotes malignant phenotypes and EMT-associated remodeling in clear cell renal cell carcinoma.
Pathology, research and practice · 2026 · PMID 42828966
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cancer and remains associated with aggressive progression and poor clinical outcomes. Cartilage intermediate layer protein 2 (CILP2), an extracellular matrix-associated secreted protein, has been implicated in tumor-related processes, but its biological role and regulatory mechanism in ccRCC remain unclear. METHODS: CILP2 expression and its association with clinical outcomes were evaluated using multiple public data…
Rank56.0
CT-based multimodal fusion model for preoperative clear cell renal cell carcinoma grading: A multicenter study.
European journal of radiology · 2026 · PMID 42962514
OBJECTIVES: To develop and evaluate a multimodal fusion framework for the preoperative World Health Organization/International Society of Urological Pathology (WHO/ISUP) low- and high-grade classification of clear cell renal cell carcinoma (ccRCC), integrating clinical characteristics, deep learning (DL), and radiomic signatures extracted from corticomedullary phase (CMP) contrast-enhanced computed tomography (CECT) images. MATERIALS AND METHODS: In this retrospective multicenter study, we evaluated a cohort of 1,0…
Rank55.0
Risk factors of surgical compliance and impact on survival in patients with kidney cancer: a population-based, propensity score matching study.
Langenbeck's archives of surgery · 2024 · PMID 39540950
BACKGROUND: To identify the impact of surgical compliance on survival in patients with kidney cancer and to explore the factors that influence surgical compliance. METHODS: Clinical date of kidney cancer patients were identified from the SEER databases, and the patients were divided into surgical compliance group and surgical noncompliance group. Cox survival analysis and Kaplan-Meier curves were used to evaluate the effect of surgical compliance on overall survival (OS) and cancer-specific survival (CSS). A diagno…
Rank53.8
[Update from d-uo: what can healthcare research contribute to renal cell carcinoma?].
Urologie (Heidelberg, Germany) · 2024 · PMID 39531073
BACKGROUND: Renal cell carcinoma (RCC) accounts for about 13.5% of all urological tumors. Healthcare research analyzes whether treatment recommendations from controlled studies or guidelines are being implemented in routine care. A prerequisite for the assessment and scientific study of the quality of care in the treatment of urological tumors is standardized documentation. OBJECTIVES: This article illustrates healthcare research in RCC by presenting current data from the prospective of the VERSUS study (VERSorgUng…
Rank53.3
Cardiovascular disease-specific mortality after partial versus radical nephrectomy for stage II renal cancer: A SEER-based propensity-matched analysis.
Translational oncology · 2026 · PMID 42906453
BACKGROUND: Surgery remains standard treatment for localized renal cancer. Whether partial nephrectomy (PN), compared with radical nephrectomy (RN), affects long-term cardiovascular disease-specific mortality (CVD-SM) in stage II disease is uncertain. We assessed this association using competing-risk methods. METHODS: Patients with T2N0M0 renal cancer diagnosed in the SEER database from 2004 to 2022 were included. Missing tumor grade and unspecified T2 subclassification were addressed by multiple imputation. Propen…
Preclinical Research87 records
Rank88.0
Global Landscape of Clinical Studies Open to Enrollment in Carbon Ion Radiotherapy: A PTCOG Review.
International journal of particle therapy · 2026 · PMID 42893060
BACKGROUND: Radiotherapy with high linear energy transfer (LET) has shown promise for improving cancer outcomes. Carbon ion radiotherapy (CIRT) combines charged-particle dose conformality with enhanced biological effectiveness. However, clinical development remains constrained by limited center availability, modest trial accrual, and few randomized studies. We reviewed the global landscape of CIRT studies open to enrollment to identify current priorities and gaps. METHODS: This Particle Therapy Cooperative Group (P…
Rank67.9
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
Cancer medicine · 2025 · PMID 39945382
BACKGROUND: Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL with checkpoint blockade may result in improved response to immunotherapy. METHODS: NCT02419495 was a multiarm phase IB study of SEL in combination with other standard regimens in patients with advanced malignancies. Arm M utilized twice weekly oral SEL and intravenous nivolumab (NIVO). Arm N utilized weekly o…
Rank65.0
FOXM1-mediated transcriptional activation of CILP2 promotes malignant phenotypes and EMT-associated remodeling in clear cell renal cell carcinoma.
Pathology, research and practice · 2026 · PMID 42828966
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cancer and remains associated with aggressive progression and poor clinical outcomes. Cartilage intermediate layer protein 2 (CILP2), an extracellular matrix-associated secreted protein, has been implicated in tumor-related processes, but its biological role and regulatory mechanism in ccRCC remain unclear. METHODS: CILP2 expression and its association with clinical outcomes were evaluated using multiple public data…
Rank47.5
Branching Patterns, Morphometry, and Topographical Anatomy of the Aortic Arch and Subclavian Arteries in the Domestic Cat (Felis catus).
Anatomia, histologia, embryologia · 2026 · PMID 42803748
Comprehensive knowledge of feline vascular anatomy is essential for accurate diagnostic imaging interpretation and safe thoracic cardiovascular surgery. This study aimed to characterize the branching patterns, quantitative morphometry, and precise topographical positions of the aortic arch branches and subclavian arteries in domestic cats (Felis catus). Twenty adult cat cadavers from Northwestern Iran were examined. Coloured latex was injected into the aortic arch, followed by fixation in 10% neutral buffered forma…
Rank45.0
Analysis of KangDuo-SR-1500 and KangDuo-SR-2000 robotic partial nephrectomy from an operative and ergonomic perspective: a prospective controlled study in porcine models.
Journal of robotic surgery · 2024 · PMID 38217779
The objective of this study is to explore the safety and effectiveness of two new models of KangDuo surgical robots for partial nephrectomy in porcine models, and evaluate the ergonomic characteristics from both subjective and objective perspectives. Twelve porcine models were equally divided for KD-SR-1500 (three-arm) and KD-SR-2000 (four-arm). The perioperative outcomes, and physical and mental workload of the surgeon were compared. Physical workload was evaluated with surface electromyography. Mental workload wa…
Rank45.0
PDZ domain containing 1 sensitizes renal cancer cells to everolimus via inhibiting phosphatase and tensin homolog phosphorylation-mediated mTOR pathway activation.
International journal of biological macromolecules · 2026 · PMID 42838165
Aberrant activation of the phosphatase and tensin homolog (PTEN)-PI3K/AKT/mTOR pathway is a key driver of renal cell carcinoma (RCC) progression, making mTOR inhibition with everolimus a critical therapeutic strategy. However, the mechanisms driving mTOR pathway activation and the emergence of drug resistance remain poorly understood. In this study, we found that phosphorylated PTEN (pPTEN at S380/T382/T383) level was increased in RCC. Increased pPTEN level was associated with impaired suppression of mTOR pathway a…
Rank45.0
Circular RNA AGAP1 Stimulates Immune Escape and Distant Metastasis in Renal Cell Carcinoma.
Molecular biotechnology · 2024 · PMID 37202649
Clear cell renal cell carcinoma (ccRCC) is the most representative subtype of renal cancer, with a highly aggressive phenotype and extremely poor prognosis. Immune escape is one of the main reasons for ccRCC growth and metastasis, in which circular RNAs (circRNAs) play critical roles. Therefore, this research studied circAGAP1-associated mechanisms in immune escape and distant metastasis in ccRCC. circAGAP1/miR-216a-3p/MKNK2 was overexpressed or down-regulated by cell transfection. EdU assay, colony formation assay…
Rank42.0
Pathological consequences of DNA damage in the kidney.
Nature reviews. Nephrology · 2023 · PMID 36702905
DNA lesions that evade repair can lead to mutations that drive the development of cancer, and cellular responses to DNA damage can trigger senescence and cell death, which are associated with ageing. In the kidney, DNA damage has been implicated in both acute and chronic kidney injury, and in renal cell carcinoma. The susceptibility of the kidney to chemotherapeutic agents that damage DNA is well established, but an unexpected link between kidney ciliopathies and the DNA damage response has also been reported. In a…
Rank34.9
Metastatic Bone Disease Is Associated With Longitudinal Muscle Loss and Reduced Survival in Kidney Cancer.
Journal of cachexia, sarcopenia and muscle · 2026 · PMID 42823780
BACKGROUND: Cachexia is a multifactorial muscle wasting syndrome and is responsible for 20%-40% of cancer-related deaths, yet no FDA-approved therapies exist. Preclinical studies suggest that metastatic bone disease may contribute to muscle wasting, but this relationship has not been evaluated in clinical populations. This study evaluated whether metastatic bone disease at diagnosis is associated with longitudinal skeletal muscle loss and whether metastatic bone disease and longitudinal skeletal muscle loss are ass…
Rank34.3
Bacteria inside kidney tumors associate with myeloid inflammation and disease progression: A TRACERx Renal study.
Med (New York, N.Y.) · 2026 · PMID 42914984
BACKGROUND: Intratumoral bacteria are increasingly recognized as active contributors to neutrophil-driven inflammation and disease progression in solid tumors. Yet, in clear cell renal cell carcinoma (ccRCC), where myeloid inflammation is a key feature of aggressive disease, live bacterial presence, their intratumoral distribution, and interaction with the tumor microenvironment remain unexplored. METHODS: We genetically characterized the microbiome of primary ccRCC tumors across two independent cohorts (TRACERx: 6…
Rank32.8
Red cells stored in non-DEHP containers: The effect of washing, irradiation or storage as paediatric units on in vitro quality parameters.
Vox sanguinis · 2026 · PMID 42901701
BACKGROUND AND OBJECTIVES: In accordance with European Union (EU) regulations, the use of the polyvinyl chloride (PVC) plasticiser diethylhexyl phthalate (DEHP) in medical devices must be phased out by 2030 in the EU. We recently evaluated the in vitro quality of red cell concentrates (RCCs) in phosphate-adenine-glucose-guanosine-saline-mannitol (PAGGSM) drawn in di(isononyl) cyclohexane-1,2-dicarboxylate (DINCH) and stored in BTHC-plasticised PVC. Here we aimed to evaluate the effects of washing, gamma irradiation…
Rank32.0
Hallmark discoveries in the biology of Wilms tumour.
Nature reviews. Urology · 2024 · PMID 37848532
The modern study of Wilms tumour was prompted nearly 50 years ago, when Alfred Knudson proposed the 'two-hit' model of tumour development. Since then, the efforts of researchers worldwide have substantially expanded our knowledge of Wilms tumour biology, including major advances in genetics - from cloning the first Wilms tumour gene to high-throughput studies that have revealed the genetic landscape of this tumour. These discoveries improve understanding of the embryonal origin of Wilms tumour, familial occurrences…
Rank32.0
Upregulated PPP1R14B is connected to cancer progression and immune infiltration in kidney renal clear cell carcinoma.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024 · PMID 37261660
BACKGROUND: Protein phosphatase 1 regulatory subunit 14B (PPP1R14B) is an oncogenic gene found in a variety of tumors, but its role in the prognosis and development of kidney renal clear cell carcinoma (KIRC) remains unknown. Our study aimed to determine whether PPP1R14B could be a prognostic biomarker for KIRC and its role in the development of KIRC. METHODS: In this work, we used The Cancer Genome Atlas (TCGA) database to explore the expression of PPP1R14B in tumor tissues, its relationship with the prognosis of …
Rank31.9
Assessing the Mutational Consequences of Chronic Arsenic Exposure Using Patient-Derived Tumor Samples and In Vitro Systems.
Environmental and molecular mutagenesis · 2026 · PMID 42920328
Inorganic arsenic, a naturally occurring metalloid found in groundwater, is a well-established human carcinogen. Epidemiological studies from highly contaminated regions link chronic arsenic exposure to increased risks of skin, lung, bladder, and kidney cancer. However, studies investigating the mechanisms driving arsenic-related mutagenicity in human tumors remain limited. To improve our understanding, we analyzed whole-exome sequencing (WES) data from tumor samples of 17 cancer patients treated in Dhaka, Banglade…
Rank30.0
TRIM2 facilitates macrophage mediated anti-tumor immunity in renal cell carcinoma through enhancing SIRPA ubiquitination and degradation.
International immunopharmacology · 2026 · PMID 42967384
SIRPA delivers an anti-phagocytic "don't-eat-me" signal through its expression on macrophage membrane surface and promotes tumor progression via membrane-independent mechanism. However, current CD47- and SIRPA-targeting agents only disrupt cell-surface inhibitory signaling, highlighting the therapeutic potential of degrading SIRPA. Here, we identified that E3 ubiquitin ligase TRIM2 interacted with SIRPA in vitro. Clinically, elevated TRIM2 expression is associated with prolonged overall and progression-free surviva…
Rank30.0
Targeting mitochondrial metabolism in renal cell carcinoma with melatonin: Preclinical evidence and clinical perspectives.
Tissue & cell · 2026 · PMID 42229285
RCC is characterized by mitochondrial dysfunction, oxidative stress, and resistance to traditional therapies such as tyrosine kinase inhibitors (TKIs). Melatonin, a pleiotropic neurohormone, has emerged as a viable treatment for renal cell carcinoma (RCC) by targeting metabolic dysregulation and carcinogenic signaling pathways. This review summarizes current experimental and clinical data that melatonin can restore mitochondrial oxidative phosphorylation, reverse the Warburg metabolic phenotype, and modify redox ho…
Rank30.0
Glut1 and MCT4 cooperatively promote ccRCC cell proliferation and are associated with glycolytic reprogramming and immune-related alterations.
Biochemical and biophysical research communications · 2026 · PMID 42732652
Clear cell renal cell carcinoma (ccRCC) is characterized by glycolytic reprogramming and a lactate-rich tumor microenvironment. We integrated multi-omics, single-cell, tissue microarray, and in vitro analyses to investigate the roles of Glut1 and MCT4 in ccRCC. Both transporters were upregulated at the mRNA and protein levels, enriched in tumor epithelial cells, and located within a glycolysis-associated co-expression module. Elevated MCT4 expression and combined Glut1/MCT4 dysregulation were associated with poor o…
Rank30.0
Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy.
Cancer letters · 2026 · PMID 42476286
Although there are several ongoing clinical trials using neoantigen peptide-based cancer vaccines, challenges still exist to implement in clinical approval such as poor antigen stability, inefficient delivery, and inadequate immune activation. To address these limitations, we developed a polymer-based polyvalent peptide and adjuvant (SPPA) that co-delivers lipid-conjugated tumor-specific peptides with Toll-like receptor 7/8 (3M - 052) and a STING (2'3'-cGAMP) agonist. This nanoplatform enables efficient peptide enc…
Rank30.0
GSN liquid-liquid phase separation induces PANoptosis by inhibiting YAP-dependent glycolysis to alleviate the progression of clear cell renal cell carcinoma.
Cancer letters · 2026 · PMID 42476284
This study was carried out to screen PANoptosis-related biomarker genes and the involved underlying mechanism in clear cell renal cell carcinoma (ccRCC). Differentially expressed (DE) PANoptosis-related genes were identified. Then prognostic biomarker genes were screened, and used to construct a prognostic model. The predictive ability of the model was explored by receiver operating characteristic (ROC) curves. Then the correlation between risk score with clinical features and immune cell infiltration were evaluate…
Rank30.0
Kidney renal clear cell carcinoma-derived migrasomes mediate immunosuppressive microenvironment by inducing M2 macrophage polarization.
Biochemical and biophysical research communications · 2026 · PMID 42659861
Kidney renal clear cell carcinoma (KIRC) is characterized by a highly immunosuppressive tumor microenvironment (TME) that drives disease progression and limits therapeutic efficacy. Migrasomes, a recently identified class of extracellular vesicles, mediate intercellular communication; however, their specific role in KIRC immunity remains largely unexplored. Here, we show that TSPAN4, a key migrasome marker, is significantly upregulated in KIRC. KIRC-derived migrasomes effectively induce macrophage polarization towa…
Rank30.0
Birt-Hogg-Dubé syndrome: From molecular mechanisms to emerging systemic therapeutic strategies.
Medicina clinica · 2026 · PMID 42810013
Birt-Hogg-Dubé (BHD) syndrome is a rare autosomal dominant disorder caused by germline mutations in the FLCN gene. It is characterized by pulmonary cysts with recurrent pneumothorax, renal tumors, and cutaneous lesions, with marked phenotypic variability. This review summarizes current evidence on the molecular basis and clinical manifestations of BHD, highlighting the role of folliculin in cellular metabolism through the AMPK-mTOR signaling pathway and related mechanisms involved in tumorigenesis. From a clinical …
Rank30.0
Mesoporous silica nanocarrier-mediated delivery of Pt(II)-Ferrocene conjugates for enhanced antitumor activity and toxicity Mitigation.
International journal of pharmaceutics · 2026 · PMID 42785529
Amino-functionalized mesoporous silica nanoparticles (MSNs) were investigated as nanocarriers for two organoheterobimetallic Pt(II)-ferrocene monocations intended for anticancer therapy. Each monocation contains a Pt(II) center bearing two cis-isopropylamine ligands and a p-ferrocenylaniline ligand directly bound to platinum, and the complexes differ only in the counterion (C1, triflate; C2, nitrate). These compounds had been previously synthesized, showing moderate cytotoxic activity against several cancer cell li…
Rank30.0
MCM10 modulates lipid metabolic reprogramming via the USP7-FASN axis to accelerate renal cell carcinoma progression.
Cancer letters · 2026 · PMID 42777936
Metabolic reprogramming, particularly dysregulated lipid metabolism, is a hallmark of clear cell renal cell carcinoma (ccRCC) progression. However, the upstream regulators responsible for lipid metabolic rewiring remain largely unknown. Here, we integrated single-cell RNA sequencing, spatial transcriptomics, and functional validation to identify MCM10 as a critical regulator of lipid metabolism in ccRCC. Single-cell and spatial analyses revealed that MCM10 was predominantly expressed in malignant epithelial cells a…
Rank30.0
ACAA2 modulates renal cancer cell proliferation, migration, and invasion through enhancing autophagic flux and fatty acid metabolism.
Biochemical and biophysical research communications · 2026 · PMID 42777612
Acetyl-CoA acyltransferase 2 (ACAA2), a critical enzyme in fatty acid β-oxidation, has been implicated in various malignancies. However, its impact on renal cell carcinoma (RCC) remains uncertain. This research explores ACAA2's function in RCC. ACAA2's prognostic significance and clinicopathological relevance in RCC were determined using Kaplan-Meier and Cox regression analyses. The effect of ACAA2 on proliferation, migration, invasiveness, and apoptosis was evaluated in vitro. Additionally, the formation of autoph…
Rank30.0
Integrative single-cell and spatial transcriptomic analyses identify LMX1B as a tumor suppressor orchestrating the GDF15-ATP4B axis in renal cell carcinoma.
Translational oncology · 2026 · PMID 42759406
BACKGROUND: Renal cell carcinoma (RCC) is characterized by profound inter- and intratumoral heterogeneity and extensive tumor microenvironment (TME) remodeling, yet the spatially resolved cellular programs and intercellular communication networks orchestrating malignant progression remain poorly defined. LMX1B, a LIM homeodomain transcription factor essential for kidney morphogenesis, has not been previously investigated in renal carcinogenesis. METHODS: We integrated single-cell RNA sequencing (scRNA-seq) and spat…
Promising Experimental Therapies70 records
Rank100.0
Visual extended reality tools in image-guided surgery in urology: a systematic review.
European journal of nuclear medicine and molecular imaging · 2024 · PMID 38589511
PURPOSE: The aim of this systematic review is to assess the clinical implications of employing various Extended Reality (XR) tools for image guidance in urological surgery. METHODS: In June 2023, a systematic electronic literature search was conducted using the Medline database (via PubMed), Embase (via Ovid), Scopus, and Web of Science. The search strategy was designed based on the PICO (Patients, Intervention, Comparison, Outcome) criteria. Study protocol was registered on PROSPERO (registry number CRD42023449025…
Rank100.0
A systematic investigation of clear cell renal cell carcinoma using meta-analysis and systems biology approaches.
Molecular genetics and genomics : MGG · 2024 · PMID 39283494
Renal cell carcinoma with clear cells (ccRCC) is the most frequent kind; it accounts for almost 70% of all kidney cancers. A primary objective of current research was to find genes that may be used in ccRCC gene therapy to understand better the molecular pathways underlying the disease. Based on PubMed microarray searches and meta-analyses, we compared overall survival and recurrence-free survival rates in ccRCC patients with those in healthy samples. The technique was followed by a KEGG pathway and Gene Ontology (…
Rank99.4
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
The Lancet. Oncology · 2026 · PMID 42633754
BACKGROUND: Total mesorectal excision (TME) is the standard treatment for most early-stage and intermediate-stage rectal cancer but can cause substantial perioperative morbidity, functional impairment, and reduced quality of life. We assessed whether long-course chemoradiotherapy (LCCRT) or short-course radiotherapy (SCRT) could increase organ preservation and reduce surgery, toxicity, and quality-of-life harms without compromising oncological outcomes. METHODS: STAR-TREC is an international, multicentre, open-labe…
Rank98.6
A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.
ESMO open · 2026 · PMID 42849355
BACKGROUND: Immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs) have improved advanced renal cell carcinoma (RCC) outcomes, yet median progression-free survival (PFS) remains <2 years. PATIENTS AND METHODS: This randomised (1 : 1 : 1), open-label, phase II study (NCT05805501) evaluated tobemstomig [bispecific anti-programmed cell death protein 1 (PD-1)/lymphocyte-activation gene 3] plus axitinib (VEGF-TKI) and tobemstomig plus tiragolumab (…
Rank98.0
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42507969
PURPOSE: Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS: This phase II trial enrolled patients with mRCC of any his…
Rank96.2
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.
European urology · 2026 · PMID 41934036
Kidney injury molecule 1 (KIM-1) is a promising biomarker in adjuvant clear cell renal cell carcinoma (ccRCC), but its relevance in advanced ccRCC or papillary RCC (pRCC) remains unclear. CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Circulating KIM-1 levels were measured at baseline and on-treatment. The primary endpoint was to explore if KIM-1 levels were raised in pRCC. Analyses were explor…
Rank96.2
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42235464
BACKGROUND: Papillary renal cell cancer (pRCC) represents the largest subgroup within non-clear cell (ncc) RCC. Compared with clear cell RCC (ccRCC), pRCC is considered less sensitive to currently available systemic therapies. Here, we report exploratory results from the pRCC subgroup of the SUNNIFORECAST trial comparing ipilimumab/nivolumab with standard of care (SOC) based on central pathological review. METHODS AND PATIENTS: SUNNIFORECAST was a prospective, investigator-initiated, phase II trial evaluating ipili…
Rank96.0
Pan-cancer multi-omics machine learning defines a lactylation-associated immune-excluded tumor state with proteomic and experimental corroboration.
Computational biology and chemistry · 2026 · PMID 42556016
BACKGROUND: Histone lactylation links lactate metabolism to chromatin regulation, but whether lactylation-program-associated transcriptional patterns delineate recurrent pan-cancer tumor states remains unclear. METHODS: We integrated mRNA, lncRNA, and miRNA profiles from 9712 TCGA tumors across 33 cancer types with GTEx references, six GEO cohorts, IMvigor210, and an institutional clear-cell renal cell carcinoma (ccRCC) cohort used for exploratory DIA-NN proteomic corroboration. Random-effects co-expression meta-an…
Rank95.6
Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191.
Hypertension (Dallas, Tex. : 1979) · 2026 · PMID 42158981
BACKGROUND: The objective of this cluster randomized controlled trial was to determine the feasibility and safety of an intensive (systolic blood pressure [SBP] <120 mm Hg) versus usual care (SBP <140 mm Hg) approach to SBP control in patients with renal cell or thyroid cancer initiating VEGFR (vascular endothelial growth factor)-tyrosine kinase inhibitors. METHODS: A phase II site-based cluster randomized controlled trial compared intensive SBP control to usual care, incorporating a centralized BP advisory core to…
Rank86.7
Cough hypersensitivity risk increases during heatwaves and can be reduced by inhalation of alkaline aerosols of endogenous ions.
Scientific reports · 2026 · PMID 42744885
Heat wave burden is rapidly rising and exacerbating human respiratory illnesses. Yet, how to protect human airways, short of deep and sustained reductions in greenhouse gas emissions, remains unclear. Here, we find, by theoretical, in vitro experimental, and human clinical studies, that heatwave exposure elevates risks of cough hypersensitivity, which can be reversed by the inhalation of alkaline hypertonic divalent salts (HDS). We find that upper-airway mucosal collapse occurs on exposing human bronchial epithelia…
Rank83.9
Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.
Journal for immunotherapy of cancer · 2026 · PMID 42431710
PURPOSE: Patients with very-high risk clear cell renal cell carcinoma (ccRCC) remain at substantial risk of recurrence after nephrectomy. However, heterogeneity in benefit from adjuvant immunotherapy observed in the KEYNOTE-564 trial, together with limited prospective data in this population, warrants further investigation. METHODS: This multicenter, prospective, non-randomized, controlled phase II trial enrolled patients with very-high risk ccRCC following nephrectomy. Patients received either adjuvant penpulimab …
Rank82.5
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.
Clinical genitourinary cancer · 2026 · PMID 42336709
BACKGROUND: Anti-PD1 immune checkpoint inhibitors (ICI) are effective in clear-cell renal-cell carcinoma (ccRCC). Preliminary data suggest inhibition of Receptor Activator of Nuclear Factor-κB Ligand (RANKL) signaling may potentiate ICI efficacy. We evaluated the activity and safety of the RANKL-inhibitor denosumab with pembrolizumab in people with pretreated advanced ccRCC. METHODS: This single-arm, multi-center phase 2 trial enrolled participants with metastatic or unresectable ccRCC progressing on or after VEGFR…
Rank81.9
[18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.
Cancer discovery · 2026 · PMID 42112793
UNLABELLED: This single-center prospective phase II trial evaluated [18F]RCCB6 (renal cell carcinoma B6) positron emission tomography (PET)/computed tomography (CT), a cluster of differentiation 70 (CD70)-targeting radiotracer, for detecting metastases in clear-cell renal cell carcinoma (ccRCC). After screening 291 patients, 150 patients with histologically confirmed ccRCC or suspected kidney cancer underwent imaging. Among 1,221 assessable extrarenal lesions, [18F]RCCB6 PET/CT achieved 94.2% sensitivity, 80% speci…
Rank81.4
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.
European urology · 2026 · PMID 42049596
Radiotherapy-based metastasis-directed therapy (MDT) has emerged as a treatment strategy for oligometastatic clear cell renal cell carcinoma (ccRCC). However, optimal integration of MDT with immune checkpoint inhibition (ICI) is unclear, especially in light of the M1 no evidence of disease subgroup analysis of KEYNOTE-564. We undertook an exploratory cohort study of two previously reported trials evaluating either MDT+ICI (NCT02855203) or MDT (NCT03575611) for oligometastatic ccRCC. The objective was primarily to c…
Rank80.8
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.
Journal for immunotherapy of cancer · 2026 · PMID 42386345
BACKGROUND: Immune checkpoint inhibitor-based combinations represent the standard of care for advanced renal cell carcinoma. The OMNIVORE trial investigated a response-adaptive strategy, including treatment discontinuation in early nivolumab responders (Arm A) and salvage ipilimumab addition in non-responders (Arm B). Here we report outcomes with extended follow-up. METHODS: OMNIVORE was a phase II response-adaptive trial in which patients received induction nivolumab monotherapy. Patients achieving a confirmed com…
Rank80.7
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42149133
PURPOSE: We investigated components of the immune tumor microenvironment as determinants of clinical outcome to anti-PD-1 therapy in patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with first-line nivolumab in the phase II, nonrandomized HCRN GU16-260 trial. EXPERIMENTAL DESIGN: Pretreatment primary ccRCCs from 72 patients were analyzed via multiplex immunofluorescence and image analysis to assess nonterminally exhausted CD8+ (CD8+PD-1+TIM-3-LAG-3-) tumor-infiltrating lymphocytes (TIL), PD-…
Rank80.0
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
Nature communications · 2026 · PMID 42420295
Biomarkers that predict response to combined radiation and anti-PD-1 therapy in clear cell renal cell carcinoma (ccRCC) are poorly defined. RAPPORT trial (NCT02855203) is a prospective phase I/II study of stereotactic ablative body radiotherapy (SABR) and pembrolizumab in 30 patients with oligometastatic ccRCC. The primary endpoint was safety; secondary endpoints included overall survival, time to local progression, distant progression-free survival, objective and disease control rates, duration of response and pat…
Rank79.6
Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis.
Nature communications · 2026 · PMID 42844281
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive kidney cancer with no established standard of care. This phase 2 trial (NCT05877820) assessed first-line tislelizumab plus lenvatinib in advanced FH-RCC (N = 20). The primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety. After a median follow-up of 20.2 months, ORR was 95% (95% CI 75.1-99…
Rank79.2
Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial.
Journal for immunotherapy of cancer · 2026 · PMID 42476727
BACKGROUND: Fecal microbiota transplantation (FMT) has shown promise in overcoming resistance to immune checkpoint inhibitors (ICIs) in early-phase cancer trials. We investigated the safety, feasibility and efficacy of FMT from ICI responders to patients with advanced cancers progressing on ICIs. METHODS: This was a single-arm phase IIa basket trial (MITRIC; NCT05286294) including patients with ICI-refractory cancer. Long-term ICI responders were used as FMT donors. Patients received FMTs in combination with ICIs; …
Rank77.0
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
Melanoma research · 2026 · PMID 42070986
To assess the combination of high dose interleukin 2 (HD IL2) and nivolumab in patients with checkpoint inhibitor-refractory melanoma or renal cell carcinoma (RCC), we performed a single-arm, Simon two-stage phase II trial for patients with unresectable stage III or IV melanoma or any histology RCC. The primary endpoint was overall response rate (ORR); secondary endpoints were adverse events and progression-free survival (PFS), defined as time to radiographic or clinical progression, whichever occurred first. Five …
Rank77.0
A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.
Future oncology (London, England) · 2026 · PMID 42719952
Kidney cancer is one of the 10 most common cancers affecting both men and women in the United States, accounting for 4% to 5% of all cancers. Most recent estimates have shown that about 81,610 new cases of kidney cancer will be diagnosed in 2024, with renal cell carcinoma (RCC). The treatment landscape of metastatic or unresectable locally advanced clear cell renal cell carcinoma (ccRCC) has changed over the past years with the approval of multiple combination regimens using immune checkpoint inhibitors (ICI) and v…
Rank77.0
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI.
Abdominal radiology (New York) · 2026 · PMID 41369900
Despite recent therapeutic advances, renal cell carcinoma (RCC) has a high mortality rate. The development of new neoadjuvant strategies requires reliable companion biomarkers of early and successful response to treatment. A change in tumor size is a late measure of response and novel targeted imaging-based biomarkers may be more accurate for treatment response prediction. Here we evaluated the potential of hyperpolarized carbon-13 MRI (HP 13C-MRI), following the injection of hyperpolarized 13C-pyruvate, to assess …
Rank74.5
Long-term exposure to trihalomethanes in drinking water and risk of liver and kidney cancer: a population-based cohort study.
Environment international · 2026 · PMID 42700668
Chlorination of drinking water effectively prevents waterborne infections but also results in the formation of potentially carcinogenic disinfection by-products, including trihalomethanes (THMs). Experimental animal studies indicate that the liver and kidney are target organs for THM carcinogenicity, yet epidemiological evidence remains limited for these sites. In this study we assessed the association of long-term exposure to THMs in drinking water with incidence of liver and kidney cancer in two large Swedish pop…
Rank67.9
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma.
Cancer medicine · 2025 · PMID 39945382
BACKGROUND: Selinexor (SEL) is a nuclear exportin 1 inhibitor that blocks the transport of nuclear proteins, including tumor suppressors, to the cytoplasm. Preclinical data suggest that the combination of SEL with checkpoint blockade may result in improved response to immunotherapy. METHODS: NCT02419495 was a multiarm phase IB study of SEL in combination with other standard regimens in patients with advanced malignancies. Arm M utilized twice weekly oral SEL and intravenous nivolumab (NIVO). Arm N utilized weekly o…
Rank67.7
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42447427
PURPOSE: Treatment options for clear cell renal cell carcinoma (ccRCC) refractory to immune checkpoint inhibitors (ICIs) and targeted therapy are needed. ALLO-316 is an allogeneic chimeric antigen receptor (CAR) T-cell product that targets CD70-expressing ccRCC and resists immune rejection by targeting and eliminating patients' CD70+ alloreactive T cells. METHODS: In the phase Ia/b TRAVERSE trial (ClinicalTrials.gov identifier: NCT04696731), patients with advanced ccRCC resistant to ICIs and vascular endothelial gr…
Prospective Cohort Studies75 records
Rank107.0
Prognostic value of primary tumor location in colorectal cancer: an updated meta-analysis.
Clinical and experimental medicine · 2023 · PMID 37405571
The clinical, histological, and molecular differences between right-sided colon cancer (RCC) and left-sided colon cancer (RCC) have received considerable attention. Over the past decade, many articles have been published concerning the association between primary tumor location (PTL) of colorectal cancer and survival outcomes. Therefore, there is a growing need for an updated meta-analysis integrating the outcomes of recent studies to determine the prognostic role of right vs left-sidedness of PTL in patients with …
Rank106.0
Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 · PMID 40536070
Observational studies indicated that the overall inflammatory potential of diets has been implicated in cancer etiology; however, the results were inconsistent. We aimed to estimate the dose-response association of dietary inflammatory potential with cancer outcomes based on prospective cohort studies. PubMed, Embase and Web of Science databases were searched up to 11 November 2023 for prospective cohort studies. The dietary inflammatory potential was assessed by the dietary inflammatory index (DII) or energy-adjus…
Rank105.6
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. S…
Rank97.0
Impact of obstructive sleep apnea on cancer risk: a systematic review and meta-analysis.
Sleep & breathing = Schlaf & Atmung · 2023 · PMID 36129602
PURPOSE: We aimed to study the effect of obstructive sleep apnea (OSA) on cancer risk. METHODS: We searched PubMed, Embase, and Cochrane databases for relevant studies. The qualities of included studies were assessed using Newcastle-Ottawa Scale (NOS). Unadjusted and adjusted analyses were performed. We also conducted subgroup analyses stratified by gender, severity of OSA, study design, and cancer type. RESULTS: After literatures search, 18 studies were included in the present study. In the unadjusted analysis, we…
Rank96.6
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy.
The Journal of urology · 2026 · PMID 41360001
PURPOSE: Hemostatic agents (HAs) are typically used during robotic-assisted laparoscopic partial nephrectomy (RALPN) to minimize perioperative bleeding. However, high-quality evidence supporting their effectiveness is limited. We aimed to determine whether HAs reduce perioperative blood loss in patients undergoing RALPN. MATERIALS AND METHODS: We conducted a prospective, randomized controlled trial of patients undergoing RALPN. Patients were randomized to HA+, in which HAs were assigned, and HA-, no HA. The primary…
Rank96.2
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42235464
BACKGROUND: Papillary renal cell cancer (pRCC) represents the largest subgroup within non-clear cell (ncc) RCC. Compared with clear cell RCC (ccRCC), pRCC is considered less sensitive to currently available systemic therapies. Here, we report exploratory results from the pRCC subgroup of the SUNNIFORECAST trial comparing ipilimumab/nivolumab with standard of care (SOC) based on central pathological review. METHODS AND PATIENTS: SUNNIFORECAST was a prospective, investigator-initiated, phase II trial evaluating ipili…
Rank96.2
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.
European urology · 2026 · PMID 41934036
Kidney injury molecule 1 (KIM-1) is a promising biomarker in adjuvant clear cell renal cell carcinoma (ccRCC), but its relevance in advanced ccRCC or papillary RCC (pRCC) remains unclear. CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Circulating KIM-1 levels were measured at baseline and on-treatment. The primary endpoint was to explore if KIM-1 levels were raised in pRCC. Analyses were explor…
Rank95.3
[A comparative study on perioperative outcomes and learning curves of domestic robot-assisted versus Da Vinci Xi robot-assisted partial nephrectomy].
Zhonghua wai ke za zhi [Chinese journal of surgery] · 2026 · PMID 41881798
Objective: To compare perioperative outcomes of robot-assisted partial nephrectomy (RAPN) performed with a China-made robotic surgical system versus the Da Vinci Xi system, and to evaluate the learning curve of the domestic system. Methods: This single-center, prospective, randomized controlled study enrolled patients scheduled for RAPN at Harbin Medical University Cancer Hospital from August 2024 to May 2025 who met predefined inclusion and exclusion criteria. Using simple randomization, patients were assigned to …
Rank95.2
Transabdominal lumbar approach (TALA) versus retroperitoneal approach for robot-assisted renal surgery: a prospective randomised controlled trial.
World journal of urology · 2026 · PMID 42742659
PURPOSE: Common robotic nephrectomy approaches access the kidney via transperitoneal (TP) or retroperitoneal (RP) routes, each with distinct trade-offs. We developed the transabdominal lumbar approach (TALA), combining advantages of both accesses with improved visualisation and strategic trocar placement, and compared it with conventional RP in a prospective randomised controlled trial using technique-oriented intraoperative endpoints. METHODS: In this single-centre, prospective, open-label RCT, 40 patients were ra…
Rank88.4
Multimodal imaging to analyze the biomechanical properties of kidney tumors, evaluating feasibility, inter-modality correspondence, and diagnostic value (UroCCR-115).
PloS one · 2026 · PMID 42418537
INTRODUCTION: Assessment of renal tissue and renal tumor stiffness may provide complementary information for tissue characterization; however, conventional imaging modalities such as multiphasic computed tomography (CT) do not directly quantify biomechanical properties. Elastography techniques, including magnetic resonance elastography (MRE) and ultrasound elastography (US-E), allow noninvasive measurement of tissue stiffness but are not routinely available in standard clinical practice. This study protocol aims to…
Rank83.9
Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.
Journal for immunotherapy of cancer · 2026 · PMID 42431710
PURPOSE: Patients with very-high risk clear cell renal cell carcinoma (ccRCC) remain at substantial risk of recurrence after nephrectomy. However, heterogeneity in benefit from adjuvant immunotherapy observed in the KEYNOTE-564 trial, together with limited prospective data in this population, warrants further investigation. METHODS: This multicenter, prospective, non-randomized, controlled phase II trial enrolled patients with very-high risk ccRCC following nephrectomy. Patients received either adjuvant penpulimab …
Rank83.1
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.
The Lancet. Oncology · 2026 · PMID 42144019
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is a non-invasive therapy for inoperable primary renal cell carcinoma. However, long-term prospective clinical trial data are scarce. We aimed to use pooled data from two clinical trials (FASTRACK and FASTRACK II) to evaluate activity and safety of SABR in the long term. METHODS: In this pooled analysis, we used data from FASTRACK, a single-institutional, phase 1, prospective clinical trial conducted at the Peter MacCallum Cancer Centre (Melbourne, VIC, Aus…
Rank82.8
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41946178
BACKGROUND: The phase II trial CABRAMET evaluates the efficacy of the VEGFR tyrosine kinase inhibitor (TKI) cabozantinib in patients with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC). Faced with historical challenges in treating BM in RCC, this study aimed to provide prospective data on systemic treatment outcomes. PATIENTS AND METHODS: This multicenter open-label trial included RCC patients with BM with less than three prior systemic treatments excluding cabozantinib. Eligible patie…
Rank81.9
[18F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [18F]FDG PET/CT and Conventional Imaging.
Cancer discovery · 2026 · PMID 42112793
UNLABELLED: This single-center prospective phase II trial evaluated [18F]RCCB6 (renal cell carcinoma B6) positron emission tomography (PET)/computed tomography (CT), a cluster of differentiation 70 (CD70)-targeting radiotracer, for detecting metastases in clear-cell renal cell carcinoma (ccRCC). After screening 291 patients, 150 patients with histologically confirmed ccRCC or suspected kidney cancer underwent imaging. Among 1,221 assessable extrarenal lesions, [18F]RCCB6 PET/CT achieved 94.2% sensitivity, 80% speci…
Rank81.4
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.
European urology · 2026 · PMID 42049596
Radiotherapy-based metastasis-directed therapy (MDT) has emerged as a treatment strategy for oligometastatic clear cell renal cell carcinoma (ccRCC). However, optimal integration of MDT with immune checkpoint inhibition (ICI) is unclear, especially in light of the M1 no evidence of disease subgroup analysis of KEYNOTE-564. We undertook an exploratory cohort study of two previously reported trials evaluating either MDT+ICI (NCT02855203) or MDT (NCT03575611) for oligometastatic ccRCC. The objective was primarily to c…
Rank80.0
Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41290048
PURPOSE: Stereotactic body radiation therapy (SBRT) represents a novel, efficacious treatment for patients with kidney tumors who are medically inoperable or decline surgery. There is limited prospective data on the impact of kidney SBRT on renal function. METHODS AND MATERIALS: This was a prospective phase 2 single-arm clinical trial (clinicaltrials.gov NCT03747133) of kidney-directed SBRT in patients with primary or metastatic renal lesions who were medically inoperable or declined surgery. The primary outcome wa…
Rank80.0
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
Nature communications · 2026 · PMID 42420295
Biomarkers that predict response to combined radiation and anti-PD-1 therapy in clear cell renal cell carcinoma (ccRCC) are poorly defined. RAPPORT trial (NCT02855203) is a prospective phase I/II study of stereotactic ablative body radiotherapy (SABR) and pembrolizumab in 30 patients with oligometastatic ccRCC. The primary endpoint was safety; secondary endpoints included overall survival, time to local progression, distant progression-free survival, objective and disease control rates, duration of response and pat…
Rank79.5
Real-world comparative outcomes of first-line immune combinations (ICI-ICI vs ICI-TKI) in metastatic renal cell carcinoma with sarcomatoid features.
Oncoimmunology · 2026 · PMID 42912018
INTRODUCTION: Although first-line immune-based combinations have reshaped the management of metastatic renal cell carcinoma (mRCC), relevant unmet clinical needs remain. Sarcomatoid feature is a negative prognostic factor that confers sensitivity to immunotherapy, yet the optimal ICI combination in this subgroup is still unclear. METHODS: The Meet-URO 33 is an Italian multicenter retrospective/prospective observational study enrolling patients with mRCC receiving first-line systemic therapy in routine clinical prac…
Rank78.1
Baseline Risk of Treatment Abandonment and Survival of Children With Common and Curable Cancers in the Zero Abandonment Cash Transfer Programme-A Multi-Centre Prospective CANCaRe Africa Study.
Pediatric blood & cancer · 2026 · PMID 42578510
BACKGROUND: The WHO Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common and curable cancers. This study assessed the risk of treatment abandonment (TxA) and the impact on survival of five of these cancers in sub-Saharan Africa in preparation for a cash transfer intervention. METHODS: This multi-centre, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphobla…
Rank77.0
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI.
Abdominal radiology (New York) · 2026 · PMID 41369900
Despite recent therapeutic advances, renal cell carcinoma (RCC) has a high mortality rate. The development of new neoadjuvant strategies requires reliable companion biomarkers of early and successful response to treatment. A change in tumor size is a late measure of response and novel targeted imaging-based biomarkers may be more accurate for treatment response prediction. Here we evaluated the potential of hyperpolarized carbon-13 MRI (HP 13C-MRI), following the injection of hyperpolarized 13C-pyruvate, to assess …
Rank75.3
Late complications and 5 years outcomes of robotic partial nephrectomy in France: prospective assessment in the French Kidney Cancer Research Network (UroCCR 10).
World journal of urology · 2023 · PMID 37407720
PURPOSE: To describe the practice of robotic-assisted partial nephrectomy (RAPN) in France and prospectively assess the late complications and long-term outcomes. METHODS: Prospective, multicenter (n = 16), observational study including all patients diagnosed with a renal tumor who underwent RAPN. Preoperative, intraoperative, postoperative, and follow-up data were collected and stored in the French research network for kidney cancer database (UroCCR). Patients were included over a period of 12 months, then followe…
Rank75.2
[Healthcare Research in Renal Cell Cancer: 7-Year-Data from the VERSUS Study by d-uo].
Aktuelle Urologie · 2026 · PMID 41698400
INTRODUCTION: Renal cell carcinoma (RCC) accounts for approximately 13.5% of all urological tumors. Healthcare research analyses whether treatment concepts developed in controlled clinical trials and recommended in clinical guidelines are implemented in routine care. This article presents healthcare research data on RCC based on current results from the prospective VERSUS study (VERSorgUngsStudie) by d-uo ("Deutsche Uro-Onkologen", German Uro-Oncologists). MATERIAL AND METHODS: The VERSUS study is a non-interventio…
Rank75.0
Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis.
World journal of urology · 2026 · PMID 42207184
BACKGROUND: Renal cell carcinoma (RCC) is a significant urological malignancy with a rising incidence, increasingly linked to metabolic dysregulation and chronic systemic inflammation. While traditional metrics such as body mass index (BMI) are commonly used, they may not fully capture the biological heterogeneity underlying carcinogenesis. This study investigated the associations of the Metabolic Score for Insulin Resistance (METS-IR) and the Systemic Inflammation Response Index (SIRI) with subsequent RCC risk, to…
Rank75.0
Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42464667
OBJECTIVES: This post-marketing surveillance study evaluated the real-world safety and effectiveness of cabozantinib in Japanese patients with advanced renal cell carcinoma (aRCC). METHODS: This prospective, observational study enrolled patients with histologically or cytologically confirmed aRCC across 102 sites in Japan. Patients received cabozantinib as monotherapy or in combination with nivolumab according to approved label regimens and were monitored for 26 weeks. The primary outcome was the incidence of adver…
Rank75.0
Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.
International journal of cancer · 2026 · PMID 42071337
Outdoor air pollution, including particulate matter (PM), is a Group 1 carcinogen based on evidence for lung cancer; however, evidence for other cancers is limited. Further research on cancer incidence rather than mortality endpoints is needed as well as examinations in non-smokers. In the Cancer Prevention Study-II Nutrition Cohort, annual predictions of particulate and gaseous pollutant concentrations were assigned to residential addresses. Extended Cox regression estimated hazard ratios (HR) and 95% confidence i…
Quality Of Life69 records
Rank110.0
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer · 2026 · PMID 41871874
Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number of patients, fully transforming the standard of care in first-line and subsequent-line settings. More …
Rank102.0
What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.
Acta ophthalmologica · 2026 · PMID 41800487
PURPOSE: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register o…
Rank100.0
Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit-Risk Assessment.
Targeted oncology · 2026 · PMID 42892667
BACKGROUND: Adjuvant pembrolizumab has improved disease-free survival after nephrectomy for high-risk renal cell carcinoma, and pembrolizumab plus belzutifan has further expanded the treatment landscape. OBJECTIVE: We compared efficacy and treatment burden across adjuvant systemic therapies and examined the benefit-risk trade-off of the combination. METHODS: Randomized trials of systemic therapy after nephrectomy were synthesized using a Bayesian network meta-analysis. Disease-free survival hazard ratios were conve…
Rank99.5
Patient-Reported Outcome Design and Analysis in Randomized Controlled Trials of Renal Cell Carcinoma: A Systematic Review.
Clinical genitourinary cancer · 2026 · PMID 42468185
The clinical utility of patient-reported outcome (PRO) endpoints in renal cell carcinoma (RCC) trials depends on prespecification, clinically meaningful thresholds, and transparent analysis. We evaluated PRO design, analysis, and reporting in RCC randomized controlled trials using the independently developed PRO Endpoint Analysis Score (PROEAS), a 24-item framework based on SISAQOL recommendations. We searched Embase, MEDLINE, Web of Science Core Collection, CENTRAL, CINAHL, and PsycINFO through December 31, 2025, …
Rank99.4
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
The Lancet. Oncology · 2026 · PMID 42633754
BACKGROUND: Total mesorectal excision (TME) is the standard treatment for most early-stage and intermediate-stage rectal cancer but can cause substantial perioperative morbidity, functional impairment, and reduced quality of life. We assessed whether long-course chemoradiotherapy (LCCRT) or short-course radiotherapy (SCRT) could increase organ preservation and reduce surgery, toxicity, and quality-of-life harms without compromising oncological outcomes. METHODS: STAR-TREC is an international, multicentre, open-labe…
Rank97.0
Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review.
Journal of cancer survivorship : research and practice · 2022 · PMID 34595697
PURPOSE: To synthesize existing evidence on the unmet supportive care needs of people affected by kidney cancer, across the cancer care continuum. METHODS: A systematic review was conducted according to the PRISMA Statement Guidelines. Electronic databases (CINAHL, MEDLINE, and PsychINFO) were searched using key search terms. Articles were assessed according to pre-specified eligibility criteria. Data extraction and quality appraisal were conducted. The findings were integrated in a narrative synthesis. RESULTS: On…
Rank97.0
Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ER.
The oncologist · 2026 · PMID 42605077
BACKGROUND: Nivolumab plus cabozantinib demonstrated significantly better clinical and patient-reported outcomes (PROs) compared with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) in CheckMate 9ER. This post-hoc analysis identified key factors contributing to improvements in health-related quality of life (HRQOL) in these patients. MATERIALS AND METHODS: Mediation analyses were conducted using first-year CheckMate 9ER data to delineate treatment effects as reflected by HRQOL improvements …
Rank96.0
Exercise, nutrition, and psychological support for kidney cancer: a scoping review.
BJU international · 2026 · PMID 41549535
OBJECTIVES: To comprehensively review the available literature on prehabilitation and rehabilitation exercise, nutrition, and psychological support interventions for patients with kidney cancer (KC), to summarise the clinically relevant efficacy and cost-effectiveness of interventions, to expose key knowledge gaps, and to inform future investigations and initiatives. METHODS: This review was performed according to the per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scop…
Rank95.6
Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191.
Hypertension (Dallas, Tex. : 1979) · 2026 · PMID 42158981
BACKGROUND: The objective of this cluster randomized controlled trial was to determine the feasibility and safety of an intensive (systolic blood pressure [SBP] <120 mm Hg) versus usual care (SBP <140 mm Hg) approach to SBP control in patients with renal cell or thyroid cancer initiating VEGFR (vascular endothelial growth factor)-tyrosine kinase inhibitors. METHODS: A phase II site-based cluster randomized controlled trial compared intensive SBP control to usual care, incorporating a centralized BP advisory core to…
Rank95.4
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy.
European urology focus · 2026 · PMID 41760424
BACKGROUND AND OBJECTIVE: Robot-assisted partial nephrectomy (RAPN) is increasingly used to treat renal cell carcinoma (RCC), but randomized data comparing long-term outcomes to those after open partial nephrectomy (OPN) remain limited. Our aim was to compare oncological, renal function, and health-related quality of life (HRQOL) outcomes at 2 yr for patients who underwent RAPN versus OPN. METHODS: This single-center phase 2 randomized controlled trial included 50 patients with suspected localized RCC who were rand…
Rank95.0
Effectiveness of a personalised 6-month programme on physical frailty in older patients treated for bladder or kidney cancer - FRAGECO program - multicenter, controlled, randomized study protocol.
BMC geriatrics · 2026 · PMID 42286520
BACKGROUND: Older adults with bladder or kidney cancer are particularly vulnerable to functional decline and postoperative complications that can exacerbate frailty. Conventional care models focus mainly on surgery and postoperative recovery, with limited continuity of support, resulting in suboptimal long-term functional outcomes. The aim is to evaluate the effectiveness of a personalized 6-month care pathway on reducing physical frailty in older adults undergoing surgery for bladder or kidney cancer, compared wit…
Rank94.0
Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial.
PloS one · 2026 · PMID 42766600
INTRODUCTION: RAMPART is an international phase III trial evaluating adjuvant immune checkpoint inhibitors (ICIs) after nephrectomy for renal cell carcinoma. ICIs have a distinct toxicity profile that can significantly impact health-related quality of life (HRQoL); however existing HRQoL questionnaires were developed in a pre-ICI era and may not fully capture the patient experience. To address this, we embedded a qualitative interview sub-study within RAMPART among UK participants to explore the impact of ICIs on H…
Rank93.2
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors.
European urology open science · 2026 · PMID 42433301
BACKGROUND: Immunotherapy-based combinations have improved overall survival (OS) in metastatic renal cell carcinoma (mRCC), but recent evidence suggests a therapeutic plateau, underscoring the need for more personalized strategies. Many patients start systemic therapy with the primary kidney tumor still in situ, and the role of cytoreductive nephrectomy (CN) in the immunotherapy era remains uncertain after CARMENA and SURTIME trials. In parallel, stereotactic body radiotherapy (SBRT) has emerged as a noninvasive op…
Rank91.7
Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.
Cancers · 2026 · PMID 42449619
Background/Objectives: Nivolumab monotherapy is a standard of care in previously treated advanced renal cell carcinoma (aRCC) and was approved based on the results of the randomized clinical trial Checkmate-025. The non-interventional study (NIS) NORA collected data on the effectiveness and safety of nivolumab monotherapy in real-world clinical routine. Its final, long-term follow-up data are presented here. Methods: NORA was a prospective, multicentre NIS recruiting at 54 German sites, evaluating the effectiveness…
Rank90.2
PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial.
Trials · 2026 · PMID 41863008
BACKGROUND: Localised renal cell carcinoma is treated with radical nephrectomy (RN) or partial nephrectomy (PN). Nephron-sparing PN increases preservation of renal function, reducing incidence of end stage renal failure and associated cardiovascular events. In patients with exophytic T1a (≤ 4 cm) tumours and normal contralateral kidney, PN is standard of care. In patients with T1b (> 4-7 cm) or endophytic T1a tumours and normal contralateral kidney, the benefits of PN over RN are less clear as there are increased s…
Rank87.0
International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal.
International journal of cancer · 2026 · PMID 41653082
We analysed reimbursement differences for prostate (PC), renal cell (RCC), and urothelial (UC) cancers drugs in Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal, assessing substantial clinical benefit (SCB) and pivotal trials characteristics. This is a retrospective analysis of PC, RCC, and UC drug-indication pairs (2005-2024). Approvals were identified via FDA and EMA. Reimbursement recommendations were reviewed. Primary endpoint was reimbursement rate by SCB, tumour type, and country. Trial ch…
Rank85.0
Low-dose morphine and airway sensations in refractory chronic cough: a randomised control trial.
ERJ open research · 2026 · PMID 42683193
BACKGROUND: Low-dose morphine is recommended as an antitussive agent for refractory chronic cough (RCC), although its precise mechanism of action remains unknown. We hypothesised that noxious airway sensations (e.g. throat irritation, tickle, urge to cough) described by RCC patients play a role in initiating coughing and are lessened by morphine. METHODS: 22 RCC patients (median age 65 years; 83% female) reporting a clinical response to low-dose morphine withdrew from therapy and enrolled in a double-blinded, rando…
Rank85.0
Role of stereotactic body radiotherapy (SBRT) for metastatic cancer patients beyond the traditional oligometastatic setting: a narrative review for an evolving concept.
Annals of palliative medicine · 2026 · PMID 42576469
BACKGROUND AND OBJECTIVE: The management of metastatic cancer is shifting from a strict division between curative local therapy and palliative systemic treatment toward a biology-driven continuum. In this setting, stereotactic body radiotherapy (SBRT), or stereotactic ablative radiotherapy (SABR), has emerged as an effective consolidative approach for patients with limited metastatic burden. Its role is now being explored beyond the classical oligometastatic paradigm, including oligoprogressive and selected polymet…
Rank85.0
De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?
Clinical genitourinary cancer · 2026 · PMID 42435529
The therapeutic landscape of metastatic renal cell carcinoma (mRCC) has evolved considerably with the introduction of immune checkpoint inhibitors (ICIs) and VEGFR-targeted therapies, leading to unprecedented improvements in survival. As durable responses and deep remissions become more frequent, the question of how to optimize treatment intensity has gained prominence. Therapeutic de-escalation, through reduced dose intensity, extended dosing intervals, treatment interruption, or integration of local therapies, ha…
Rank80.0
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42179010
OBJECTIVES: Cabozantinib treatment is associated with improved survival in renal cell carcinoma (RCC) patients with bone metastasis. We evaluated the direct effects of cabozantinib on bone metastasis in advanced RCC (aRCC). METHODS: In this multicenter, open-label study, adult Japanese aRCC patients with bone metastasis received oral cabozantinib 60 mg once daily until drug discontinuation/data cut-off. The primary endpoint was the objective response rate (ORR) of bone target lesions (modified MD Anderson criteria)…
Rank79.8
Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial.
Cell reports. Medicine · 2026 · PMID 42013852
Comparative data on stereotactic body radiotherapy (SBRT) in oligometastatic renal cell carcinoma (RCC) is lacking. This single-center, phase 2 non-randomized controlled trial enrolls patients with treatment-naive oligometastatic RCC. Patients choose to receive sunitinib alone (control arm, n = 24) or plus SBRT (SBRT arm, n = 24). The primary endpoint, objective response rate (83.3% vs. 29.2%; p < 0.001), is higher in the SBRT arm. With a median follow-up of 40.6 months, the 1-year local control rate is 91.5%. Prog…
Rank77.0
A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma.
Future oncology (London, England) · 2026 · PMID 42719952
Kidney cancer is one of the 10 most common cancers affecting both men and women in the United States, accounting for 4% to 5% of all cancers. Most recent estimates have shown that about 81,610 new cases of kidney cancer will be diagnosed in 2024, with renal cell carcinoma (RCC). The treatment landscape of metastatic or unresectable locally advanced clear cell renal cell carcinoma (ccRCC) has changed over the past years with the approval of multiple combination regimens using immune checkpoint inhibitors (ICI) and v…
Rank73.0
Improved Shared Decision-making for Patients with Renal Cell Carcinoma: Results of the SDM-RCC Study.
European urology oncology · 2026 · PMID 42242942
BACKGROUND AND OBJECTIVE: To improve shared decision-making (SDM) for renal cell carcinoma (RCC), we implemented an SDM intervention consisting of a patient decision aid and health care professional (HCP) training. This study evaluates its effectiveness. DESIGN, SETTING, AND PARCTICIPANTS: Multicenter prospective pretest-post-test study including adults with localized RCC or metastatic clear cell RCC. The pretest group received standard care; the post-test group was included after SDM intervention implementation. O…
Rank67.4
Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.
Nature medicine · 2026 · PMID 41606120
Immune checkpoint inhibitors (ICIs) improve outcomes in metastatic renal cell carcinoma (mRCC) but are hindered by immune-related adverse events (irAEs). Modulation of the gut microbiome may enhance efficacy and mitigate toxicity, yet the safety and mechanisms of healthy donor fecal microbiota transplantation (FMT) in mRCC remain unexplored. In this phase 1 trial, 20 treatment-naive patients with mRCC received encapsulated healthy donor FMT (LND101) combined with ipilimumab/nivolumab (n = 16), pembrolizumab/axitini…
Rank60.0
Moving Beyond Responders: A Post Hoc Analysis Identifying Criteria for Chronic Cough Control.
Chest · 2026 · PMID 42140485
BACKGROUND: Minimally important differences (MIDs) often define treatment response in refractory chronic cough (RCC). However, MIDs represent the smallest change in an outcome that patients perceive as important and do not indicate whether cough has improved to a level that would be considered adequately controlled. Therefore, defining criteria for cough control may provide a complementary benchmark for evaluating treatment success. RESEARCH QUESTION: How can cough control be defined using thresholds anchored to pa…
Randomized Controlled Trials76 records
Rank110.0
Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.
Journal of endocrinological investigation · 2024 · PMID 38530620
BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…
Rank108.8
Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Cancer · 2026 · PMID 42779347
The objective of this systematic review and meta-analysis was to evaluate the validity of progression-free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma. The MEDLINE, Embase, and Cochrane CENTRAL databases were searched from inception to June 10, 2025. Associations between treatment effects on OS, PFS, and ORR were assessed using Pearson correlation coefficients (r). Surrogate threshold…
Rank108.3
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42634038
Single-port robot-assisted partial nephrectomy (SP-RAPN) is increasingly used for selected renal tumors, but its comparative value over multi-port robot-assisted partial nephrectomy (MP-RAPN) remains uncertain. We performed a systematic review and meta-analysis of comparative studies, prioritizing propensity score-matched data when available. PubMed, Scopus, Web of Science, and Google Scholar were searched. Three studies involving 442 patients were included (210 SP-RAPN and 232 MP-RAPN). SP-RAPN was associated with…
Rank108.0
Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis.
Cancer · 2026 · PMID 42590929
BACKGROUND: Disease-free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting. METHODS: The authors conducted a systematic review and trial-level meta-analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. D…
Rank107.6
Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Medical oncology (Northwood, London, England) · 2026 · PMID 42484760
To update a network meta-analysis of first-line immunotherapy combinations in advanced renal cell carcinoma (RCC) using short-term data for primary analysis and long-term plus newly published randomized controlled trials (RCTs) for subgroup analyses. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese databases for articles from inception to 22 December 2024, performing a Bayesian network meta-analysis. Overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and…
Rank107.4
First-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma: a network meta-analysis and cost-effectiveness analysis.
Frontiers in immunology · 2026 · PMID 42876805
OBJECTIVE: This study aimed to systematically evaluate the efficacy of first-line immune checkpoint inhibitors (ICIs) combined with targeted therapy for advanced renal cell carcinoma (RCC) and assess their cost-effectiveness from the perspective of the Chinese healthcare system. METHODS: Phase III randomized controlled trials comparing ICI-targeted combinations versus sunitinib as first-line treatment for advanced RCC were identified through systematic searches of PubMed, EMBASE, and the Cochrane Library. A network…
Rank107.2
Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.
La Clinica terapeutica · 2026 · PMID 42340793
BACKGROUND: Radical nephrectomy for high-complexity renal tumors, stage T2-T4, size ≥7 cm, and/or inferior vena cava (IVC) involvement, represents one of the most technically demanding procedures in urologic oncology. Robot-assisted radical nephrectomy (RARN) has expanded rapidly in adoption, yet its comparative benefit over laparoscopic radical nephrectomy (LRN) in the high-complexity subpopulation remains undefined. No systematic review has restricted analysis to T2-T4 disease or applied a multidisciplinary outco…
Rank106.6
Selective P2X3 versus dual P2X2/3 receptor antagonists in refractory chronic cough: a systematic review and dose-response meta-analysis of randomized controlled trials.
Purinergic signalling · 2026 · PMID 42319606
Extracellular adenosine triphosphate (ATP)-mediated purinergic signalling via P2X3 and heteromeric P2X2/3 ion channel receptors underlies hypersensitisation of vagal airway afferents in refractory chronic cough (RCC), making this pathway a key therapeutic target. Two pharmacological strategies have emerged: dual P2X2/3 receptor antagonism and selective P2X3 inhibition. While dual antagonists (gefapixant) demonstrate robust antitussive efficacy, their clinical use is limited by taste disturbance resulting from P2X2/…
Rank105.9
Kidney-sparing Treatments for Local Recurrence in Renal Cell Tumours After Partial Nephrectomy or Focal Therapy: A Systematic Review.
European urology focus · 2026 · PMID 41412889
BACKGROUND AND OBJECTIVE: Kidney-sparing treatments are salvage options for renal cell carcinoma (RCC) after local recurrence. However, there is no level 1 evidence in the literature examining the efficacy of focal therapies (FTs) and partial nephrectomy (PN) in a head-to-head, randomised comparison. METHODS: A systematic search (PROSPERO CRD420251033642) was performed. The present analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement. KEY FINDINGS AND LIMITATIONS: Ove…
Rank105.9
Robot-assisted versus non-robotic partial nephrectomy for completely endophytic renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42828586
Completely endophytic renal tumors (CERTs), which are entirely confined within the renal parenchyma, present substantial technical challenges during nephron-sparing surgery. We conducted a systematic review and meta-analysis to compare robot-assisted partial nephrectomy (RAPN) with laparoscopic partial nephrectomy (LPN) and open partial nephrectomy (OPN) specifically for CERTs. PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library were searched through August 24, 2026. Eligible comparative studies direct…
Rank105.8
Sutureless versus renorrhaphy in robot-assisted off-clamp partial nephrectomy: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42704544
BACKGROUND: The necessity of routine parenchymal renorrhaphy during off-clamp robot-assisted partial nephrectomy (RAPN) remains uncertain. This study aimed to compare perioperative, functional, safety, and oncological outcomes between sutureless and conventional renorrhaphy. METHODS: We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. Comparative studies evaluating sutureless versus conventional renorrhaphy during purely off-clamp RAPN were included. Trifecta achievement was the pri…
Rank105.4
Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 42350220
Immune checkpoint inhibitor (ICI)-based combination therapies have transformed the management of metastatic renal cell carcinoma (mRCC). However, their benefit in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) favorable-risk disease remains uncertain, raising concerns about potential overtreatment. We conducted a meta-analysis incorporating extended follow-up survival data to evaluate the long-term benefits of ICI-based combinations in this subgroup. PubMed, EMBASE, Web of Science, and the…
Rank105.2
Comparative perioperative outcomes of Hugo™ RAS versus laparoscopic and Da Vinci platforms for partial nephrectomy: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42860500
Renal cell carcinoma (RCC) is a common urologic malignancy, and for localized T1 tumors, nephron-sparing surgery is now the standard of care. Laparoscopic and image-guided techniques have advanced as robotic platform procedures offer greater operator dexterity and procedural control. The da Vinci platform has dominated robot-assisted partial nephrectomy, but high costs and closed architecture limit broader use. The Hugo™ RAS system, featuring a modular design, has emerged as a promising alternative, with early stud…
Rank105.2
Comparison of AirSeal versus conventional insufflation system for robot-assisted partial nephrectomy: a meta-analysis and systematic review.
Journal of robotic surgery · 2024 · PMID 38922386
A systematic review and meta-analysis were performed to investigate the efficacy of the AirSeal Valveless Trocar Needle Insufflation System in robot-assisted partial nephrectomy (RAPN). The study compared the differences in perioperative outcomes between the AirSeal insufflation group (AIS) and the conventional insufflation group (CIS). A systematic search of databases such as PubMed, Embase, Cochrane library, and Web of science was performed to identify studies reporting perioperative outcomes between the AirSeal …
Rank105.2
Transperitoneal versus retroperitoneal single-port robot-assisted partial nephrectomy: systematic review and meta-analysis of perioperative and functional outcomes.
Journal of robotic surgery · 2026 · PMID 42474829
To systematically compare the safety and efficacy of the transperitoneal (TP) and retroperitoneal (RP) approaches in single-port robot-assisted partial nephrectomy (SP-RAPN). PubMed, Web of Science, and Embase were searched for comparative studies published before October 2025. The primary evaluated outcomes were grouped as Perioperative Outcomes (operative time, blood loss, ischemia time, positive surgical margin, postoperative eGFR, and hospital stay) and Surgical Safety (complication rate). Study inclusion and e…
Rank105.1
A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma.
European urology oncology · 2026 · PMID 41241654
BACKGROUND AND OBJECTIVE: Radical nephroureterectomy is the standard of care for management of upper tract urothelial carcinoma (UTUC), but treatment-associated morbidity is not uncommon. Intracavitary therapy has emerged as a less invasive alternative for selected cases, particularly carcinoma in situ (CIS) and low-grade papillary tumors. We conducted a systematic review to evaluate the outcomes, recurrence rates, and adverse events associated with intracavitary therapy (immunotherapy or chemoablation) for UTUC. M…
Rank102.9
Open versus robot-assisted partial nephrectomy for highly complex renal masses: a meta-analysis of perioperitive and functional outcomes.
Journal of robotic surgery · 2023 · PMID 37415066
Robot-assisted partial nephrectomy (RAPN) is increasingly being used for the complex surgical management of renal masses. The comparison of RAPN with open partial nephrectomy (OPN) has not yet led to a unified conclusion with regard to perioperative outcomes. To conduct a systematic review and meta-analysis of the literature on the perioperative outcomes of RAPN compared with OPN. We performed a systematic search in PubMed, Embase, Web of Science, and Cochrane Library database for randomized control trials (RCTs) a…
Rank102.4
Immunotherapy in Bellini Duct Carcinoma: A Systematic Review.
Oncology research · 2026 · PMID 42769789
Background: Collecting duct carcinoma (CDC; Bellini duct carcinoma) is a rare, aggressive renal cancer with no established standard of care, and evidence for immune checkpoint inhibitor (ICI)-based therapy in CDC remains emerging and fragmented. We aimed to systematically synthesise efficacy and safety data on immunotherapy in adult patients with CDC. Methods: PubMed and Web of Science were searched from inception to 29 March 2025, with targeted post-search monitoring of key journals and ClinicalTrials.gov updated …
Rank102.0
What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.
Acta ophthalmologica · 2026 · PMID 41800487
PURPOSE: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register o…
Rank100.1
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41786248
BACKGROUND: Nivolumab plus ipilimumab (NIVO + IPI) demonstrated significant long-term survival and response benefits in patients with previously untreated advanced renal cell carcinoma (aRCC) in the phase III CheckMate 214 trial (NCT02231749). We report final efficacy and safety results with 9.3 years median follow-up. PATIENTS AND METHODS: Patients (N = 1096) were randomized to NIVO 3 mg/kg plus IPI 1 mg/kg every 3 weeks × four doses, followed by NIVO (3 mg/kg or 240 mg every 2 weeks or 480 mg every 4 weeks); or s…
Rank100.0
Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis.
Clinical & experimental metastasis · 2024 · PMID 39680251
Studies conducted in the last few years have suggested a connection between clinical outcomes and the time of immune checkpoint inhibitors (ICIs) infusion. However, few data are available regarding the differences between early and late time-of-day (ToD) administration in metastatic renal cell carcinoma (mRCC) patients receiving immunotherapy and immune-based combinations. In this meta-analysis, we aimed to fully investigate the influence of timing of administration on the efficacy of mRCC immunotherapy, by compari…
Rank100.0
Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.
Cancer metastasis reviews · 2026 · PMID 42645539
Immune checkpoint inhibitor (ICI)-based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCTs) on first-line ICI-based regimens. Following PRISMA guidelines, we searched PubMed, Web of Science and Scopus (January 2018-October 2025) for phase III RCTs investigating first-line ICI-based therap…
Rank100.0
Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review.
European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2024 · PMID 38836904
PURPOSE: Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with cancer, such as melanoma, renal cell carcinoma, head and neck cancer, non-small cell lung cancer (NSCLC), and urothelial carcinoma. The extension of life expectancy has led to an increased incidence of bone metastases (BM) among patients with cancer. BM result in skeletal-related events, including severe pain, pathological fractures, and nerve palsy. Surgery is typically required for the treatment of BM in patients with an imp…
Rank100.0
Visual extended reality tools in image-guided surgery in urology: a systematic review.
European journal of nuclear medicine and molecular imaging · 2024 · PMID 38589511
PURPOSE: The aim of this systematic review is to assess the clinical implications of employing various Extended Reality (XR) tools for image guidance in urological surgery. METHODS: In June 2023, a systematic electronic literature search was conducted using the Medline database (via PubMed), Embase (via Ovid), Scopus, and Web of Science. The search strategy was designed based on the PICO (Patients, Intervention, Comparison, Outcome) criteria. Study protocol was registered on PROSPERO (registry number CRD42023449025…
Rank100.0
Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA): Are We Getting Evidence-Based Results? A Systematic Review According to the Levels of Evidence.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512924
Background and Objectives: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is an emerging minimally invasive therapeutic option for pancreatic and selected extra-pancreatic lesions. However, its clinical adoption is limited by heterogeneous indications, non-standardized techniques, and variable quality of evidence. This systematic review assessed the published literature on EUS-RFA and classified available evidence according to the Oxford Centre for Evidence-Based Medicine levels of evidence. Materia…
Safety And Adverse Effects142 records
Rank110.0
Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis.
Journal of endocrinological investigation · 2024 · PMID 38530620
BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of…
Rank107.2
Meta-analysis and systematic review of factors predicting conversion to radical nephrectomy following robotic-assisted partial nephrectomy in renal cancer patients.
Journal of robotic surgery · 2024 · PMID 39443332
Evaluating the risk factors for the conversion from robotic-assisted partial nephrectomy (RAPN) to radical nephrectomy (RN). Through a comprehensive database search encompassing PubMed, Web of Science, Embase, and the Cochrane Library, we identified pertinent English-language research published by June 2024. We utilized the NOS scale for quality assessment. The aggregate effect was quantified via the odds ratio (OR), alongside a 95% confidence interval (CI). Sensitivity analyses were conducted using both fixed-effe…
Rank106.8
Perioperative, functional and oncologic outcomes of percutaneous ablation versus minimally invasive partial nephrectomy for clinical T1 renal tumors: outcomes from a pooled analysis.
Journal of robotic surgery · 2024 · PMID 39105944
The objective of this study was to perform a comprehensive pooled analysis aimed at comparing the efficacy and safety of percutaneous ablation (PCA) versus minimally invasive partial nephrectomy (MIPN), including robotic and laparoscopic approaches, in patients diagnosed with cT1 renal tumors. We conducted a comprehensive search across four major electronic databases: PubMed, Embase, Web of Science, and the Cochrane Library, targeting studies published in English up to April 2024. The primary outcomes evaluated in …
Rank106.4
Percutaneous ablation versus robotic‑assisted partial nephrectomy for cT1 renal cell carcinoma: an evidence-based analysis of comparative outcomes.
Journal of robotic surgery · 2024 · PMID 39078530
This investigation sought to conduct a comprehensive meta-analysis to assess the comparative effectiveness and safety of percutaneous ablation (PCA) versus robotic-assisted partial nephrectomy (RAPN) among individuals diagnosed with cT1 renal tumors. This study rigorously followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to conduct a systematic review and meta-analysis. A systematic search was carried out in the PubMed, Embase, Web of Science, and Cochrane Library d…
Rank106.2
Single‑port versus multi‑port robotic-assisted partial nephrectomy: a systematic review and meta-analysis of propensity score-matched cohort studies.
International urology and nephrology · 2026 · PMID 42287517
PURPOSE: The effectiveness of single-port (SP) versus multi-port (MP) robotic-assisted partial nephrectomy (RAPN) has been compared in many studies, but the comparative superiority remains unclear. The purpose of this article is to comprehensively review the existing literature and conduct a more precise comparison of the two surgical methods. METHODS: We performed a thorough literature search in PubMed, Web of Science, Embase, and Cochrane CENTRAL databases to identify relevant studies published before April 2026.…
Rank106.0
Comparison of single-port versus multi-port robotic assisted partial nephrectomy: a systematic review and meta-analysis of perioperative and oncological outcomes.
Journal of robotic surgery · 2024 · PMID 39136882
The safety and efficacy of single-port and multi-port robot-assisted partial nephrectomy (SP-RAPN and MP-RAPN, respectively) were assessed for treating partial nephrectomy in this study. A systematic review of PubMed, Cochrane Library, and Web of Science databases was conducted up to June 2024 to compare studies on SP-RAPN and MP-RAPN. Primary outcomes included perioperative results, complications, and oncological outcomes. Eight studies involving 1014 patients were analyzed. For binary outcomes, comparisons were p…
Rank105.2
Comparison of AirSeal versus conventional insufflation system for robot-assisted partial nephrectomy: a meta-analysis and systematic review.
Journal of robotic surgery · 2024 · PMID 38922386
A systematic review and meta-analysis were performed to investigate the efficacy of the AirSeal Valveless Trocar Needle Insufflation System in robot-assisted partial nephrectomy (RAPN). The study compared the differences in perioperative outcomes between the AirSeal insufflation group (AIS) and the conventional insufflation group (CIS). A systematic search of databases such as PubMed, Embase, Cochrane library, and Web of science was performed to identify studies reporting perioperative outcomes between the AirSeal …
Rank105.2
Comparative perioperative outcomes of Hugo™ RAS versus laparoscopic and Da Vinci platforms for partial nephrectomy: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42860500
Renal cell carcinoma (RCC) is a common urologic malignancy, and for localized T1 tumors, nephron-sparing surgery is now the standard of care. Laparoscopic and image-guided techniques have advanced as robotic platform procedures offer greater operator dexterity and procedural control. The da Vinci platform has dominated robot-assisted partial nephrectomy, but high costs and closed architecture limit broader use. The Hugo™ RAS system, featuring a modular design, has emerged as a promising alternative, with early stud…
Rank105.0
Robot-assisted versus open partial nephrectomy in patients with a solitary kidney: a systematic review and meta-analysis of perioperative and functional outcomes.
Journal of robotic surgery · 2026 · PMID 42934344
A patient whose renal tumor develops in a solitary kidney has no contralateral organ able to compensate, and therefore offers the clearest setting in which operative injury to the kidney can be studied. Robot-assisted partial nephrectomy (RAPN) has become routine practice among the wider surgical population, yet no systematic appraisal has established whether it is both safe and effective when the tumor is confined to a solitary kidney. To address this gap we conducted a systematic review and meta-analysis comparin…
Rank104.0
Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 42878911
PURPOSE: The aim of our study was to evaluate the clinical, diagnostic, therapeutic, and prognostic features of immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS). METHODS: We conducted a single-center retrospective case series of seven patients with IM3OS treated at Hospital del Mar between 2020 and 2025, together with a systematic review and descriptive patient-level synthesis of the published literature. PubMed/MEDLINE and Embase were searched for reports pu…
Rank100.0
Risk of bladder, kidney and prostate cancer from occupational exposure to welding fumes: a systematic review and meta-analysis.
International archives of occupational and environmental health · 2024 · PMID 38231405
BACKGROUND: Our aimed to conduct a meta-analysis of cohort studies on risk of genitourinary (GU) cancers in workers exposed to welding fumes (WF). METHODS: We performed a systematic review of studies published on Pubmed, Scopus and Embase following PRISMA criteria. Two researchers selected cohort studies on WF exposure. From 2582 articles, 7 non-overlapping studies were included. Quality of studies was scored according to CASP. We run a random effects meta-analysis to calculate the relative risk (RR) and 95% confid…
Rank100.0
Anti-Angiogenic Tyrosine Kinase Inhibitor-Related Toxicities Among Cancer Patients: A Systematic Review and Meta-Analysis.
Targeted oncology · 2024 · PMID 38761350
BACKGROUND: Targeting of angiogenesis has become a major therapeutic approach for the treatment of various advanced cancers. There are many unresolved questions on the toxicity of anti-angiogenic tyrosine kinase inhibitors (TKIs). OBJECTIVE: We performed a meta-analysis to assess the toxicity prevalence of the different anti-angiogenic TKIs among cancer patients and in subpopulations of interest including patients with renal cell carcinoma. PATIENTS AND METHODS: We searched the MEDLINE and Cochrane Library database…
Rank100.0
Efficacy and safety of surgical management for Rathke's cleft cysts in pediatric patients: a systematic review and meta-analysis.
Neurosurgical review · 2024 · PMID 39738909
Rathke's cleft cysts (RCCs) are benign, cystic lesions that account for less than 5% of cases in the pediatric population. While asymptomatic RCCs often require only conservative management, symptomatic cases may necessitate surgical intervention. Advances in surgical techniques have improved the safety of these procedures. This comprehensive review and single-arm meta-analysis evaluates the outcomes of surgical management in pediatric patients. PubMed, Embase, and Web of Science were systematically searched for st…
Rank100.0
Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit-Risk Assessment.
Targeted oncology · 2026 · PMID 42892667
BACKGROUND: Adjuvant pembrolizumab has improved disease-free survival after nephrectomy for high-risk renal cell carcinoma, and pembrolizumab plus belzutifan has further expanded the treatment landscape. OBJECTIVE: We compared efficacy and treatment burden across adjuvant systemic therapies and examined the benefit-risk trade-off of the combination. METHODS: Randomized trials of systemic therapy after nephrectomy were synthesized using a Bayesian network meta-analysis. Disease-free survival hazard ratios were conve…
Rank100.0
Immune checkpoint inhibitor combinations across clinically distinct metastatic renal cell carcinoma populations with limited or heterogeneous trial evidence: A systematic review, evidence map, and meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 42641831
Immune checkpoint inhibitor (ICI) combinations are standard for metastatic renal cell carcinoma (mRCC), but evidence is uneven across distinct populations. We searched PubMed, Embase and Cochrane CENTRAL through June 3, 2026, and synthesized original studies reporting efficacy or safety in non-clear cell RCC, brain, bone or liver metastases, adults aged 75 years or older, poor performance status, trial ineligibility, frailty, renal impairment or hemodialysis, and sarcomatoid differentiation. Independent studies wer…
Rank97.0
Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
World journal of urology · 2023 · PMID 35867141
PURPOSE: The high incidence of upper urinary tract urothelial carcinoma (UTUC) in Taiwan is largely due to exposure to aristolochic acid (AA), a principal component of Aristolochia-based herbal medicines. Here we systematically review the molecular epidemiology, clinical presentation and biomarkers associated with AA-induced UTUC. METHODS: This is a narrative review. Medline, Embase, and Web of Science were searched from inception to December 31, 2021. Studies evaluating the association, detection, and clinical cha…
Rank97.0
Association between neonatal phototherapy and future cancer: an updated systematic review and meta-analysis.
European journal of pediatrics · 2023 · PMID 36352244
Phototherapy is the main treatment of neonatal hyperbilirubinemia to prevent encephalopathy. It is generally believed to be safe; however, some studies have shown it might be associated with cancer development. In this systematic review and meta-analysis, we aimed to assess the effect of neonatal phototherapy on future cancer risk. A systematic search in 13 databases was conducted in December 2018 and updated in August 2022 to identify studies that report cancer development after exposure to phototherapy. Throughou…
Rank96.0
Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system.
European journal of clinical pharmacology · 2024 · PMID 39285057
BACKGROUND: Recent evidence suggests an association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and a higher risk of renal cancer. OBJECTIVE: We conducted a pharmacovigilance analysis using the US FDA Adverse Event Reporting System (FAERS) to investigate the disproportionate association between SGLT2 inhibitors and renal cancer. METHODS: We used AERSMine to mine data from FAERS, covering the period from 2014 Q1 to 2023 Q3. The control group was treated with other glucose-lowering medications (ATC-A10B…
Rank96.0
Restricted mean survival time-based network meta-analysis of first-line therapies for metastatic clear cell renal cell carcinoma.
Urologic oncology · 2026 · PMID 42892578
To compare hazard ratio (HR)- and difference in restricted mean survival time (dRMST)-based network meta-analyses of first-line immune checkpoint inhibitor-based regimens for metastatic clear-cell renal cell carcinoma. We also introduce a RMST-based framework contextualizing survival benefit alongside toxicity, corticosteroid burden, and drug-acquisition cost. Five phase III trials comparing ICI-based combinations with sunitinib in mccRCC were included. Published trial-level HRs informed HR-based NMAs, while recons…
Rank96.0
Efficacy and safety of single-fraction stereotactic body radiotherapy (SBRT) for the curative treatment of extracranial primary Tumors: A collaborative systematic review on behalf of the SBRT Focus Group of the European Society for Radiotherapy & Oncology (ESTRO).
Clinical and translational radiation oncology · 2027 · PMID 42898625
Single-fraction stereotactic body radiotherapy (SF-SBRT) represents one of the most advanced frontiers in modern radiation oncology. While ultra-hypofractionation has entered everyday clinical practice in different fields of the oncological care, curative treatments in one session are increasingly attractive for the potential favorable combination of logistic advantages with safety and clinical outcomes. This collaborative systematic review promoted by the ESTRO SBRT Focus Group in participation with members of dif…
Rank90.5
Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42927856
BACKGROUND: Pembrolizumab plus lenvatinib is a first-line standard of care for advanced clear-cell renal-cell carcinoma (ccRCC). The phase 3 LITESPARK-012 study (NCT04736706) evaluated efficacy and safety of adding belzutifan (HIF-2α inhibitor) or quavonlimab (anti-CTLA-4) to this regimen. PARTICIPANTS AND METHODS: Adults with previously untreated advanced ccRCC were randomized 1:1:1 to 400 mg pembrolizumab IV Q6W plus 20 mg lenvatinib orally daily and 120 mg belzutifan orally daily (Arm A); coformulated quavonlima…
Rank90.4
Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial.
The Lancet. Oncology · 2026 · PMID 42945979
BACKGROUND: VEGFR tyrosine kinase inhibitors (TKIs) are considered the backbone for the treatment of metastatic clear-cell renal cell carcinoma. We hypothesise that the administration of bevacizumab during scheduled breaks in pazopanib (TKI) treatment can improve tolerability and prolong progression-free survival compared with historical controls. METHODS: In this single-arm, phase 1/2 trial in five US academic cancer centres, patients (aged ≥18 years) with histologically confirmed metastatic clear-cell renal cell …
Rank90.1
Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carcinoma after anti-PD-(L)1 therapy.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42927855
BACKGROUND: The phase 3, randomized, open-label LITESPARK-011 trial (NCT04586231) investigated belzutifan plus lenvatinib versus cabozantinib in participants with advanced clear-cell renal-cell carcinoma (ccRCC) following anti-PD-(L)1 therapy. At earlier analyses, belzutifan plus lenvatinib significantly improved progression-free survival (PFS) and objective response rate (ORR) versus cabozantinib. Overall survival (OS) was tested but did not reach significance. We present the final analysis of LITESPARK-011. PARTI…
Rank88.9
Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.
JAMA oncology · 2026 · PMID 42879162
IMPORTANCE: Renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus is associated with substantial perioperative risk and frequent recurrence despite nephrectomy and thrombectomy. No established neoadjuvant local therapy exists for this high-risk population. OBJECTIVE: To evaluate the feasibility, safety, clinical outcomes, and exploratory biomarker effects of neoadjuvant stereotactic ablative radiotherapy (SABR) targeting IVC tumor thrombus before nephrectomy and thrombectomy. DESIGN, SETTING, AND …
Rank88.0
Global Landscape of Clinical Studies Open to Enrollment in Carbon Ion Radiotherapy: A PTCOG Review.
International journal of particle therapy · 2026 · PMID 42893060
BACKGROUND: Radiotherapy with high linear energy transfer (LET) has shown promise for improving cancer outcomes. Carbon ion radiotherapy (CIRT) combines charged-particle dose conformality with enhanced biological effectiveness. However, clinical development remains constrained by limited center availability, modest trial accrual, and few randomized studies. We reviewed the global landscape of CIRT studies open to enrollment to identify current priorities and gaps. METHODS: This Particle Therapy Cooperative Group (P…
Treatments That Failed Clinical Trials59 records
Rank99.3
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · PMID 39255440
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of sele…
Rank99.0
The long-term impact of single intraoperative instillation of pirarubicin after radical nephroureterectomy on local and systemic cancer control: a prospective, multicenter, randomized trial.
World journal of urology · 2025 · PMID 40080123
PURPOSE: Although the preventive effect against intravesical recurrence (IVR) has been established for single instillation of chemotherapy during or after radical surgery of upper urinary tract urothelial carcinoma (UTUC), there has been no research on the long-term outcome. This study aims to investigate the IVR and long-term survival outcome of a single intraoperative instillation of pirarubicin during radical nephroureterectomy (RNU). METHODS: In this prospective, multicenter, randomized trial, 97 patients under…
Rank98.6
Suitability of the MP1000 system for robot-assisted partial nephrectomy: a multicenter randomized controlled noninferiority trial.
International journal of surgery (London, England) · 2024 · PMID 38349210
PURPOSE: This study aimed to compare the safety and effectiveness of the MP1000 surgical system with the da Vinci Si robot system in robot-assisted partial nephrectomy (RAPN) through a prospective, single-blinded, randomized controlled trial. MATERIALS AND METHODS: A total of 62 patients who were scheduled to undergo RAPN were randomly assigned to either the da Vinci Si robot or MP1000 group. A noninferiority test was conducted with a noninferior intermediate value of 10%. The study compared installation and operat…
Rank98.6
A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma.
ESMO open · 2026 · PMID 42849355
BACKGROUND: Immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted tyrosine kinase inhibitors (TKIs) have improved advanced renal cell carcinoma (RCC) outcomes, yet median progression-free survival (PFS) remains <2 years. PATIENTS AND METHODS: This randomised (1 : 1 : 1), open-label, phase II study (NCT05805501) evaluated tobemstomig [bispecific anti-programmed cell death protein 1 (PD-1)/lymphocyte-activation gene 3] plus axitinib (VEGF-TKI) and tobemstomig plus tiragolumab (…
Rank98.0
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42507969
PURPOSE: Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS: This phase II trial enrolled patients with mRCC of any his…
Rank97.9
Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial.
International braz j urol : official journal of the Brazilian Society of Urology · 2024 · PMID 39133792
INTRODUCTION: We aim to compare the safety and effectiveness of the KangDuo (KD)-Surgical Robot-01 (KD-SR-01) system and the da Vinci (DV) system for robot-assisted radical nephroureterectomy (RARNU). MATERIALS AND METHODS: This multicenter prospective randomized controlled trial was conducted between March 2022 and September 2023. Group 1 included 29 patients undergoing KD-RARNU. Group 2 included 29 patients undergoing DV-RARNU. Patient demographic and clinical characteristics, perioperative data, and follow-up ou…
Rank96.6
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy.
European urology · 2024 · PMID 37684178
There is a paucity of high-level evidence on small renal mass (SRM) management, as previous classical randomised controlled trials (RCTs) failed to meet accrual targets. Our objective was to assess the feasibility of recruitment to a cohort-embedded RCT comparing cryoablation (CRA) to robotic partial nephrectomy (RPN). A total of 200 participants were recruited to the cohort, of whom 50 were enrolled in the RCT. In the CRA intervention arm, 84% consented (95% confidence interval [CI] 64-95%) and 76% (95% CI 55-91%)…
Rank96.6
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy.
The Journal of urology · 2026 · PMID 41360001
PURPOSE: Hemostatic agents (HAs) are typically used during robotic-assisted laparoscopic partial nephrectomy (RALPN) to minimize perioperative bleeding. However, high-quality evidence supporting their effectiveness is limited. We aimed to determine whether HAs reduce perioperative blood loss in patients undergoing RALPN. MATERIALS AND METHODS: We conducted a prospective, randomized controlled trial of patients undergoing RALPN. Patients were randomized to HA+, in which HAs were assigned, and HA-, no HA. The primary…
Rank96.4
Randomized controlled trial of the effect of general anesthetics on postoperative recovery after minimally invasive nephrectomy.
Korean journal of anesthesiology · 2024 · PMID 37232074
BACKGROUND: General anesthetic techniques can affect postoperative recovery. We compared the effect of propofol-based total intravenous anesthesia (TIVA) and desflurane anesthesia on postoperative recovery. METHODS: In this randomized trial, 150 patients undergoing robot-assisted or laparoscopic nephrectomy for renal cancer were randomly allocated to either the TIVA or desflurane anesthesia (DES) group. Postoperative recovery was evaluated using the Korean version of the Quality of Recovery-15 questionnaire (QoR-15…
Rank96.2
Transperitoneal vs retroperitoneal laparoscopic radical nephrectomy: a double-arm, parallel-group randomized clinical trial.
BMC urology · 2024 · PMID 38310213
OBJECTIVE: To compare the outcomes of patients undergoing Retroperitoneal laparoscopic Radical nephrectomy (RLRN) and Transperitoneal laparoscopic Radical nephrectomy (TLRN). METHODS: A total of 120 patients with localized renal cell carcinoma were randomized into either RLRN or TLRN group. Mainly by comparing the patient perioperative related data, surgical specimen integrity, pathological results and tumor results. RESULTS: Each group comprised 60 patients. The two group were equivalent in terms of perioperative …
Rank96.0
Intraoperative ultrasonography (IOUS)-guided vs conventional laparoscopic nephrectomy: a randomised control trial.
BJU international · 2024 · PMID 37470129
OBJECTIVES: To assess the efficacy of routine use of intraoperative ultrasonography (IOUS) in improving perioperative outcomes in patients undergoing IOUS-guided laparoscopic nephrectomy (IOUS-LN) and conventional laparoscopic nephrectomy (C-LN). PATIENTS AND METHODS: This was a parallel-arm, single-blinded, randomised controlled trial (CTRI/2021/12/038906). All patients undergoing LN, either for benign or malignant causes, were included. Patients undergoing partial/cytoreductive nephrectomy, with venous thrombus w…
Rank96.0
The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial.
BMC medicine · 2026 · PMID 41530764
BACKGROUND: Enhanced cough sensitivity is proposed as a potential cause for refractory chronic cough (RCC), and modulation of sensory nerve hyperresponsiveness is suggested as an effective treatment. However, the treatment of RCC has considerable potential for enhancement, particularly in terms of the targets and side effects. We aimed to investigate the efficacy and safety of duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, in patients with RCC. METHODS: This is a prospective, randomized, double…
Rank96.0
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
JAMA oncology · 2023 · PMID 37410476
IMPORTANCE: Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to respond to ICI monotherapy. Hypofractionated radiotherapy has the potential to improve the therapeutic ratio of ICIs. OBJECTIVE: To assess the addition of radiotherapy to ICIs compared with ICI monotherapy in patients with advanced solid tumors. DESIGN, SETTING, AND PARTICIPANTS: This open-label, multicenter, randomized…
Rank95.8
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
The Lancet. Oncology · 2024 · PMID 38942046
BACKGROUND: The standard of care for patients with intermediate-to-high risk renal cell carcinoma is partial or radical nephrectomy followed by surveillance. We aimed to investigate use of nivolumab before nephrectomy followed by adjuvant nivolumab in patients with high-risk renal cell carcinoma to determine recurrence-free survival compared with surgery only. METHODS: In this open-label, randomised, phase 3 trial (PROSPER EA8143), patients were recruited from 183 community and academic sites across the USA and Can…
Rank95.8
Smart Continence Care for People With Profound Intellectual and Multiple Disabilities Within Dutch Residential Care Facilities: Economic Evaluation Alongside a Cluster Randomized Trial.
Journal of medical Internet research · 2025 · PMID 41071602
BACKGROUND: Persons with profound intellectual and multiple disabilities in residential care facilities may benefit from smart continence care (SCC), which is incontinence material (IM) with integrated sensors that notify caregivers when the IM is saturated and requires changing. SCC aims to reduce weekly leakages and improve the quality of life. OBJECTIVE: Given the growing demand for health care services and the decreasing workforce, it is essential to assess the cost-effectiveness and cost-utility of such techno…
Rank95.4
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy.
European urology focus · 2026 · PMID 41760424
BACKGROUND AND OBJECTIVE: Robot-assisted partial nephrectomy (RAPN) is increasingly used to treat renal cell carcinoma (RCC), but randomized data comparing long-term outcomes to those after open partial nephrectomy (OPN) remain limited. Our aim was to compare oncological, renal function, and health-related quality of life (HRQOL) outcomes at 2 yr for patients who underwent RAPN versus OPN. METHODS: This single-center phase 2 randomized controlled trial included 50 patients with suspected localized RCC who were rand…
Rank95.4
Quality-of-life outcomes of the ROBOtic-assisted versus Conventional Open Partial nephrectomy (ROBOCOP) II trial.
BJU international · 2024 · PMID 38816992
OBJECTIVES: To comprehensively compare quality-of-life (QoL) outcomes between open partial nephrectomy (OPN) and robot-assisted PN (RAPN) from the randomised ROBOtic-assisted versus Conventional Open Partial nephrectomy (ROBOCOP) II trial, as QoL data comparing OPN and RAPN are virtually non-existent, especially not from randomised controlled trials (RCTs). PATIENTS AND METHODS: The ROBOCOP II was a single-centre, open-label RCT between OPN and RAPN. The pre-planned analyses of QoL outcomes are presented. Data were…
Rank95.3
Jetstream Atherectomy with Paclitaxel-Coated Balloons: Two-Year Outcome of the Prospective Randomized JET-RANGER Study.
Vascular health and risk management · 2023 · PMID 36936551
BACKGROUND: The JET-RANGER study (NCT03206762) was a multicenter (11 US centers) randomized trial, core lab adjudicated, designed to demonstrate the superiority of Jetstream + Paclitaxel coated balloon (JET+PCB) versus angioplasty (PTA) + PCB in treating femoropopliteal (FP) arterial disease. The one-year primary endpoint of JET-RANGER has been recently published. The 2-year outcome data are presented in this report. METHODS: There were 43 patients who completed the 1-year follow-up. Two were lost to follow-up and …
Rank95.0
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Nature medicine · 2024 · PMID 38942995
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab. However, its effect on those receiving tyrosine kinase inhibitor-based combinations is unknown. In this open-label, randomized, investigator-initiated, phase 1 study, 30 participants with locally advanced or mRCC with histological confirmation of clear cell, papillary or sarcomatoid component were randomized …
Rank94.9
A cluster randomized controlled trial of a train-the-trainer behavioral intervention delivered via respite care centers to improve nutritional outcomes and quality of life persons with dementia and their caregivers.
The journal of nutrition, health & aging · 2025 · PMID 41124731
OBJECTIVE: To evaluate a behavioral intervention, Partners at Meals (PAM), designed to empower caregivers (CGs) to improve caloric intake, weight, and quality of life (QOL) of persons with dementia (PWD), and to address dysfunctional behaviors during mealtime. The study also aimed to assess differences in caregiver psychosocial outcomes, including depression, burden, and QOL. DESIGN: A cluster randomized controlled experimental design was used, in which participating Respite Care Centers (RCCs) were randomized to e…
Rank94.9
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
European urology · 2022 · PMID 35843776
BACKGROUND: In the phase 3 KEYNOTE-426 (NCT02853331) trial, pembrolizumab + axitinib demonstrated improvement in overall survival, progression-free survival, and objective response rate over sunitinib monotherapy for advanced renal cell carcinoma (RCC). OBJECTIVE: To evaluate health-related quality of life (HRQoL) in KEYNOTE-426. DESIGN, SETTING, AND PARTICIPANTS: A total of 861 patients were randomly assigned to receive pembrolizumab + axitinib (n = 432) or sunitinib (n = 429). HRQoL data were available for 429 pa…
Rank94.6
Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach.
World journal of urology · 2022 · PMID 34671856
INTRODUCTION: This study aimed to determine the prognostic value of a panel of SIR-biomarkers, relative to standard clinicopathological variables, to improve mRCC patient selection for cytoreductive nephrectomy (CN). MATERIAL AND METHODS: A panel of preoperative SIR-biomarkers, including the albumin-globulin ratio (AGR), De Ritis ratio (DRR), and systemic immune-inflammation index (SII), was assessed in 613 patients treated with CN for mRCC. Patients were randomly divided into training and testing cohorts (65/35%).…
Rank94.2
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
European journal of cancer (Oxford, England : 1990) · 2023 · PMID 36459768
BACKGROUND: Vorolanib is a highly potent tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor. This three-arm, randomised, registered study aimed to assess the combination of vorolanib and everolimus or vorolanib alone versus a control arm of everolimus as second-line treatment in patients with metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients with advanced or metastatic RCC who had received one prior VEGFR-TKI …
Rank94.1
Molecular determinants of response to PD-L1 blockade across tumor types.
Nature communications · 2021 · PMID 34172722
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical responses in subsets of cancer patients across multiple indications, including non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and renal cell carcinoma (RCC). Herein, we complement PD-L1 immunohistochemistry (IHC) and tumor mutation burden (TMB) with RNA-seq in 366 patients to identify unifying and indication-specific molecular profiles that can predict response to checkpoint blockade across these tumor types. Multiple…
Rank94.0
CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma.
Technology in cancer research & treatment · 2026 · PMID 42308169
IntroductionThere is currently no biomarker for progression-free survival (PFS) for patients undergoing treatment for metastatic renal cell carcinoma (RCC). The aim of our study was to evaluate computed tomography perfusion (CTp) blood flow as an early marker of PFS in patients with mRCC treated with targeted agents.MethodsAssociations between CTp blood flow and PFS were evaluated from prospective randomized evidence using univariable and multivariable Cox proportional hazards regression models with Harrell's conco…
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.